Symptoms in patients with cancer by van den Beuken-van Everdingen, M.H.J.
  
 
Symptoms in patients with cancer
Citation for published version (APA):
van den Beuken-van Everdingen, M. H. J. (2009). Symptoms in patients with cancer. Maastricht:
Datawyse / Universitaire Pers Maastricht.
Document status and date:
Published: 01/01/2009
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 
 
Symptoms in 
Patients with Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Marieke van den Beuken, Maastricht 2009  
University Hospital Maastricht, Department of Anaesthesiology, Pain Management and 
Research Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands 
e-mail: m.vanden.beuken@mumc.nl 
 
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any 
means, without the permission in writing from the author 
 
ISBN: 978-90-5278-797-8 
 
 
Layout: Tiny Wouters 
Cover design: adapted from www.xanga.com 
Production: Datawyse / Universitaire Pers Maastricht 
 
Printing of this thesis was financially supported by Grünenthal BV, Therabel BV, Pfizer BV and 
Mundipharma BV. 
 Symptoms in 
Patients with Cancer 
 
 
 
 
Proefschrift 
 
ter verkrijging van de graad van doctor 
aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus, Prof. mr. G.P.M.F. Mols, 
volgens het besluit van het College van Decanen,  
in het openbaar te verdedigen  
op donderdag 15 januari 2009 om 14.00 uur 
 
 
door 
 
 
Maria Henrica Johanna van den Beuken-van Everdingen 
 
Geboren op 20 oktober 1960 te Utrecht 
UNIVERSITAIRE
PERS MAASTRICHT
P
M
 Promotores 
 
 Prof. dr. M. van Kleef 
 Prof. dr. H.C. Schouten 
 
 
Copromotores 
 
 Dr. J. Patijn  
Mw. Dr. J.M. de Rijke 
  
 
Beoordelingscommissie 
 
Prof. dr. M.F. von Meyenfeldt (voorzitter) 
Prof. dr. S.H. Ahmedzai, University of Sheffield Medical School 
Prof. dr. C.D.A. Stehouwer 
Prof. dr. R. de Wit 
Prof. dr. W.W. Zuurmond, Academisch Ziekenhuis, Vrije Universiteit te 
Amsterdam 
 
 
 
 
  
Wie niets weet 
en weet dat hij niets weet 
weet meer 
dan hij die iets weet 
en niet weet wat hij niet weet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Voor “mijn” mannen: 
       Loek 
Joop, Sef, Wisse en Dirk 
 
 Contents 
 
Chapter 1 General introduction 9 
 
Chapter 2 Prevalence of pain in patients with cancer. 19 
 A systematic review of the past 40 years 
 
Chapter 3 High Prevalence of Pain in Patients with Cancer  47 
 In a large population-based study in The Netherlands 
 
Chapter 4 Quality of Life and Symptoms in Patients with Cancer 65 
 
Chapter 5 A randomised clinical trial of an intensive nursing-based  91 
 pain education programme for cancer outpatients with  
 pain  
 
Chapter 6 Concerns of Former Breast Cancer Patients about  113 
 Disease Recurrence. A validation and prevalence study 
 
Chapter 7 Summary and General discussion 131 
 
 Samenvatting 161 
 
 Appendices 175 
 
 Appendix I: Quality criteria for prevalence studies of pain  177 
 in patients with cancer.  
 
 Appendix II: Dutch version of the CARS 179 
 
 Dankwoord 183 
 
 Curriculum vitae 189 
  
  
 
 
 
 
 
Chapter 1 
 
 
 
 
 
 
General introduction 
 
 
 
 
 
 
 
10⏐Chapter 1 
 General introduction⏐11 
General Introduction  
Patients with cancer face many problems as well during the active treatment 
phase, after curative treatment as near the end of life. In addition, the problem 
is growing: in 2002, an estimated eleven million new cancer cases and seven 
million cancer deaths were reported worldwide; nearly 25 million persons were 
living with cancer (five-year prevalence).1 The world-wide incidence rate of 
cancer is expected to grow to 15 million new cases in 2020.2 
In the Netherlands, in 2005, 74.500 new cancer cases and 38.500 cancer 
deaths were reported.3 The age-adjusted incidence of cancer until 2015 will 
level for men and show a slight increase for women. However, due to aging of 
the Dutch population the absolute number of new cancer cases will rise to 
50.000 in men and to 45.000 in women in 2015.4 
Since 1990 the rate of cancer deaths is decreasing in man and is stable in 
women. The expectation is that this trend will hold to 2015.(4) Due to the stabile 
or slight increasing incidence in combination with the decreasing death rate, 
the age-adjusted cancer prevalence will rise considerably. It is expected that 
the 20-year prevalence of cancer will rise from 366.000 in 2000 to 692.000 in 
2015: The prevalence will be doubled in 15 years!4 
 
The problems these patients with cancer meet, have as well physical as 
psychological, social and spiritual aspects. 
As a result on “too often a patient’s distress is narrowly defined by the health 
care system and their illness is described in terms of biology of 
disease…..while associated suffering of the patient is ignored”5 a huge 
literature has developed around the idea of quality of life.  
“Quality of life” naturally follows from the World Health Organisation’s definition 
of health as complete physical, mental and social well-being, not merely the 
absence of disease.6 However, despite the increased interest in quality of life, 
there is still no consensus on the definition of this concept.7 The most suitable 
approach for defining quality of life is “satisfaction with life”.7 
Cancer clinicians have long recognized that their treatment must strike a 
balance between quantity and quality of life. Cancer-care shifts to “patient-
centred” care, which shares the same aspirations as palliative care e.g.: quality 
of life, including good symptom control, holistic patient-centred care and open 
and sensitive communication that addresses the physical, psychological, social 
and spiritual needs of patients and their families.8 
 
Looking at the physical problems, pain is one of the most feared and 
burdensome symptoms. Despite the abundant literature on this topic, accurate 
prevalence estimates of pain in cancer patients are not available. Early reports 
on the prevalence of pain in cancer patients draw attention to high figures that 
12⏐Chapter 1 
ranged from 52 to 77%.9-13 More recent studies on the prevalence of pain in 
patients with cancer showed figures that ranged from 24-60% in patients on 
active anti-cancer treatment14-17 and 62-86% in patients with advanced 
cancer,18-23 which illustrates that this problem has not been solved.  
These high prevalence figures contrast sharply with the rapidly increasing 
interest in pain and pain relief in the past decade. Apparently, greater insight 
into the pathophysiological mechanisms of pain and the wider availability of 
anti-nociceptive therapies, such as opioids, co-analgesics and NMDA-receptor-
antagonists, have not influenced the prevalence of pain in cancer patients. 
Moreover, the WHO introduced a pain ladder24 in 1986 that has been accepted 
worldwide. Combined with appropriate dosage guidelines, it should be able to 
provide tools for adequate pain relief in 70-90% of the patients.25-28  
The prevalence of non-pain physical symptoms is much less addressed and 
mainly in patients with advanced or metastatic disease.18,29-33 A recent 
systematic review on symptom prevalence in patients with incurable cancer34 
identified 37 symptoms, almost all occurring in >10% of the patients. Five 
symptoms (fatique, pain, lack of energy, weakness and appetite loss) occurred 
in more than 50% of the patients. The authors concluded that more studies are 
needed based on symptom intensity, symptom burden and impact on quality of 
life to improve individually tailored treatment.34 
Studies on non-pain symptoms in ambulatory or cured patients are scarce and 
mainly focussed on a particular type of cancer (e.g. breathlessness in patients 
with lung cancer,35 fatigue in breast cancer survivors36 or vertigo in 
nasopharyngeal carcinoma survivors37).  
Cancer related psychological distress occurs in one third of patients.38 Major 
depressive disorder is estimated to occur in 10-25% of patients with cancer.38 
Anxiety disorders are found in 15-28% of the patients.39 These estimates were 
made around the time of diagnosis. Hardly any research is done to establish 
the prevalence of anxiety, depressive disorders or other psychological distress 
in the years after the diagnosis.  
Psychiatric morbidity and other psychological aspects are best studied among 
breast cancer patients, while fewer reports regard cancer of other sites.40-42 In 
breast cancer patients, 30% of the women were still experiencing psychological 
distress many years after the completion of treatment.43 Specific problems 
often persisted, such as poor body image, decreased sexuality and fear of 
disease recurrence.44,45 Even twenty years after the initial treatment, there was 
an increased prevalence of post-traumatic stress disorder (PTSD), which 
indicated unremitting psychological sequelae long after diagnosis and 
treatment.46  
 
Reasons for the still too high prevalence of physical symptoms in patients with 
cancer is best studied in patients with pain. The gap between what is possible 
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in pain control and what is achieved is caused by many different patient 
centred, care provider centred and government centred factors. Fear for 
medication in general and opioids in particular, patients wanting to be “good” 
patients, lack of knowledge, lack of interest and requests from care providers, 
are well-known barriers against adequate pain control.47-56  
In a recent systematic review of institutional interventions designed to improve 
the assessment and treatment of pain57 no clinical trials that specifically 
targeted physicians behaviour could be targeted. Nursing educational 
interventions involving didactic sessions have been shown to improve nurses’ 
knowledge and correct misperceptions about pain and analgesic prescribing 
but have not been shown to improve pain or patient’s satisfaction.57 Several 
studies suggest that educational interventions using tailored counselling 
sessions directed at the patients can improve pain scores and alter negative 
pain beliefs and misconceptions.57 
 
There is an ongoing discussion whether psychological symptoms are 
associated with survival in patients with cancer. Depression has been 
associated with shortened survival after five years but not after ten years.58 
Psychological interventions have found to be beneficial and non-beneficial with 
respect to survival.38 A recent review concerning psychotherapy and survival in 
cancer concluded: there is no reason to assume that psychotherapy promotes 
survival.59  
However, psychological symptoms do have a considerable negative influence 
on quality of life in patients with chronic diseases.60-63  
Summary 
The number of patients who have survived cancer or are living with cancer is 
growing. These patients are confronted with numerous physical, psychological, 
social and spiritual problems. However, most research on symptoms and 
symptom management has been performed in patients with breast cancer and 
in patients with advanced disease. Very few studies focussed on symptoms in 
other cancers, in cured patients or in patients during active treatment. 
In this thesis we attempt 1. to make reliable estimations of the prevalence and 
severity of pain in cancer patients and to map predictors of cancer pain, 2. to 
make reliable estimations of the prevalence of non-pain symptoms in order to 
find whether treating physicians should be extra alert on a particular symptom 
in a particular type of cancer or treatment phase, 3. to determine the quality of 
life of patients with cancer in different cancer types and treatment phases and 
to investigate the impact of physical and psychological symptoms on quality of 
life, 4. to evaluate whether an intensive home-based pain education 
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programme given by nurses can affect levels of pain, pain knowledge, quality 
of life, anxiety and depression, 5. to evaluate the psychometric properties of the 
Dutch version of the CARS (Concerns About Recurrence Scale) and 6. to 
measure the prevalence of concerns about disease recurrence in former breast 
cancer patients, to identify potential predictors and to establish how fear of 
recurrence affects quality of life.  
With this thesis we hope to make things better. 
Outline of this thesis 
In chapter 2 we report on a systematic review of the literature on the 
prevalence of pain. Despite the abundant literature on this topic, accurate 
prevalence estimates of pain in cancer patients are not available. We 
investigated the prevalence of pain in cancer patients according to the different 
disease stages and types of cancer. 
A systematic review of the literature was conducted. An instrument especially 
designed for judging prevalence studies on their methodological quality was 
used. Methodological acceptable articles were used in a meta-analyses.  
In chapter 3  we describe a population-based study on the prevalence of pain 
in patients with cancer.  
At present, no definite conclusions can be drawn about the real extent of the 
pain suffered by cancer patients. A population-based study was conducted to 
obtain reliable information about the prevalence and severity of pain in cancer 
patients (all phases) and about predictors of pain. A representative sample of 
cancer patients was recruited in the area from a cancer registry. Pain was 
assessed by the Brief Pain Inventory (BPI). Adequacy of pain treatment was 
assessed with the Pain Management Index (PMI). 
In hapter 4  we describe a population-based study on the prevalence of non-
pain physical symptoms and psychological symptoms in patients with cancer.  
The objective of this study was: to measure the prevalence of non-pain 
physical symptoms and psychological symptoms in patients with cancer, to 
investigate the impact of physical and psychological symptoms on quality of life 
and to enquire whether treatment had been received for the complaints/ 
symptoms . 
Quality of life and non-pain symptoms were measured by the EORTC-C30 
version 3. We added two items: 1. did you have a dry mouth? and 2. did you 
feel listless? Depression and anxiety were measured by the Dutch version of 
the Hospital Anxiety and Depression Scale (HADS).  
Chapter 5 describes a randomised clinical trial of an intensive nursing 
intervention for cancer patients suffering from pain their home situation.  
c
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The prevalence of pain in patients with cancer is still too high. Factors related 
to ineffective pain treatment fall into three categories: the health care system, 
professional care providers and patients. In patients, various barriers lead to 
non-compliance. Previous educational interventions have increased their pain 
knowledge and decreased short-term pain levels. In this randomised controlled 
trial, we investigated how an intensive home-based education programme 
given by nurses affected short-term and long-term pain levels.  
One hundred and twenty cancer patients were randomised to receive either the 
Pain Education Programme (PEP) or usual care. Pain, knowledge, quality of 
life, anxiety and depression were measured at baseline, after four weeks and 
after eight weeks. In the intervention group, results of symptom levels were 
communicated to the treating physician. 
Chapter 6  describes the validation of the Dutch version of the Concerns About 
Recurrence Scale (CARS).  
The present study had three aims: first, to evaluate the psychometric properties 
of the Dutch version of the CARS (CARS-DLV). Second, to measure the 
prevalence of concerns about disease recurrence in former breast cancer 
patients and identify potential predictors and third, to establish how fear of 
recurrence was effecting quality of life 
A prospective study was carried out on breast cancer patients (n=136) who had 
undergone curative treatment. Eligible patients completed an extensive 
questionnaire consisting of the CARS (fear of recurrence), HADS (anxiety and 
depression), BPI (pain), RAND (quality of life), LOT (optimism) and the PCS 
(catastrophzing). 
Finally, in chapter 7, the main findings of this thesis are discussed in the 
context of the recent literature. Furthermore, we give practical advices to 
improve symptom care in patients with cancer.  
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Abstract 
Background/aim 
Despite the abundant literature on this topic, accurate prevalence estimates of pain in cancer 
patients are not available. We investigated the prevalence of pain in cancer patients according to 
the different disease stages and types of cancer. 
 
Methods 
A systematic review of the literature was conducted. An instrument especially designed for judging 
prevalence studies on their methodological quality was used. Methodological acceptable articles 
were used in the meta-analyses. 
 
Results 
Fifty- two studies were used in the meta-analysis. Pooled prevalence rates of pain were calculated 
for four subgroups: 1: studies including  patients after curative treatment: 33% (95% confidence 
interval (CI) 21-46%); 2: studies including  patients under anti-cancer treatment: 59% (CI 44-73%); 
3: studies including patients characterised as advanced/metastatic/terminal disease: 64% (CI 58-
69%)  and 4: studies including  patients at all disease stages: 53% (CI 43-63%). Of the patients 
with pain more than one-third graded their pain as moderate or severe. Pooled prevalence of pain 
was more than 50% in all cancer types with the highest prevalence in head /neck cancer patients 
(70%; 95% CI 51-88%). 
 
Conclusion 
Despite the clear World Health Organisation recommendations, cancer pain still is a major 
problem. 
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Introduction 
In cancer patients, pain is one of the most feared and burdensome symptoms. 
Early reports on the prevalence of pain in cancer patients draw attention to high 
figures that ranged from 52 to 77%.1-5 More recent studies on the prevalence of 
pain in patients with cancer showed figures that ranged from 24-60% in 
patients on active anti-cancer treatment6-9 and 62-86% in patients with 
advanced cancer,10-15 which illustrates that this problem has not been solved.  
These high prevalence figures contrast sharply with the rapidly increasing 
interest in pain and pain relief in the past decade. Apparently, greater insight 
into the pathophysiological mechanisms of pain and the wider availability of 
anti-nociceptive therapies, such as opioids, co-analgesics and NMDA-receptor-
antagonists, have not influenced the prevalence of pain in cancer patients. 
Moreover, the WHO introduced a pain ladder16 in 1986 that has been accepted 
worldwide. Combined with appropriate dosage guidelines, it should be able to 
provide tools for adequate pain relief in 70-90% of the patients.17-22  
In 1985, Bonica attempted to evaluate the prevalence of cancer pain worldwide 
by extrapolating the prevalence rates retrieved from 47 selected reports 
published in 15 countries.23 The mean pain prevalence in patients with various 
stages of cancer was 50%. In patients with advanced/metastatic/terminal 
cancer, the percentage was 71%. However, these prevalence figures have to 
be interpreted with caution, because sample size differences were not taken 
into account in the calculation of the mean prevalence and no information was 
given about the search methods used to select the articles or about differences 
between patient groups other than type and stage of cancer. 
It took almost two decades before another systematic review was performed to 
estimate the prevalence of cancer pain.24 The authors included the review by 
Bonica and made an additional literature search (period 1980-2000), which 
resulted in 54 more studies. Although the search method was described, it was 
not clear how these articles had been selected, because the total number of 
articles retrieved in the search was not mentioned. Furthermore, the 
methodological quality of the studies that reported pain prevalence rates was 
not taken into account.25 
The end result was a very heterogeneous sample of articles, for example, with 
respect to the methods of data collection: six studies had surveyed medical 
records and five studies had used retrospective data collected from proxies 
(bereaved care providers or other informants). It is well-known that these two 
methods can result in prevalence figures that differ from data obtained directly 
from the patient.26-32 Although the authors stated that it was not possible to 
perform a meta-analysis owing to the variation in measurements, they reported 
combined weighted mean prevalences of pain in patients with all/various 
stages versus patients with metastatic or terminal disease. No description was 
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given of how the weighted mean average had been calculated. Prevalence 
rates were 40% (range 18-100%) and 74% (range 53-100%), respectively. 
In 2005, Goudas et al.33 aimed to present an literature overview of 
epidemiological data on cancer- related pain over the period 1982 to 2001. 
They restricted their search to the field of epidemiology and found 464 studies. 
Only surveys that explicitly targeted the prevalence of cancer pain were 
included, which left 28 studies. The authors argued that it was not possible to 
combine these surveys, because of differences in settings, study populations, 
primary cancer sites and the methods employed. The only classification they 
could make was by sample size: <1000 patients (n=22), 1000-10,000 (n=4) 
and >10,000 (n=2). In this way, a comprehensive but fairly unstructured 
enumeration of prevalence figures was presented.33 
Despite the large body of literature on pain in cancer patients, none of the 
previous reviews provided accurate prevalence estimates. We performed a 
systematic review that included statistical pooling of the study results in an 
attempt to obtain accurate figures on the prevalence of cancer pain over the 
period 1966-2005. 
Methods 
A systematic literature search was performed using the following databases: 
Medline 1966-Sept 2005, Embase 1989- Sept 2005, Pubmed1975- Sept 2005, 
Cinahl 1982- Sept 2005, Cochrane Systematic reviews, Cochrane Central, the 
Cancer Library 2002. 
Our keywords comprised “pain” and “prevalence”, or “symptom” and 
“prevalence” in combination with each of the following terms: “cancer”, 
“neoplasm”, “terminal”, “end-stage”, “advanced”, “hospice” or “palliative” in the 
title, abstract or keywords. Reference lists of the retrieved articles were 
inspected manually to identify any papers that had been missed. 
Inclusion / exclusion criteria 
Studies were included if they reported on the prevalence, irrespectively of the 
type of prevalence used, of cancer pain in an adult cancer population and were 
written in the languages English or Dutch. Publications were excluded if they 
comprised case studies, letters, prevalence studies performed at pain clinics 
(institute bias), or had only selected patients with pain. 
 Prevalence of Pain in Patients with Cancer⏐23 
Study characteristics 
Subgroups 
A consistent finding in earlier reviews on cancer pain was that pain was more 
prevalent in the more advanced stages.23,24,34 In anticipation of this difference, 
we a priori subdivided the studies into four groups based on the disease 
characteristics described in the methods/results sections:  
1) studies that included patients after finishing curative treatment, 2) studies 
that included patients receiving anti-cancer treatment, with curative or palliative 
intention 3) studies that included patients with advanced, metastatic and/or with 
terminal disease and 4) studies that included all disease stages (1 to 3). 
Pain prevalence 
Data were documented on pain prevalence, pain severity, recall periods for 
pain (point prevalence, pain in the past week / month(s) / year) and the scale or 
instrument used to measure pain: VAS (Visual Analogue Scale), NRS 
(numerical rating scale), VRS (verbal rating scale), pain “yes”/”no”. When pain 
was reported as VAS scores or numeric scores, the rating of Serlin35 was used 
to convert severity into none (0), mild (1-4), moderate (5-6) or severe (≥7).  
General study characteristics 
General characteristics were recorded from each study: author(s), year of 
publication, aim of the study (prevalence or other), sample size, setting (in-
patient, out-patient, home, hospice or palliative care unit, referred to palliative 
care service), method of data collection (questionnaire patient or proxy, 
interview patient or proxy, medical record), type of prevalence (point, week, 
month, year), use of validated or non-validated instruments, distribution of 
gender, distribution of age and type of cancer (head and neck, gastro-intestinal, 
lung / bronchus, breast, urogenital, gynaecological, all types of cancer). 
Methodological quality and pooling of data  
In addition to documenting the general characteristics mentioned above, a 
more detailed analysis was conducted on the quality of the articles. The studies 
were evaluated using methodological criteria based on Leboeuf-Yde and 
Lauritsen36 (Table 2.1), which were the first to be especially constructed for 
prevalence studies. Walker37 improved the criteria by adding a criterion to 
identify proxy reporting and suggested that some weighting should be given to 
the different criteria. In our paper, the criteria specifically for lower back pain 
were substituted by an adequate description of the disease stage and/or 
condition of the cancer patients and a weighting factor was introduced for each 
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criterion (Table 2.1). This resulted in a quality score that ranged from 0 to 19 
points. The cut-off level for methodological acceptability was set at 14 points, 
which was 75% of the total points that could be achieved.36 All the studies were 
reviewed independently by two researchers (MvdB, MdR). Differences between 
interpretations were resolved using a discussion and consensus approach. The 
quality score was used to determine whether the data were suitable for 
inclusion in the meta-analysis. Only articles with a quality score of ≥14 were 
selected and subsequently divided into the four groups described above. To 
obtain pooled prevalence rates related to the type of cancer, a separate meta-
analysis was performed on the studies that reported pain prevalence in patients 
with specific types of cancer. We were able to identify 41 data-sets that 
reported on head and neck, gastro-intestinal, lung, breast, urogenital, or 
gynaecological cancer. In the meta-analysis, we used the reciprocal of the 
variance from individual studies as a weighting factor, which relates closely to 
sample size. This weighting factor was chosen to reflect the amount of 
information that each study contains.25 Then, the pooled prevalence was 
calculated for each group and the precision (95% confidence interval) and 
statistical significance of the overall estimate were determined. To investigate 
whether the variation in prevalence rates between the studies was more than 
could be attributed to chance alone, a test for homogeneity was carried out, 
which turned out to be statistically significant. The extra variation was 
incorporated into the analysis using a random effects model. Bivariate analyses 
were performed to explore whether the study period (before 1990, 1990-1999, 
2000 and later), location of the study (continent of origin), average age of the 
population (<65 years, ≥65 years), type of prevalence (point, week, month) and 
type of cancer were associated with the outcome. All the analyses were 
performed using STATA SE 8 (meta, metareg). 
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Table 2.1 Quality criteria for prevalence studies. 
A. The final sample should be 
representative of the target population 
1.  At least one of the following should apply for the 
study: an entire target population, randomly 
selected sample, or sample stated to represent the 
target population (2 points). 
 
2.  At least one of the following: reasons for non-
response described, non-responders described, 
comparison of responders and non-responders, or 
comparison of sample and target population (2 
points). 
 
3.  Response rate >90% (2 points). 
     Response rate 70-90% (1 point). 
     Response rate <70% (0 point). 
B. Quality of Data 4.  Were the data primary from a prevalence study (2 
points) or was it taken from a survey not specifically 
designed for that purpose (1 point)? 
 
5.  The same mode of data collection should be used 
for all subjects (2 points) if not (1 point). 
 
6.  The data have been collected directly from the 
patient by means of a validated 
questionnaire/interview  (3 points). 
 No validated questionnaire/interview (2 points). 
 Data have been collected from proxies or 
retrospectively from medical record (1 point). 
C. General description of the method and 
results should include: definitions of 
pain prevalence 
7.  Description of the target population and setting 
where patients were found (2 points). 
8.  Description of stage of disease, type of cancer, sex, 
age. All: 2 points, 2 or 3: 1 point. 
9.  Final sample size (1 point). 
10. Prevalence recall periods should be stated (1 
point). 
Results 
Selected articles 
Based on the keywords, we found 4737 articles. After removing double hits, the 
abstracts were screened for figures on the prevalence of cancer pain and the 
inclusion and exclusion criteria were applied. This left 356 articles, of which 
another 196 had to be excluded. Reasons for exclusion were: no study had 
been performed (n=36), no pain prevalence was mentioned (n=68), all the 
patients had pain (n=45), the pain prevalence was indistinguishable between 
cancer and non-cancer patients (n=21), a secondary analysis had been 
conducted on combined articles (n=3), the publication comprised an overview 
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article (n=14), the same population had been reported on twice (n=5), other 
(n=4).  
The quality score of 34% (n=54) of the remaining 160 articles was 14 points or 
more (Figure 2.1). A combination of shortcomings in representativeness and 
data collection method (the two criteria with the heaviest weighting) was the 
main reason for not reaching the required score of 14 points: response rate of 
less than 70%, response rate not mentioned, data retrieved from medical 
records prospectively, or retrospectively, lack of description of the non-
responders, sample not representative and/or data collected by proxy or from 
medical record. A more detailed description of the excluded articles is given in 
the appendix. All included studies were published in English. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Distribution of the methodological quality scores.  
 
General characteristics 
General characteristics of the 54 articles are listed in Table 2.2. In 46 studies, 
(part of) the aim of the study had been to determine the prevalence of pain in 
cancer patients. This had not been a primary goal in the other eight 
studies.11,13,38-44 One study looked at unmet needs, one described the 
experiences of a palliative care program, two compared usual care with 
intensive care, one was on the influence of demographic and disease specific 
variables on pain and one compared differences in symptoms between cancer 
and non-cancer patients. 
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Prevalence of pain 
A total of 54 articles reached the cut-off level of 14 points, but two articles45,46 
reported the prevalence of moderate to severe pain alone and were therefore 
excluded from the meta-analyses. 
The results of the stratified meta-analyses on the prevalence of pain, yes or no, 
in the 4 patient groups are presented in Figure 2.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 The prevalence of pain per disease groupa. 
 Forest plotsb indicating the number of studies included, the number of patients per 
study, the prevalence rate of pain per study and the overall prevalence found in the 
meta-analyses (diamond). 
a group 1 = patients after curative treatment, group 2 = patients during anti-cancer 
treatment, group 3 = patients with advanced, metastatic or terminal disease and group 
4 = all disease stages 
b The number of boxes indicates the number of studies included. The area of the 
boxes indicates the number of patients in this study. The diamonds at the bottom show 
the results of the meta-analyses with the 95% confidence intervals 
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In group 1, seven studies included patients after curative treatment (n=726), in 
group 2, seven studies included patients on anti-cancer treatment (n=1408), in 
group 3, 22 studies included patients with advanced, metastatic or terminal 
disease (n=9763) and in group 4, 16 studies included cancer patients with all 
stages (n=8088). The prevalence rates of pain were 33% (95% confidence 
interval (CI) 21-46%), 59% (CI 44-73%), 64% (CI 58-69%) and 53% (CI 43-
63%), respectively. 
 
Pooled prevalence of pain was significantly higher in groups 2, 3 and 4 than in 
group 1 (p=0.004, p<0.004, p=0.009), respectively. No significant differences 
were found between patients on treatment and patients with advanced or 
metastatic disease (p=0.51).  
Assessment of pain severity was described in 17 studies. None of the articles 
in group 1 (patients after curative treatment) mentioned the severity of pain. 
One study47 reported moderate to severe distress in 89% of the patients 
because of pain. 
In group 2, the severity of pain was measured in four studies: 36% of the 
patients (n=743) rated their pain as moderate to severe (VAS>4). In group 3, 
the severity of pain was measured in six studies and the pain was rated as 
moderate to severe by 45% of the patients (n=3405).  
In group 4, the severity of pain was described in seven studies: 31% (n=5441) 
of the patients rated their pain as moderate to severe. 
 
In the bivariate regression analyses, none of the covariates (type of cancer, 
period of publication, continent of origin, mean age of the study population, 
type of prevalence, use of validated or non-validated questionnaires or 
interviews) were significantly associated with the pain prevalence rates. 
Type of cancer 
A total of 36 data-sets (11 studies) were made of pain prevalence in six specific 
types of cancer (Table 2.3). Prevalence rates in groups 2-4 were pooled (3300 
patients). In all the cancer types, prevalence of pain was more than 50%; the 
highest prevalence was found in the head and neck cancer patients (70%). 
Bivariate regression analysis did not reveal any significant associations 
between the pain prevalence rate and type of cancer. 
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Table 2.3 Results of the meta-analyses: pooled pain prevalence in 6 types of cancer (cured 
patients were excluded). 
 Groups 2-4 
Type of cancer % pain (95% CI)a Nb no. of patients 
   Head/neck 70% (51-88) 3  95 
   Gastro-intestinal 59% (44-74) 9  564 
   Lung/bronchus 55% (44-67) 7  1546 
   Breast 54% (44-64) 7  420 
   Urogenital 52% (40-60) 4  336 
   Gynaecological 60% (50-71) 6  372 
a CI = confidence interval; b N = number of reports 
Discussion 
This systematic review on prevalence of pain in cancer patients was the first to 
pool only articles that met the quality criteria formulated specifically to review 
prevalence studies. 
A total of 54 articles met the predefined quality standards and the data from 52 
could be pooled. Pain prevalence in patients with cancer was high: 64% (CI 
58-69%) in patients with metastatic, advanced or terminal disease, 59% (CI 
44-73%) in patients on anti-cancer treatment and 33% (CI 21-46%) in patients 
who had been cured of cancer.  
Pain prevalence in patients with advanced/metastatic disease was lower (64%) 
than that previously reported.23,24,33,48 The higher prevalence rates (71-74%) 
found in earlier reviews23,24  were probably due to the inclusion of studies on 
data obtained by proxy. Ratings of pain control given by the family were 
significantly poorer than those given by the patients29,30: 75% of the care 
providers overestimated the patient’s pain intensity by an average of 35 mm 
(11-97 mm) on a 100 mm scale.31 
The prevalence of pain found in studies including patients with all stages was 
higher than previously reported.24 This result has to be interpreted with caution: 
There may have been too much difference in the condition of the patients 
included in these studies to allow pooling of the data. 
The prevalence of pain in patients during anti-cancer treatment and in patients 
after finishing curative anti-cancer treatment was not earlier published in a 
review. The prevalence of pain in patients during anti-cancer treatment (59%) 
was not significantly different from that in patients with advanced/metastatic 
disease (64%). It is likely that there was considerable overlap in the condition 
of the patients in these two groups, because only two studies 6,49 on anti-cancer 
treatment patients included patients on curative/radical treatment alone. The 
other studies included more patients who were on palliative treatment than on 
curative treatment, so patients with and without metastases were combined.  
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A total of eighteen studies reported, at least some, information about pain 
severity. More than one third of the patients with pain rated their pain as 
moderate to severe (VAS>4). Although distinction between the presence or 
absence of pain in a population will enable the calculation of pain prevalence, it 
cannot provide information about the severity, duration, frequency or amount of 
interference. To facilitate the comparison of studies and coordinate the 
planning of needs from pain services, multi-dimensional tools should be used in 
research. Most patients will accept mild pain, whereas moderate and severe 
pain will require attention.35 
In our meta analyses, the variation in prevalence rates between the studies 
was more than could be attributed to chance alone. The hypothesis was that 
factors like type of cancer studied, study period, continent of origin, mean age 
of the study population, type of prevalence or the use of validated or non-
validated questionnaires would be associated with the prevalence of cancer 
pain. No significant relationship was found between pain prevalence and type 
of cancer. However, we used fairly broad categories, due to the limited number 
of studies. For example, the gastro-intestinal cancer group included colon, 
oesophagus, and pancreas tumours, while the urogenital cancer group 
included prostate and bladder cancer. Although many books refer to 
malignancies with a high risk of pain (bone, pancreas, oesophagus) or a low 
risk of pain (lymphoma, leukaemia, soft tissue)50 51 it is not clear which studies 
provided  arguments for these statements. 
Contrary to our expectations, period of publication and/or continent of origin 
were not responsible for the heterogeneity. There has been growing attention 
to pain and pain management over the past fifty years and our knowledge is 
increasing. The gap between what is possible in pain control and what is 
achieved is caused by many different patient centred, care provider centred 
and government centred factors. Fear of medication in general and opioids in 
particular, patients wanting to be “good” patients, lack of knowledge, lack of 
interest and requests from care providers, are well-known barriers against 
adequate pain control.26,52-60  
Since 1984, the global consumption of morphine has more than tripled.61 
Although an increase in opioid consumption in cancer patients is considered to 
reflect an increased awareness towards pain treatment62, the effect on the 
prevalence of pain is yet unknown. Unfortunately, from this systematic review, 
it did not become clear either, whether the increased opioid consumption is 
associated with the prevalence of pain. Studies conducted in the ten countries 
responsible for 90% of the increase showed the same prevalence rates as 
studies from Africa and Asia where the availability of essential drugs for 
medical purposes is insufficient. However, the Asian studies were probably 
non-representative of the continent due to the adequate use of the WHO ladder 
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at the special palliative care units 63.  Only one study that was included in the 
meta analyses originated from Africa. 
Age is another study characteristic that might explain the heterogeneity. 
However, it is not necessarily associated with a larger number of symptoms in 
patients with cancer64 and the literature on  age and cancer pain is scarce and 
conflicting. In this review, no differences were found in prevalence of pain 
between elderly and younger patients. Less pain was reported by 903 cancer 
patients in the SUPPORT study65 on 3571 older subjects. The adjusted odds 
ratio for higher levels of pain was 0.85 per increasing decade of age. 
Compared to the age group 65-74 years in a retrospective study on 13625 
elderly cancer patients,66 the odds ratios in the age group 75-84 years and the 
age group ≥85 years were 0.68 and 0.52, respectively. In contrast, other 
studies found a relation between more advanced age and undermedication.26,66 
Type of prevalence (point, week or month) did not influence the prevalence of 
pain. The difference between a period prevalence and a point prevalence is the 
number of new cases that occur within the defined period.67 Although cancer 
pain can fluctuate in severity, it does not tend to disappear for a few weeks or 
even months, in contrast with headaches for example that occur more 
episodically. 
The use of validated or non-validated questionnaires or interviews did not 
appear to be responsible for the heterogeneity in prevalence rates. This implies 
that in daily practice, simply asking “the pain question” without the use of 
extensive and time-consuming questionnaires will detect any patients with pain. 
Symptom detection relies on three types of data collection method: 
documented, elicited and volunteered.68 All the studies included in our meta-
analyses used questionnaires or interviews. Pain questionnaires may amplify 
true morbidity due to over-endorsement bias, i.e. the tendency for patients to 
answer questions concerning symptoms written on a checklist in a particularly 
enthusiastic manner.68 Nevertheless the results of questionnaires are probably 
more reliable than those of documented symptoms, because 57-76% of 
medical oncologists do not ask about  pain.26 In addition, pain was only 
mentioned in 10% of the medical records kept by oncologists 26.  Therefore, 
reliance on data noted in medical records underestimates the prevalence and 
severity of pain. Also, volunteered symptoms will underestimate symptom 
prevalence, because of the patient barriers mentioned above. 
Other explanations for the heterogeneity could be differences in patient 
characteristics caused by variation in the selection processes between the 
studies, or the absence or ill-defined description of the pain severity or level 
that caused systematic discrepancies. Furthermore, differences in response 
rate might still have influenced the prevalence of pain. 
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Our systematic review had some flaws. It should be taken into consideration 
that the instrument used to judge methodological quality (Table 2.1) was 
devised subjectively to review the prevalence of lower back pain.36,37 The 75% 
threshold for acceptability was set arbitrarily.36,37 To make the instrument 
suitable to review the prevalence of cancer pain, we substituted the criteria for 
the definition of lower back pain for the criteria on disease stage in cancer. 
These may be points for further improvement. Proxy reporting and 
retrospective studies on medical records probably deserve even less weighting. 
The adequate description of disease stage probably deserves more weighting, 
but subdivision of the use of validated or non-validated questionnaires does not 
seem to be necessary. 
All included studies dealt with period prevalences and not with point 
prevalences. However, considering the long duration of the disease the 
difference of the two prevalence measures is small. Another limitation is that 
we did not know to what extent other pain conditions influenced the reported 
prevalence of pain. 
 
Future studies on the prevalence of pain in cancer patients should take 
representativeness, response rates and the description of non-responders into 
full consideration and provide information on the severity, duration, frequency 
and amount of interference. The use of multi-dimensional tools in research will 
facilitate the comparison of studies and the planning of needs from pain 
services.  
Studies on the prevalence of pain in cancer survivors are scarce. This topic 
should be addressed in future studies. 
Conclusion 
The pooled data from 52 articles showed that pain was prevalent in cancer 
patients: 64% in patients with metastatic or advanced stage disease, 59% in 
patients on anti-cancer treatment and 33% in patients after curative treatment. 
More than one third of the patients with pain in the reviewed articles graded 
their pain as moderate or severe. Despite the clear WHO recommendations, 
cancer pain still is a major problem. The increasing number of cancer survivors 
who live to an advanced age means that it is of paramount importance to 
reduce the prevalence of pain at all stages of the disease process. 
36⏐Chapter 2 
Appendix 
Reasons for not reaching the quality score of 14 points 
Response rate of less than 70%,14,105-114  
Response rate not mentioned,1,12,66,115-135  
Data retrieved from medical records prospectively,22,136-150   
Data retrieved from medical records retrospectively,2-5,15,114,151-173  
Lack of description of the non-responders,1-4,7,12,14,15,22,41,52,66,105-109,112,113,115-
129,132-149,151-192  
Sample not representative1,7,12,14,15,52,106,109-113,117,119,122,123,125,127,130,131,133-135,144-
146,148,151,153-155,158,165-168,171,175,177,179-182,184,188,189,192-194  
Data collected by proxy or from medical record.1-5,15,66,105,108,118,120,129,136,137,139-
142,145,147,148,151,152,154,155,157-168,171,172,174,178,185,187,191,194-197 
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Abstract 
Objective 
At present, no definite conclusions can be drawn about the real extent of the pain suffered by 
cancer patients.  
 
Methods  
A population-based study was conducted to obtain reliable information about the prevalence and 
severity of pain in cancer patients (all phases) and about predictors of pain. A representative 
sample of cancer patients was recruited in the area from a cancer registry. Pain was assessed by 
the Brief Pain Inventory (BPI). Adequacy of pain treatment was assessed with the Pain 
Management Index (PMI). 
 
Results 
We found that 55% of the 1429 respondents had experienced pain past week; in 44% (n=351), the 
pain was moderate to severe pain (BPI score ≥4).  
Total prevalence of pain / moderate to severe pain was present in 49% / 41% in patients with 
curative treatment ≥6 months ago, 57% / 43% in patients with current curative treatment or 
treatment <6 months ago, 56% / 43% in patients with current palliative anti-cancer treatment and in 
75% / 70% in patients for whom treatment was no longer feasible).  
Positive predictors of the prevalence of pain were lower education level, more advanced disease 
and haematological (excluding (non)-Hodgkin lymphoma), gastro-intestinal, lung, or breast 
malignancies. 
According to the PMI, analgesic treatment was inadequate in 42% of the patients. Negative 
predictors of adequate treatment were current curative anti-cancer treatment and low education 
level.  
 
Conclusion 
A substantial proportion of cancer patients does suffer from moderate to severe pain and does not 
receive adequate pain treatment. 
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Introduction 
By using a combination of appropriate dosage guidelines and the use of the 
WHO pain ladder,1 it should be possible to achieve adequate pain relief in 70-
90% of patients with cancer.2-7 Studies described in the literature give the 
impression that this level of pain relief is not being fulfilled. Early publications 
drew attention to high prevalence rates that ranged from 52 to 77%.8-12 More 
recent studies showed prevalence figures that ranged from 24-60% in patients 
on active anti-cancer treatment13-17 and 62-86% in patients with advanced 
cancer.18-23 These data illustrate that the problem of cancer pain has not yet 
been solved. A systematic review24 performed by our research group revealed 
methodological flaws in many prevalence studies. Only 54 out of 160 (33%) 
cancer pain prevalence studies appeared to be of acceptable quality for further 
analysis. Based on pooled data, prevalence rates of cancer pain were high: 
54% in all disease phases combined, 60% in patients with metastatic or 
advanced disease and 58% in patients under anti-cancer treatment. Few data 
were available on the severity of the pain in different phases of cancer they 
were mostly inconclusive.13,18,19,25-39 The same applied to the relation between 
the prevalence of cancer pain and the type of cancer,13,16,28,29,36,40-42 phase of 
disease,43-46 age,47,48 gender,49 marital status and education level. More studies 
with well-designed methodology are needed to gain greater insight into the real 
extent of the pain suffered by cancer patients. 
To make reliable estimations of the prevalence and severity of pain in cancer 
patients and to map predictors of cancer pain, a population-based study was 
conducted on a large group of patients that included all disease phases. 
Methods 
Patients 
Over a 5 month period between November 2004 and June 2005, cancer 
patients were recruited at 4 general hospitals, one university hospital, one clinic 
for radiotherapy, 11 nursing home organisations, 5 hospices and by a large 
number of general practitioners (GPs), in the area of a comprehensive cancer 
centre (Comprehensive Cancer Centre Limburg),  in the Netherlands. Patients 
were eligible if they 1. had been diagnosed with cancer, 2. had been informed 
of their diagnosis, 3. were 18 years or older, 4. able to understand and 
complete the questionnaire and 5. agreed to participate in the study. 
 
A consistent finding in reviews on cancer pain was that the prevalence of pain 
was higher in the patients with more advanced disease.24,43,44,50 Therefore, we 
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subdivided the patients into four categories: group 1a. patients who had been 
treated with curative intent, last treatment more than six months ago, group 1b. 
patients receiving anti-cancer treatment with curative intent or last treatment 
less than six months ago, group 2. patients who were receiving palliative anti-
cancer treatment and group 3. patients for whom anti-cancer treatment was not 
or no longer feasible. These categories are indicated as disease group 1a, 
disease group 1b etc. 
Measurements 
A self-report patient questionnaire and a medical data form filled in by the 
treating physician were developed for this study to obtain the following sets of 
measurements: 
Demographic data: gender, age, marital status (cohabiting, widow(er), 
divorced, single) and education level: low (none or primary education), middle 
(lower and higher general secondary education and intermediate vocational 
education and high (pre-university education, higher vocational education, 
university). 
Medical data: cancer type, disease group and date of last treatment (medical 
form) and information about medication received (patient questionnaire). 
Pain was measured by the pain questions from the EORTC-C3051 (verbal 
rating scale) and by four questions (pain now and pain over the past week: 
least, worst and average) derived from the Brief Pain Inventory (BPI).52 Scores 
could be given on an 11-point Likert scale that ranged from 0 (no pain) to 10 
(worst pain ever). The BPI has a high internal consistency with coefficient 
alphas that ranged from .78 to .97 in various cancer population samples in 
different countries.39,53-61   
Adequacy of pain treatment was measured by Ward’s variation(62) of the Pain 
Management Index (PMI),26 which is based on the patient’s worst level of pain, 
categorized as 0 (no pain), 1 (VAS 1-3) mild pain, 2 (VAS 4-7) moderate pain, 
or 3 (VAS 8-10) severe pain. The pain level is then subtracted from the most 
potent level of analgesic treatment received by the patient, scored as 0 (no 
analgesic dug), 1 (non-opioids), 2 (weak opioids), or 3 (strong opioids). Scores 
can range from –3 (a patient had not received analgesic drugs, but had severe 
pain) to +3 (a patient had received strong opioids and did not have pain). 
These scores are then dichotomised: negative scores indicate the inadequate 
prescription of analgesic drugs, whereas scores of 0 or higher are considered 
to indicate acceptable pain treatment. 
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Procedure 
At the outpatient clinics of the medical institutes, the treating physician filled out 
the medical data form on all the consecutive patients with cancer over a period 
of 10 days and gave them a flyer that explained the goals of this study.  
The day after the visit to the outpatient clinic, each patient was sent the self-
report questionnaire, an patient information brochure and an informed consent 
form at their home address. Patients were asked to return the questionnaire 
even if they did not wish to participate. 
To identify patients for disease group 3 all the GPs in the region were informed 
about the study and invited to recruit suitable patients. Every four weeks, they 
were contacted by telephone. The GPs informed eligible patients about the 
study and gave them the necessary papers. At the nursing homes and 
hospices, a physician and/or nurse were asked to recruit patients for disease 
group 3, to inform them about the study and give them the necessary papers. 
GPs and nursing home doctors filled in separate medical forms. 
Statistics 
Descriptive statistics were obtained with SPSS version 12.0. All the regression 
analyses were performed using STATA SE 8. 
Outcome variables were the presence of moderate to severe pain (yes/no) and 
inadequate use of analgesia according to the PMI (yes/no). The results of the 
BPI were used for the pain analyses. Pain was considered mild with the BPI 
score 1-3, moderate with score 4-6 and severe with score 7-10. Logistic 
regression analyses were used to identify factors associated with the 
dichotomous outcome variables. In a stepwise regression model, the 
contribution of the following variables was examined: age, gender, marital 
status (living alone vs not living alone), education (low, middle, high (reference 
group), cancer type (prostate cancer as reference category) and disease group 
with p<0.10 as the criterion to add a variable.  
To account for selection bias namely the underrepresentation of patients aged 
80 years or older, all regression analyses were performed using the sampling 
weight option with weight equal to the inverse of the probability to be included 
in the study. 
 
The study was approved by the Medical Ethics Committee of the University 
Hospital Maastricht, by the local ethics committees of the hospitals and by the 
group that coordinates studies involving general practitioners (CEL).  
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Results 
In the out-patient settings, 1782 questionnaires were given to eligible patients 
and 1348 were returned correctly filled in (response 76%). Only 81 
questionnaires were offered to patients by the 87 participating GPs (out of 
417), 5 hospices and 12 nursing home organisations. All the patients returned 
the questionnaire; a total of 1429 could be analysed. 
Patient characteristics are listed in Table 3.1. Most patients were between 60 
and 80 years of age, married and living at home. The sample was 
representative for tumour types according to the cancer registration of the 
comprehensive cancer centres in the Netherlands.63   
No significant differences in the distribution of gender, cancer types or disease 
group were found between the participants (n=1429) and non-participants 
(n=434) (Table 3.1). However, there was significant overrepresentation of 
patients aged ≥80 years among the non-participants. To account for this 
potential selection bias, weighting was used in all the analyses.  
The informed consent form was not returned by 64% (n=276) of the non-
participants. No reason for refusal was given by 59 of the 158 non-participants 
who returned the informed consent form. Reasons for non-participation in the 
remaining 99 patients were: too ill or too tired (6%), no longer have cancer 
(4%), no pain (2%), too blind/deaf/old or demented (2%), deceased (2%), co-
morbidity (1%), psychological problems (1%) and miscellaneous(4%).  
In the total study population, 55% of the patients had pain. In 44% (n=351) pain 
moderate to severe (VAS≥4). Pain percentages and confidence intervals per 
disease group are shown in Figure 3.1. In group 1a (n=388), 49% of the 
patients were suffering from pain (n=190), of whom 41% (n=78) had moderate 
to severe pain. In group 1b (n=385), 57% were suffering from pain (n=218), of 
whom 43% (n=94) had moderate to severe pain. In group 2 (n=575), 56% 
experienced pain (n=320), of whom 43% (n=136) had moderate to severe pain. 
In group 3 (n=81), 75% were suffering from pain (n=61), of whom 70% (n=43) 
had moderate to severe pain. 
No striking differences were found in the prevalence of average pain in the past 
week and the different cancer types (Figure 3.2). 
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Table 3.1 Demographic characteristics. 
 Participants 
n (%) 
Gender Men 
   Women 
   Missing  
 686 (48) 
 743 (52) 
Age groups (years) 20-40 
   40-60 
   60-80 
   ≥80 
 55 (4) 
 475 (33) 
 800 (56) 
 99 (7) 
Marital status Cohabiting 
   Widow(er) 
   Divorced 
   Single 
   Missing  
 1059 (74) 
 179 (13) 
 76 (5) 
 94 (7) 
 21 (1) 
Education Primary school           
   Secondary school     
   College/university 
 812 (57) 
 360 (25) 
 257 (18) 
Residence Home (not alone) 
   Home (alone) 
   Nursing home 
   Hospice 
   Hospital 
   Other 
 1082 (76) 
 278 (20) 
 19 (1) 
 23 (1) 
 1 (0) 
 26 (2) 
Type of cancer Head and neck 
   Gastrointestinal 
   Lung 
   Breast 
   Prostate 
   Urogenital other 
   Gynaecological 
   (Non)Hodgkin 
   Haematological other 
   Other 
 65 (4) 
 222 (15) 
 141 (10) 
 367 (26) 
 203 (14) 
 103 (7) 
 109 (8) 
 64 (4) 
 89 (6) 
 66 (6) 
Disease groupa Group 1a 
   Group 1b 
   Group 2 
   Group 3 
 
 388 (27) 
 385 (27) 
 575 (40) 
 81 (6) 
Total  1429 (100) 
a 1a=patients who received anti-cancer treatment with curative intent ≥6 months ago, 1b= patients 
receiving anti-cancer treatment with curative intent or last treatment less than 6 months ago, 
2=patients receiving palliative anti-cancer treatment and group 3=treatment not or no longer 
feasible. 
 
Logistic regression analysis revealed that gender, age and marital status were 
not found to be significant predictors of the prevalence of pain, whereas the 
status of “treatment not feasible” held a significantly greater risk (odds ratio 
(OR) 3.3, 95% confidence interval (CI) 1.9-5.6) than the status of “current 
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palliative anti-cancer treatment” (Table 3.2). In addition, a low (OR 2.0, CI 1.4-
2.8) or middle education level (OR 1.7, CI 1.2-2.3) held a significantly higher 
risk than a high education level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Prevalence of pain in patients with cancer per disease groupa. 
 a 1a= patients who received anti-cancer treatment with curative intent ≥6 months ago, 
1b= patients receiving anti-cancer treatment with curative intent or last treatment less 
than 6 months ago, 2= patients receiving palliative anti-cancer treatment and group 3= 
treatment not or no longer feasible 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Prevalence of pain in patients with cancer by typea. 
 a gyn = gynaecological, prost = prostate, uro = other urogenital, H/N = head and neck, 
GE = gastro-intestinal, haemato = other haematological, (N)HL = m. Hodgkin and non-
Hodgkin. 
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The risk of moderate to severe pain was significantly higher in patients with 
gastro-intestinal (OR 1.5, CI 0.9-2.5), lung (OR 1.7, CI 1.0-2.9), breast (OR 1.6, 
CI 1.0-2.5), other haematological malignancies, including 27% multiple 
myeloma (OR 3.0, CI 1.7-5.4), or “other” malignancies, including 8% two 
different tumours, 18% central nervous system and 23% melanomas (OR 2.5, 
CI 1.3-4.9) than in patients with prostate cancer (Table 3.2). 
 
Table 3.2 Significant predictors of the prevalence of moderate to severe pain in patients with 
cancer a. 
 Nb Odds ratio Confidence interval p-valuec 
Education level 
  Low 
  Middle 
  High 
 
812 
360 
257 
 
1.97 
1.66 
1.00 (reference) 
 
1.38-2.82 
1.21-2.28 
 
<0.001 
  0.002 
Disease groupd 
  1a 
  1b 
  2 
  3 
 
388 
385 
575 
  81 
 
0.84 
1.13 
1.00 (reference) 
3.28 
 
0.60-1.16 
0.82-1.55 
 
1.93-5.56 
 
  0.291 
  0.459 
 
<0.001 
Cancer type 
  head and neck 
  gastro-intestinal 
  lung 
  breast 
  prostate 
  other urogenital 
  gynaecological 
  (non)-Hodgkin 
  other haematological 
  other 
 
  65 
222 
141 
367 
203 
103 
109 
  64 
  89 
  66 
 
1.61 
1.53 
1.71 
1.57 
1.00 (reference) 
1.38 
1.63 
1.16 
3.01 
2.53 
 
0.80-3.24 
0.94-2.47 
0.98-2.97 
1.01-2.46 
 
0.75-2.54 
0.90-2.93 
0.55-2.43 
1.69-5.38 
1.31-4.89 
 
0.183 
0.085 
0.057 
0.046 
 
0.304 
0.106 
0.693 
0.001 
0.006 
a age and gender appeared not to be significant factors; b N=number of patients; c p-value was 
considered significant at p≤0.10; d 1a= patients who received anti-cancer treatment with curative 
intent ≥6 months ago, 1b= patients receiving anti-cancer treatment with curative intent or last 
treatment less than 6 months ago, 2= patients receiving palliative anti-cancer treatment and group 
3= treatment not or no longer feasible.   
 
 
According to the pain management index (PMI), the treatment of pain was 
insufficient in 42% of the 1383 patients (Table 3.3). Less than 30% of the 
patients used medication belonging to the WHO 3-step pain ladder: 15% 
(n=202) used step 1 medication (paracetamol and/or NSAID’s), 6% (n=78) 
used step 2 medication (weak opioids) and 7% (n=95) used step 3 medication 
(strong opioids). Adjuvant pain medication (tricyclic antidepressants, anti-
epileptics, N-Methyl-D-Aspartate antagonists) was being used by 7% (n=95) of 
the patients (Table 3.3). In many cases, pain medication was not being used 
according to the WHO guidelines: 42% of the patients using a weak opioid 
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were not on step 1 medication, while this applied to 53% of the patients using 
strong opioids. Seven patients who were using strong opioids were also on 
weak opioids.  
 
Table 3.3 Management in patients with cancer by disease groupa. 
 1a (n=374) 
n (%) 
1b (n=375) 
n (%) 
2 (n=559) 
n (%) 
3 (n=75) 
n (%) 
Total (n=1383) 
n (%) 
PMI2 
  Insufficient  
 
154 (41) 
 
183 (48) 
 
226 (40) 
 
18 (24) 
 
581 (42) 
      
Medicationb 
  WHO 1  
  WHO 2  
  WHO 3  
  Co-analgesics 
 
48 (13) 
9 (  2) 
9 (  2) 
19 (  5) 
 
42 (11) 
16 (  4) 
11 (  3) 
23 (  6) 
 
79 (14) 
39 (  7) 
41 (  7) 
35 (  6) 
 
33 (44) 
14 (19) 
34 (45) 
18 (24) 
 
202 (15) 
78 (  6) 
95 (  7) 
95 (  7) 
a 1a= patients who received anti-cancer treatment with curative intent ≥6 months ago, 1b= patients 
receiving anti-cancer treatment with curative intent or last treatment less than 6 months ago, 2= 
patients receiving palliative anti-cancer treatment and group 3= treatment not or no longer feasible; 
Pain Management Index insufficient meant a negative score on the PMI; b WHO 1, 2, 3 = World 
Health Organisation 3-step analgesic ladder 1, 2 and 3, co-analgesics included are tricyclic anti-
depressants, anti-epileptics and NMDA-receptor antagonists. 
 
Current curative anti-cancer treatment (OR 1.3, CI 1.0-1.7) and a low education 
level (OR 1.5, CI 1.1-2.0) were negative predictors (Figure 3.3) of adequate 
pain treatment. Advanced age (OR 0.8, CI 0.6-0.9) and more advanced 
disease (OR 0.5, CI 0.27-0.82) were positive predictors of adequate pain 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Predictors of under-treatment of pain in patients with cancer1 (Odds ratios and 
confidence intervals). 1 gender and cancer localisation were not significant factors; 2 
disease group 2 as reference; 3 high education level as reference. 
1
Age > 65 yrs.
Disease Group 1a2
Disease Group 1b
Disease Group 3
Education Low3
Education Middle
10.77 2.00
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Discussion 
A high prevalence of pain (55%) was found in our total study population of 
1429 cancer patients; 44% had moderate to severe pain.  
In group 1a, 20% of the patients were suffering from moderate to severe pain, 
which was an even higher percentage than that reported in patients with 
chronic postoperative pain (5-10%),65 osteoarthritis of the knee (10-14%)66 or 
back pain (18-32%).67 
Moderate to severe pain was reported by 22% and 23% of the patients 
currently under anti-cancer treatment, respectively curative or palliative. Earlier 
studies reported prevalences of between 23 and 63%.13,17,27,68  
In the patients for whom treatment was not feasible, 75% had pain. In a recent 
systematic review69 of symptom prevalence in 37 studies on patients with 
incurable cancer, the pooled prevalence rate of pain was 71% in 21917 
patients. In our population, 53% reported moderate to severe pain. Other 
studies found 20–65% with moderate to severe pain.18,19,26,30,33-35 
 
In the literature, little information is available about predictors of the prevalence 
of cancer pain. In our study, a low or middle education level held a significantly 
higher risk of pain than a high education level (OR 2.0 and 1.6 respectively). 
One study31 found a higher (non-significant) prevalence of pain in cancer 
patients with basic schooling than in patients with high education levels. 
Studies on chronic pain in the general population reported that persons with 
low education had more pain complaints (occurrence and intensity); the 
difference was highly significant.70-73 Explanations might be less involvement of 
these patients in treatment issues74 and increased financial strain.70 Another 
prominent predictor of moderate to severe pain was the disease group (phase), 
which was in accordance with the consistent finding in reviews on the 
prevalence of cancer pain.43,44,50,75    
Although textbooks associate particular malignancies with a high risk of pain 
(bone, pancreas, oesophagus) or a low risk (lymphoma, leukaemia, soft 
tissue),76,77 it is not clear what evidence these statements are based on. 
Previously,75 we did not find any significant relationships between pain 
prevalence and tumour type. A recent study on a cohort of end-stage cancer 
patients78 concluded that cancer pain was not restricted to specific sites. 
Reyes-Gibby et al studied patients under anti-cancer treatment and found high 
prevalences of moderate to severe pain in patients with head and neck, gastro-
intestinal and breast malignancies.17 Nevertheless, type of cancer did not prove 
to be a predictor, although our patients with gastro-intestinal, lung, breast, other 
haematological and “other” malignancies had a significantly higher risk of 
moderate to severe pain than the prostate cancer patients. This was 
remarkable, because 46% of our prostate cancer patients were in the palliative 
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groups 2 and 3. Our linear regression analyses showed that head and neck 
cancer held a fairly high risk of mild pain.  
The focus of attention should lie on providing relief to patients with moderate to 
severe pain. Subdivision of pain severity into mild, moderate or severe is 
arbitrary. Especially the NRS scores 4 (mild17,32,39,53,59,79-82 or moderate13,18,83-86) 
and 7 (moderate18,82,84,86 or severe13,17,25,32,39,53,59,79,82,83,85,87) give rise to 
discussion. In our study, the brief pain inventory pain and  the EORTC quality 
of life questionnaire were used to measure pain. Therefore we were able to 
examine how our patients interpreted their pain: more of the patients 
considered a score of 4 to represent moderate pain than mild pain, while 
slightly more patients considered a score of 7 to represent severe pain rather 
than moderate pain.  
 
On the pain management index (PMI), 42% of our patients had negative 
scores, which indicated inadequate analgesic treatment. Previous studies 
reported negative PMI-scores in 30-82% of the patients.19,55,59,61,62,84,88-93 
Although the PMI is widely used to determine the adequacy of pain 
management, it does not take into account adequate dosage and the use of co-
analgesics.94 This probably explains why patients with metastatic disease (who 
make greater use of strong opioids) have the highest pain scores despite their 
encouraging PMI rates.94,95  
Patients on curative anti-cancer treatment had a significantly higher risk of not 
being treated adequately for their pain than patients on palliative anti-cancer 
treatment. This is in agreement with earlier reports in which patients with better 
performance status17,91,96 or without metastases91 were at risk of having 
negative PMI scores. This suggests that cancer patients experience the well-
known barriers against adequate pain relief, such as fear of medication in 
general and opioids in particular and fear of starting opioids too early so no 
treatment will be available when the disease progresses.62,97-101 
Our results showed that patients with low education levels were at greater risk 
of receiving inadequate pain treatment than patients with high education levels. 
Possible explanations are that people with lower education communicate less 
effectively with their care providers about their pain, or are more afraid of 
opioids than people with higher education levels. This should be investigated in 
further studies. In contrast with our finding that older age protected against 
undertreatment of pain, earlier reports did not find any age differences in 
treatment86,92 or poorer PMI scores in elderly patients.26,90 Gender did not 
appear to be a predictor of PMI scores. This was in agreement with two recent 
studies,90,92 whereas Cleeland reported poorer scores in women.96  
 
There were some limitations in this study. Despite the proper format and effort 
made to encourage GPs, nursing home physicians and nursing staff at the 
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hospices to recruit patients with advanced disease, the number of patients was 
small. Therefore, this group may not have been representative of all patients 
with metastatic/advanced disease. Selection by GPs, nursing home physicians 
and nursing staff at the hospices could have excluded patients in the most 
terminal phase of illness. It is not clear how this selection influenced the 
prevalence of pain. Several studies showed that the prevalence of pain 
decreased at the very end of life,40,102-104 which would mean that we slightly 
overestimated the prevalence of pain in group 3. However, some studies 
showed an increase in the prevalence of pain at that phase.78,105  
The fairly broad categories of cancer types make it difficult to translate pain risk 
to the individual patients. 
It was not possible to make more detailed subdivisions into specific types (e.g. 
pancreas, stomach, oesophagus, etc. instead of gastrointestinal), because of 
the limited numbers in each group. 
Conclusion 
The number of people who have106 cancer is growing due to early detection 
and progress in anti-cancer treatment.107 In 2005, the 20-year prevalence of 
cancer in the Netherlands was estimated to be over 450,000 persons (2.8%) 
and is expected to reach 692000 in 2015.107  
Our pain prevalence rate of 55% was far too high. The prevalence of moderate 
to severe pain in patients treated with curative intent was as high as that of 
back pain. A quarter of the patients under anti-cancer treatment and more than 
half of the patients with advanced/terminal disease were suffering from 
moderate to severe pain. Pain management was insufficient in almost half of 
the patients in this study. This illustrates the need for better education about 
pain and pain control in the curricula of medical professionals. Systematic 
recording of pain intensity in cancer patients, irrespective of the phase of 
disease, is mandatory. 
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Abstract 
Objective 
To measure the prevalence of non-pain physical symptoms and psychological symptoms in 
patients with cancer, to investigate the impact of physical and psychological symptoms on their 
quality of life and to enquire whether treatment had been received for the complaints/symptoms . 
 
Methods 
A representative sample of 1429 cancer patients were recruited and classified according to their 
treatment status (1a. curative treatment > 6 months ago, 1b. curative treatment ≤6 months ago, 2. 
palliative treatment and 3. treatment no longer feasible) and tumour type. Quality of life and non-
pain symptoms were measured by the EORTC-C30 version 3. We added two items: 1. did you 
have a dry mouth? and 2. did you feel listless? We also asked whether the patients had received 
treatment for their symptoms. Depression and anxiety were measured by the Dutch version of the 
Hospital Anxiety and Depression Scale (HADS). Oneway Anova was used to detect differences in 
global quality of life between patients with different types of cancer. When Anova was significant, 
post-hoc tests (Tukey hsd) were performed to identify significant differences between cancer types. 
Linear regression analyses (forced entrance procedure) were performed (STATA SE 8) to 
investigate the influence of physical and psychological symptoms on global quality of life. 
 
Results 
The prevalence of moderate to severe symptoms increased significantly with each disease group. 
Vomiting and irritability were the least prevalent symptoms, fatigue and worries were the most 
prevalent symptoms in all groups. Patients in group 1 (curative treatment) experienced symptoms 
that were independent of cancer type. Patients in group 2 (palliative treatment) experienced 
symptoms that varied with cancer type. Quality of life decreased significantly each step from group 
1 through 3. Fatigue, appetite loss, constipation, dry mouth, depression and anxiety had 
independent negative influences on quality of life. Patients with gastro-intestinal cancer, malignant 
lymphoma and other haematological malignancies had significantly poorer quality of life than 
patients with prostate cancer. In 45–90% of patients, symptoms remained untreated. 
 
Conclusion 
Non-pain physical symptoms and psychological symptoms are frequent in patients with cancer at 
all disease phases. Many symptoms remain untreated. Systematic recording of symptom intensity 
is mandatory, irrespective of the phase of disease. 
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Introduction 
Due to early detection and progress in anti-cancer treatment the number of 
people who have cancer is growing.1 In 2005, the 20-year prevalence of cancer 
in the Netherlands was estimated to be over 450,000 persons (2.8%) and it is 
expected to increase to 692,000 in 2015.1  
Many patients with cancer have multiple symptoms that affect their feeling of 
well-being and their physical and social functioning. Several investigations 
showed that multiple symptoms were associated with poorer patient 
outcome.2-11 The prevalence of pain in patients with cancer has been studied 
extensively and recently reviewed.12 In contrast, non-pain physical symptoms 
have received far less attention and have mainly  been assessed in patients 
with advanced or metastatic disease.13-18 A recent systematic review on 
symptom prevalence in patients with incurable cancer19 has identified 37 
symptoms. Each symptom had a prevalence of >10%. More than 50% of the 
patients reported five specific symptoms (fatigue, pain, lack of energy, 
weakness and loss of appetite). It was concluded that to improve individually-
tailored treatment, more studies are needed based on symptom intensity, 
symptom burden and impact on quality of life.19 
Very few studies have been performed on non-pain symptoms in outpatients 
and long-term cancer survivors. Their main focus was on one symptom in 
relation with a specific cancer type (e.g. breathlessness in patients with lung 
cancer,20 fatigue in breast cancer survivors21 or vertigo in nasopharyngeal 
carcinoma survivors).22 
 
Cancer-related psychological distress occurs in one third of patients,23 while 
major depressive disorders are estimated to occur in 10-25%.23 Most authors 
consider the criteria over-inclusive and prefer to focus on “depressive 
symptoms”. In three systematic reviews, 7-58%24,25 of patients with cancer 
have depressive symptoms; in the case of solid tumours the range is 20-50%.26 
Anxiety disorders are found in 15-28%.27 These percentages are based on 
measurements taken at around the time of diagnosis. Very little research has 
addressed the prevalence of depressive disorders over the course of many 
years after diagnosis. Psychiatric morbidity and other psychological symptoms 
have been well-documented in breast cancer patients, but there has been less 
focus on other types.28-30  
 
The aims of this study on cancer patients were 1. to measure the prevalence of 
non-pain symptoms (classified according to treatment status and tumour type) 
in order to find whether treating physicians should be extra alert on a particular 
symptom in a particular type of cancer or treatment phase, 2. to determine the 
quality of life of patients with cancer in different cancer types and treatment 
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phases and to investigate the impact of physical and psychological symptoms 
on quality of life and 3. to enquire whether the patients had received treatment 
for their complaints/symptoms.  
Methods 
Patients 
Between November 2004 and June 2005, a representative sample of cancer 
patients were recruited at 4 general hospitals, one university hospital, one clinic 
for radiotherapy, 11 nursing home organisations, 5 hospices and by a large 
number of general practitioners (GPs) in the province Limburg, the 
Netherlands. Patients were eligible to participate in the study if they 1. had 
been diagnosed with cancer, 2. had been informed about their diagnosis, 3. 
were 18 years or older, 4. were able to understand and complete the 
questionnaire and 5. gave informed consent. 
 
The treating physicians were asked to classify the patients into four disease 
groups according to their treatment status: 1a. curative treatment >6 months 
ago, 1b. current (or ≤6 months ago) curative treatment, 2. palliative anti-tumour 
treatment and 3. treatment no longer feasible.31 
Measurements 
A patient self-report questionnaire and a medical data form (to be filled in by 
the treating physician) were developed to obtain the following sets of 
measurements: 
Demographic data: gender, age, marital status (cohabiting, widow(er), 
divorced, single) and education level (low, middle, high). 
Medical data: cancer type, disease group and date of last treatment (medical 
form) and information about symptom management received (patient 
questionnaire). 
Quality of life and non-pain symptoms were measured using the EORTC-C30 
version 3.32 The EORTC-C30 is 1. cancer-specific, 2. multidimensional, 3. 
suitable for self-administration and 4. applicable across a range of cultural 
settings. It has five functional scales, three symptom scales, a global 
health/quality of life scale and six single items. We added two items: 1. did you 
have a dry mouth? and 2. did you feel listless? We also asked whether the 
patients had received treatment for their symptoms.  
Depression and anxiety were measured using the Dutch version of the Hospital 
Anxiety and Depression Scale (HADS).33 The HADS showed good 
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performance to assess symptom severity and caseness of anxiety disorders 
(Cronbach’s α: .68 - .93) and depression (Cronbach’s α: .67 - .90) in somatic, 
psychiatric and primary care patients, with a sensitivity and specificity of 
approximately 0.80.34 Patients are grouped according to their depression and 
anxiety subscale scores 0-7 non-cases, 8-10 borderline and 11-21 definite.33 
Data collection 
At all the outpatient clinics, the treating physician filled out the medical data 
form on all the consecutive cancer patients over a period of ten days and gave 
them a flyer that explained the goals of this study.  
The day after the visit to the outpatient clinic, each patient was sent the self-
report questionnaire, a patient information brochure and an informed consent 
form at their home address. Patients were asked to return the questionnaire 
even if they did not wish to participate. 
To identify patients for disease group 3, all the GPs in the region were informed 
about the study and invited to recruit suitable patients. Every four weeks, 
research assistants contacted the GPs by telephone. The GPs informed 
eligible patients about the study and gave them the necessary papers. At the 
nursing homes and hospices, a physician and/or nurse were asked to recruit 
patients for disease group 3, to inform them about the study and give them the 
necessary papers. GPs and nursing home doctors filled in separate medical 
forms. 
Statistics 
Descriptive statistics were obtained with SPSS version 12.0. Chi-square tests 
were used to reveal significant differences in the prevalence of moderate to 
severe symptoms between the patients with different types of cancer.  
Oneway Anova was used to detect differences in global quality of life between 
patients with different types of cancer. When Anova was significant, post-hoc 
tests (Tukey hsd)35 were performed to identify significant differences between 
cancer types. 
To obtain a clear view of the influence of different variables on global quality of 
health, two linear regressions models were built. In the first model, only 
demographic variables and disease-specific variables were entered, using a 
forced entrance procedure. In the second model, all the physical and 
psychological variables were entered, adjusted for age and sex,  also using a 
forced entrance procedure. These linear regression analyses were performed 
with STATA SE 8. To account for selection bias, namely the under-
representation of patients aged 80 years or older, the regression analyses were 
performed using the sampling weight option, i.e. weight was equal to the 
inverse of the probability. 
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The study was approved by the Medical Ethics Committee of the University 
Hospital Maastricht, by the local ethics committees of the hospitals and by the 
group that coordinates studies involving general practitioners. All the 
participants gave informed consent. 
Results 
In the outpatient settings, 1782 questionnaires were sent to eligible patients 
and 1348 were returned correctly filled in (response 76%). Only 81 
questionnaires were offered to patients by the 87 participating GPs (out of 
417), five hospices and twelve nursing home organisations; all the patients 
returned the questionnaire. A total of 1429 could be analysed. 
Most patients were between 60 and 80 years of age, married and living at 
home. The sample was representative for tumour types according to the cancer 
registration of the comprehensive cancer centres in the Netherlands.36 Detailed 
patient characteristics can be found in our earlier report on the prevalence of 
pain.31  
No significant differences in the distribution of gender, cancer type or disease 
group were found between the participants (n=1429) and non-participants 
(n=434). However, there was significant overrepresentation of patients aged 
≥80 years among the non-participants.  
The informed consent form was not returned by 64% (n=276) of the non-
participants. No reason for refusal was given by 59 of the 158 non-participants 
who returned the informed consent form. Reasons for non-participation in the 
remaining 99 patients were: too ill or too tired (6%), no longer have cancer 
(4%), no pain (2%), too blind/deaf/old or demented (2%), deceased (2%), co-
morbidity (1%), psychological problems (1%) and miscellaneous (4%).  
Prevalence of moderate to severe non-pain physical symptoms 
per disease group 
The prevalence of moderate to severe physical symptoms (EORTC score of 3 
or 4) differed significantly between the four disease groups. Except for 
diarrhoea, all the prevalences increased with increasing group number (Figure 
4.1a). Vomiting was the least prevalent physical symptom in all four groups. In 
groups 1a (curative treatment >6 months ago), 1b (current curative treatment), 
2 (palliative treatment) and 3 (treatment no longer feasible) the percentages 
were 1%, 3%, 6% and 10%, respectively. Moderate to severe physical 
complaints of feeling weak, feeling tired and need to rest had the highest 
prevalences  in all four groups. Percentages varied from 16%, 28% and 24% in 
group 1a to 65%, 69% and 74% in group 3. 
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Figure 4.1a Prevalence of moderate to severe physical non-pain symptoms in patients with cancer 
per disease Group. 
*EORTC reference values46 no reference values were found for listlessness and dry 
mouth. 
Prevalence of moderate to severe psychological symptoms per 
disease group 
The prevalence of moderate to severe psychological symptoms (EORTC score 
3 or 4) differed significantly between the disease groups and increased with 
increasing group number, except for irritability (Figure 4.1b). Irritability was the 
least prevalent psychological symptom in all four groups. In groups 1a, 1b, 2 
and 3, the percentages were 15%, 17%, 22% and 18%, respectively. Moderate 
to severe worries had the highest prevalence in all four groups, with 
percentages of 20%, 28%, 38% and 55%, respectively. 
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Figure 4.1b Prevalence of moderate to severe psychological symptoms in patients with cancer per 
disease group. 
 *EORTC reference values: irritable, difficulties remembering, tense, difficulties 
concentrating and worries.46 HADS reference values: depression, anxiety.113 
 
Prevalence of moderate to severe non-pain physical and 
psychological symptoms per cancer type 
Tables 4.1a, b and c show the prevalences of moderate to severe symptoms in 
different types of cancer per disease group. Group 3 contained too few patients 
to compare the prevalences of symptoms between the different cancer types.  
Prevalences of nine out of 19 symptoms (twelve physical and seven 
psychological) did not differ significantly between the cancer types. 
Prevalences of eight physical symptoms (dyspnoea (groups 1a, 1b and 2), 
trouble sleeping (group 2), feeling weak (group 2), loss of appetite (group 1b), 
diarrhoea (group 2), tiredness (groups 1a and 2), need to rest (groups 1a, 1b, 
2) and dry mouth (groups 1a, 1b)) were significantly different between the 
cancer types in at least one group. This also applied to the psychological 
symptoms anxiety (1a) and difficulties concentrating (1a).  
In all four disease groups the prevalence of dyspnoea was significantly different 
among the different cancer types. When the lung cancer patients were 
excluded from the analyses, the prevalence rates of dyspnoea were no longer 
significantly different in groups 1a and 1b. The same applied to tiredness in 
groups 1a and 2, concentrating in group 1a, appetite and need to rest in group 
1b.  
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Diarrhoea was significantly more prevalent in the gastro-intestinal cancer 
patients in all disease groups. As expected dry mouth was especially prevalent 
in the head and neck cancer patients. Also anxiety was especially prevalent in 
the head and neck cancer patients. 
Quality of Life (QoL) 
Figure 4.2 shows the overall quality of life (QoL) per disease group per cancer 
type.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Quality of Life (median, first and third quartiles and rangea) per group per cancer type. 
 a open circles represent patients whose scores were >1.5 times lower than the first 
quartile; * individual cases. 
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Linear regression analysis with demographic and disease-specific variables 
(type of cancer and disease group) showed that the patients in groups 1a and 
1b had significantly better quality of life than the patients in group 2 (p=0.00). 
Patients in group 3 had significantly poorer quality of life than the patients in 
group 2 (p=0.00). Patients with gastro-intestinal cancer (p=0.03), malignant 
lymphoma (p=0.00) and other haematological malignancies (p=0.03) had 
significantly poorer quality of life than the patients with prostate cancer (Table 
4.2). 
 
Table 4.2 Global quality of life (linear regression) according to demographic characteristics, 
treatment status and cancer type. 
Independent variables Coefficient (ß) Standard Error Confidence 
Interval 
P-value 
Gender  -2.322  1.797  -5.85 –  1.20  .196 
Age  .045  .056  -  .06 –    .15  .420 
Education 
  Primary school 
  Secondary school 
 College/universitya 
 
 -3.269 
 -2.458 
 
 1.759 
 1.455 
 
 -6.72 –    .18 
 -5.31 –    .40 
 
 .063 
 .091 
Groupc 
  1a 
  1b 
  2a 
  3 
 
 11.807 
 5.698 
 
 -14.900 
 
 1.544 
 1.521 
 
 2.982 
 
 8.78 – 14.84 
 2.72 –   8.68 
 
 -20.75 – -9.05 
 
 .000b 
 .000b 
 
 .000b 
Cancer type 
  Head and neck 
  Gastrointestinal 
  Lung 
  Breast 
  Prostatea 
  Urogenital other 
  Gynaecological 
  (non-) Hodgkin 
  Haematological  
  Other 
 
 -  4.614 
 -  4.940 
 -  4.797 
 -  2.374 
 
 -  1.995 
 -  2.202 
 -10.271 
 -  7.378 
 -  5.464 
 
 1.544 
 1.521 
 2.601 
 2.632 
 
 2.663 
 3.262 
 3.320 
 3.335 
 3.389 
 
 -10.92 –  1.69 
 -  9.46 – -  .42 
 -  9.90 –    .31 
 -  7.54 –  2.79 
 
 -  7.22 –  3.23 
 -  8.60 –  4.20 
 -16.78 –  3.76 
 -13.92 – -  .83 
 -12.11 –  1.18 
 
 .151 
 .032b 
 .065 
 .367 
 
 .454 
 .500 
 .002b 
 .027b 
 .107 
a reference category; b significant variable; c 1a=curative treatment ≥6 months ago, 1b=curative 
treatment <6 months ago, 2=palliative treatment and group 3=treatment no longer feasible. 
 
 
Linear regression analysis with demographic variables and physical and 
psychological symptoms showed that fatigue (p=0.00), pain (p=0.00), loss of 
appetite (p=0.00) and constipation (p=0.05) had significantly negative effects 
on quality of life. Dry mouth had a marginally (p=0.058) negative effect. 
Patients with an anxiety disorder had significantly poorer quality of life than 
patients without such a disorder (p=0.00). Depressed patients had  significantly 
poorer quality of life than patients without depression (p=0.00) (Table 4.3). 
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Table 4.3 Global quality of life (linear regression) according to demographic characteristics, 
physical and psychological symptoms. 
Independent variables Coefficient (ß) Standard Error Confidence Interval P-value 
Gender  -.161  .864  -1.86 –    1.53  .852 
Age  .011  .039  -  .07 –     .89  .772 
Education 
  Primary school 
  Secondary school 
 College/universitya 
 
 -3.269 
 -2.458 
 
 1.759 
 1.455 
 
 -6.72 –     .18 
 -5.31 –     .40 
  
 .063 
 .091 
Anxiety (HADS)c 
  No anxiety 
  Borderline 
  Anxious* 
 
 6.721 
 2.245 
 
 1.709 
 1.707 
 
 3.37 –  10.07 
 -1.10 –   5.59 
 
 .000b 
 .189 
Depression (HADS)d 
  No depression 
  Borderline 
  Depresseda 
 
 
 11.067 
 1.822 
 
 
 1.805 
 1.803 
 
 
 7.53 –14.61 
 -1.71 –   5.36 
 
 
 .000b 
 .312 
Dyspnoea  -  .023  .016  -  .06 –    .01  .166 
Fatigue  -  .261  .024  -  .31 –   -.21  .000b 
Nausea and vomiting  .011  .034  -  .06 –    .08  .746 
Paine  -  .155  .020  -  .19 –   -.12  .000b 
Insomnia  .013  .016  -  .02 –    .04  .421 
Appetite loss  -  .082  .023  -  .13 –   -.04  .000b 
Constipation  -  .036  .018  -  .07 –   -.00  .050b 
Diarrhoea  -  .003  .022  -  .05 –    .04  .871 
Dry mouth  -  .032  .017  -  .07 –    .00  .058 
Listlessness  -.  005  .025  -  .05 –    .04  .846 
a reference category; b significant variable; c Hospital Anxiety and Depression Scale: no anxiety = 
HADS <8, borderline anxiety = HADS 8-10, anxiety = HADS ≥11; d Hospital Anxiety and 
Depression Scale: no depression = HADS <8, borderline depression = HADS 8-10, depression = 
HADS ≥11; e although this manuscript deals with non-pain symptoms, pain was included in the 
regression analysis to prevent confounding. 
 
Treatment 
In answer to the question whether the patients had received treatment for their 
symptoms, it appeared that 45–90% of the moderate to severe non-pain 
physical symptoms had remained untreated (Figure 4.3). The symptoms with 
significantly negative impacts on quality of life (fatigue, loss of appetite, dry 
mouth) had received the least treatment. 
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Figure 4.3 Non-treatment rates of various moderate to severe symptoms. 
Discussion 
Many patients with cancer are poly-symptomatic.3,13,37-40 In our study, the 
prevalence of physical and psychological symptoms increased with increasing 
group number. Patients in the curative treatment groups 1a and 1b 
experienced symptoms that were independent of the cancer type. Symptoms 
reported in the patients in the palliative treatment group varied with cancer 
type. In terms of disabling symptoms, cancer type was only important in more 
advanced disease. An exception was head-and-neck cancer, in which the 
curative treatment groups had significantly higher prevalences of dry mouth 
(expected as consequence of the therapy) and anxiety complaints.  
 
Although symptom management research has generally focused on individual 
symptoms, patients and clinicians know clearly that symptoms may occur in 
combination and are often detrimental to each other.41 In 2001 the concept of 
symptom clusters was introduced.4 However, at present, the clinical 
implications of symptom clusters are limited.42 Therefore, we  discussed the 
symptoms individually per disease group,31 while keeping in mind the impact 
they may have had on each other. 
Disease group 1a (curative treatment >6 months ago) 
Only a few studies have been performed on the prevalence of symptoms after 
curative treatment. They mainly focussed on one symptom and a specific 
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cancer type (e.g. fatigue in breast cancer,21 Hodgkin’s disease43 or ovarian 
cancer,44 vertigo in nasopharyngeal carcinoma,22 or xerostomia in head-and-
neck cancer45). In our study, the prevalences of most of the moderate to severe 
physical and psychological symptoms after curative treatment were 
comparable with those in the general Norwegian population.46 A few of our 
prevalences were higher than in the general Norwegian population: trouble 
sleeping (22% vs 16%), tiredness (28% vs 22%), difficulties concentrating 
(12% vs 6%) and worries (20% vs 9%). No differences were found  in the 
prevalence of moderate to severe symptoms between the different cancer 
types in this group. Cella et al. reported cancer-related fatigue in 33% of a 
mixed group of cancer survivors who had completed treatment more than five 
years before.47 Our findings were in accordance with this (30%) and with earlier 
reports on cancer-related fatigue in breast cancer survivors (30-35%)48-50 and 
Hodgkin’s disease survivors (24-27%).51,52 In contrast, other groups did not find 
any differences in fatigue between healthy controls and survivors of breast 
cancer,21 ovarian cancer44 or Hodgkin’s disease.53 Consensus exists on a 
number of issues: fatigue may endure for many months or years,49,54,55 there is 
a strong correlation between fatigue and psychological distress56-58 and fatigue 
has a significantly negative effect on overall quality of life.59-61  
As expected, far more former head and neck patients had moderate to severe 
complaints of a dry mouth (46%) than all other patients. This is in accordance 
with the literature that 41% of the head and neck patients still had moderate to 
severe complaints of a dry mouth >5 years after treatment.45 We found that the 
presence of a dry mouth was a negative predictor (borderline significance) of 
quality of life.  
More research has been done into global health outcomes in cancer survivors. 
In our patients, self-perceived global health was the same as that in the general 
Norwegian population.46 This was in accordance with a recent study on cancer 
survivors 5–10 years post-diagnosis. Their physical and mental health status 
was comparable with population norms.62 In contrast, another recent 
population-based comparison between cancer survivors and matched controls 
found substantially increased burden of illness in the cancer survivors, even 
≥11 years after diagnosis, which manifested itself in various concerns and 
included: absenterism from work, poor general health perception and needing 
help with daily activities.63 Earlier studies found conflicting results: the typical 
cancer survivor of multiple primary cancers experienced modest but lasting 
QoL deficits;64 cancer survivors had similar health-related QoL to the general 
population without chronic co-morbidity;65 ovarian cancer survivors reported 
good physical health and energy, excellent psychological health and improved 
pleasure in life and personal relationships.44 Increasing numbers of authors are 
advocating Survivor Care Plans,66,67 because many cancer survivors become 
lost in the transition from cancer patient to cancer survivor.68 Such plans should 
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contain guidelines for surveillance, long-term and late effects of treatment, non-
cancer care and health maintenance and address issues such as psychological 
concerns, employment, insurance and economic status.66  
Disease group 1b (current curative treatment) 
Physical and psychological symptoms were reported more frequently by 
patients in group 1b than by the general Norwegian population.46 No 
differences were found in the prevalence of burdensome symptoms between 
the cancer types. Unfortunately, hardly any research could be found on 
symptom burden during curative treatment. Studies that addressed non-pain 
symptoms were mostly out-patient-based and it was impossible to separate the 
curative patients from the palliative patients.20,69-72 Only one study addressed 
the problem of fatigue in patients treated with curative intent.73  
Quality of life was significantly better in group 1b than in group 2. Therefore, 
future research should address curative patients separately from palliative 
patients. 
Our finding of moderate to severe fatigue in 40.5% was in accordance with the 
rates in curative patients (26-45%),73 but lower than those in the out-patient 
(mixed groups) studies (55% and 54%).69,72 Far more head and neck patients 
had moderate to severe complaints of a dry mouth (50%) than the other 
patients. Surprisingly, they were suffering from significantly more anxiety 
(HADS ≥11) (29%) than the patients with other cancer types in group 1b (mean 
13%), while anxiety disorders in group 1b (HADS ≥8) were much more 
prevalent than in the general population (27<->18%).74 In earlier reports, 
anxiety disorders were found in 22–34% of cancer outpatients.29,75,76 Korfage 
measured anxiety in prostate cancer patients over a period of five years. High 
pre-treatment anxiety was present in 28% of the patients, but it decreased 
significantly post-treatment. The sensitivity of anxiety at baseline as a 
screening tool was 71%.30 In a cohort of breast cancer patients, the prevalence 
of anxiety decreased from 40% post-surgery to 16% six months later.77 Anxiety 
had a significantly negative influence on quality of life, so we recommend 
screening for anxiety in daily practice.  
Disease group 2 (palliative therapy) 
In group 2, all the symptoms occurred more frequently than in the general 
population46 and group 1b. The number and type of symptoms depended on 
the cancer type. Dyspnoea was significantly more prevalent in patients with 
lung cancer and in patients with haematological malignancies. Diarrhoea was 
associated with gastro-intestinal cancer and gynaecological cancer; sleeping 
problems were associated with lung, breast and other haematological 
malignancies and fatigue-related symptoms were associated with gastro-
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intestinal and other haematological malignancies. The most prevalent 
symptoms were feeling weak, feeling tired and need to rest (i.e. the EORTC 
construct fatigue). Earlier studies reported some degree of fatigue in more than 
80% of outpatients receiving chemotherapy or radiotherapy.   
Only two studies were found that explicitly focussed on patients during 
palliative treatment.13,78 When the three studies were combined, prevalence 
rates of moderate to severe symptoms were: dyspnoea 10–29%, need to rest 
43%, sleeping problems 22-33%, feeling weak 31%, appetite loss 18-51%, 
nausea 14-15%, vomiting 6%, constipation 15-23%, diarrhoea 6%, feeling tired 
45-69%, dry mouth 17-28%, listlessness 13-45%, difficulties concentrating 
20%, feeling tense 15-24%, worries 38%, feeling irritated 22%, difficulties 
remembering 16%, anxiety 13-40% and depression 19-30%. An explanation for 
the wide variation in the prevalence of loss of appetite is that Bradley’s 
population were undergoing radiotherapy. The prevalence ranges for anxiety 
and depression might be due to differences in definition: anxiety/depressive 
disorder (HADS ≥8) or anxiety/depression (HADS ≥11).33 In our study, 45-90% 
of the moderate to severe symptoms remained untreated. These were much 
higher percentages than those in earlier reports. Puts et al.78 stated that 
symptoms had received insufficient treatment in 17% while 27% gave answers 
such as “nothing can be done”, or “it is a side-effect”, or “this symptom comes 
with having cancer”. In one study, 44% of the patients stated that the 
healthcare professionals were aware of their symptoms.78 Those findings 
suggest an analogy with the reasons for undertreatment of cancer-related pain 
that included care provider as well as patient-related barriers: physicians and 
nurses did not have formal assessment procedures,79-81 patients were reluctant 
to inform their care providers about pain because of concerns that they would 
bother their physician or distract him/her from treating the cancer,82,83 patients 
wanted to be “good” patients and a good patient does not complain,83-85 
patients believed that nothing could be done to ease the pain (fatalism),84,86 or 
thought they had to endure the pain because they have cancer.86 In addition, 
patients may fear that their pain is indicative of disease progression and they 
do not want to face that possibility.87 Patients were reluctant to take medication: 
fear of addiction continues to be a major concern of patients and their families 
(27-83%).82,84,86 Thirty to seventy-two per cent of the patients expressed 
concerns about tolerance84,86 and about 25% of patients believe that pain 
medications are “bad” for the body.88  
Disease group 3 (treatment no longer feasible)  
Physical and psychological symptoms were most frequent in these patients. 
Unfortunately, the group was too small to compare the prevalences of 
symptoms between cancer types. The 46% prevalence of moderate to severe 
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dyspnoea was in accordance with the literature. A review by Ripamonti89 
showed moderate to severe dyspnoea in 10-63% of advanced cancer patients. 
More recently, dyspnoea was reported in 35% (19–77%) of advanced cancer 
patients in a review.19 In the last two weeks of life 39% had dyspnoea.19 The 
prevalence of constipation in our group 3 patients was considerably lower than 
the 40–60% previously reported.19,90,91 Apparently, ongoing education has paid 
off and increased the awareness of physicians, nurses and pharmacists.  
Moderate to severe complaints of a dry mouth (58%) were less frequent than 
the rates reported in earlier studies (78–97%).92-94 As expected, a dry mouth 
was most prevalent in head and neck cancer. It had a considerably negative 
impact on QoL. In the literature a dry mouth was ranked as the third most 
distressing symptom,93 or was described as “very distressing”.95  
A complaint that mainly applied to group 3 patients was moderate to severe 
listlessness (30%). In earlier studies the prevalence was 12-32%.19 Problems 
with cognitive functioning were also found exclusively in group 3.  
Our patients had highly compromised quality of life compared to the general 
population (45 vs 74).46 
Quality of life (QoL) 
None of the demographic parameters exerted a significant influence on QoL.  
Quality of life was significantly better in patients in disease group 1a than in 
patients under palliative treatment. However, also patients under curative anti-
cancer treatment (group 1b) had a significantly better QoL than patients during 
palliative anti-cancer treatment, while the later group was significantly better 
than group 3.  
Gastro-intestinal cancer, malignant lymphoma and other haematological 
malignancies were associated with significantly poorer QoL than other types. In 
group 2 high prevalences of symptoms that compromised QoL were present in 
the patients with other haematological malignancies (fatigue, sleeping 
problems and dyspnoea) and in patients with gastro-intestinal cancer (fatigue). 
In the malignant lymphoma patients, none of the separate symptom 
prevalences were significantly higher than those in the patients with other 
cancer types. An explanation for this might be a combination of many non 
significant symptoms that put a heavy burden on QoL in malignant lymphoma 
patients.  
Quality of life was significantly better in the patients without depression or 
anxiety. The literature on anxiety is discussed above in the section on group 
1b. 
A strong body of evidence demonstrated the coexistence of depression and 
cancer.26 The prevalence rates of depression in patients with solid tumours 
ranged from 20 to 50%.26 In a cohort of breast cancer patients the prevalence 
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of anxiety and depression was 33% at diagnosis, 15% after one year and 45% 
after the diagnosis of recurrence.96 Improvement in mental health in men with 
prostate cancer was statistically significant and clinically meaningful at 6-
months follow-up.30 Contrastingly, in two other studies, one on early versus late 
breast cancer97 and one on early versus late chronic lymphatic leukaemia 
(CLL), depression and anxiety disorders and quality of life were not statistically 
different between the early and late groups.23 Pancreatic cancer had the 
highest rates of depression (56.3%) and anxiety (56.7%).29 Distress was 
significantly higher in lung cancer (43%) and brain cancer (42.7%) patients, but 
lower in gynaecological (29.6%), prostate (30.5%) and colon (31.6%) cancer 
patients.29  
The other literature showed that psychological symptoms had a considerably 
negative effect on quality of life in patients with chronic diseases98-101 and 
cancer.26,102 In our study, the influence of depression was significant. 
Inadequate diagnosis of distress, particularly depression, among cancer 
patients caused higher rates of non-compliance101 and shorter survival.103   
Other symptoms associated with significantly poorer quality of life were the 
fatigue (group 1a), loss of appetite, constipation and (marginally) dry mouth 
(group 1a). The incidence of the anorexia cachexia syndrome was difficult to 
determine, but in general, it occurred in 15% to 40% of patients with cancer 
and in more than 80% of patients with advanced disease.104 In the literature, 
loss of appetite was ranked as one of the five most challenging symptoms by at 
least 60% of the patients.105 Furthermore, loss of appetite and weight loss were 
associated with poorer prognosis.106,107  
Patients on opioid therapy reported that the most common and often most 
debilitating side- effect was constipation.108 However, the aetiology of 
constipation is multifactorial: the chief culprits include immobility, inadequate 
fluid intake, poor nutrition and medication (e.g. opioids, anti-emetics, anti-
cholinergics and NSAIDs).109 Constipation not only had significantly negative 
effects on QoL, but also generated high health-care-related financial cost 
(medical and nursing time).109 
Many symptoms remained untreated. Although, adequate therapy is not always 
available, there is a striking resemblance with the undertreatment of pain. 
Probably, the barriers in pain treatment83,110 hold truth for the non-pain 
symptoms. 
Limitations 
This study has some limitations. Despite the proper format and effort made to 
encourage GPs, nursing home physicians and nursing staff at the hospices to 
recruit patients for group 3, the numbers remained small. Therefore, this group 
may not have fulfilled our intention of being representative of patients with 
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metastatic/advanced disease. Selection by GPs, nursing home physicians and 
nursing staff at the hospices may have excluded many terminal patients. It is 
not clear how this selection influenced the prevalence of symptoms. Mostly, no 
differences in symptom prevalence were reported between the palliative and 
terminal (last two weeks) phase.18,111 Labori in contrast found that all symptoms 
increased from baseline to 1–4 weeks before death.15 Dry mouth and 
fatigue,112 nausea and urinary symptoms19 were found to improve toward the 
end of life.  
The fairly broad range of cancer types made it difficult to translate symptom 
burden to individual patients. Owing to the limited numbers in each group, it 
was not possible to make more detailed subdivisions (e.g. pancreas, stomach, 
oesophagus, etc. versus gastrointestinal). 
Our analyses showed significant differences in the prevalences of 10 out of the 
19 symptoms between the various cancer types in at least one group. 
However, when lung cancer was excluded, only seven symptoms differed 
significantly and mainly in the patients in group 2. Possibly, many of our 
patients with lung cancer were misclassified into groups 1a and 1b, because 5-
year survival in non-small-cell-lung carcinoma is 10-15%, while 3-year survival 
in small-cell-lung cancer is <10%.36  
The patients themselves provided the data on the treatment of symptoms. Lack 
of awareness of what all the medication was for could have overestimated the 
rate of undertreatment. 
Conclusion 
Many patients with cancer are often poly-symptomatic.3,13,37-40  
The prevalence of all symptoms increases with increasing group number. 
Patients (being) treated with curative intent experience symptoms that are 
independent of cancer type. In patients treated with palliative therapy, 
symptoms vary with cancer type. Quality of life decreases significantly with 
increasing group number.  
In clinical practice and future research, it is advisable to divide patients 
according to their treatment status, instead of dividing them into outpatients 
and patients with advanced disease. 
Fatigue, loss of appetite, constipation, dry mouth, depression and anxiety have 
independent negative influences on quality of life.  
Many of the non-pain symptoms remain untreated, although (partly) effective 
treatment is available for most symptoms. This illustrates the need for better 
education about symptoms and symptom control in the curricula of medical 
professionals. Systematic recording of symptom intensity is mandatory in 
patients with cancer, irrespective of the phase of the disease. 
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Abstract 
Introduction 
The prevalence of pain in patients with cancer is still too high. Factors related to ineffective pain 
treatment fall into three categories: the health care system, professional care providers and 
patients. In patients, various barriers lead to non-compliance. Previous educational interventions 
have increased their pain knowledge and decreased short-term pain levels. In this randomised 
controlled trial, we investigated how an intensive home-based education programme given by 
nurses affected short-term and long-term pain levels. 
 
Methods 
120 cancer patients were randomised to receive either the Pain Education Programme (PEP) or 
usual care. Pain, knowledge, quality of life, anxiety and depression were measured at baseline, 
after four weeks and after eight weeks. In the intervention group, symptom levels were 
communicated to the treating physician. 
 
Results 
Pain knowledge increased significantly in the intervention group. Their level of pain had decreased 
at four weeks, but not at eight weeks. Significant decreases in pain only lasted in the patients with 
a high pain score at baseline. No correlation was found between increased pain knowledge and 
decreased pain levels. 
 
Conclusion 
The PEP education programme given by nurses lowered pain intensity levels of cancer patients 
and increased their pain knowledge. More attention should be paid to patient education and to 
communication between patients and health professionals about pain and pain management. 
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Introduction 
Many patients with cancer have (multiple) symptoms that can affect their 
feeling of well-being and their physical and social functioning.  
One of the most feared and burdensome physical symptoms in patients with 
cancer is pain. A recent review has shown that the prevalence of pain in 
patients with cancer is still high: 64% in patients with metastatic, advanced or 
terminal disease and 59% in patients on anti-cancer treatment.1 
Factors related to ineffective pain management fall in three categories: the 
health care system, health care providers and patients.2 In the health care 
system, more attention focuses on “curing” patients with cancer than on 
“caring” for them, which also includes symptom management.3 Health care 
providers tend to lack attention for and knowledge about pain management4-9 
and as a consequence, do not always treat pain according the WHO 
guidelines.5,10 Patients generally lack knowledge about pain and pain 
management and are reluctant to report pain to their physician.11,12 Fears such 
as drug addiction, tolerance and concerns about side-effects also influence 
their pain medication intake6,11. However, patients indicated that they would 
appreciate help with their physical and psychosocial problems and information 
about them.13-15 
 
With respect to the ineffective pain management in the health care system 
category, no RCT’s have been published whose intention was to focus the 
attention on the combination of care and pain aspects. In the health care 
provider category, Goldberg and Morison conducted a systematic review of 
institutional interventions designed to improve the assessment and treatment of 
pain in cancer patients.16 Their review included three trials that studied the 
effects of education for nurses on pain-related topics.17-19 It was concluded that 
the education sessions improved the nurses’ knowledge about pain and their 
attitudes towards it.16 However, these interventions did not lead to any 
significant decreases in pain severity in their patients.16 None of the RCT’s 
specifically targeted other health care providers or physicians.  
 
In our study, we focussed on the patient-related factors in pain knowledge and 
management. A review of 17 RCTs on pain and pain management education 
for patients20-36 suggested that tailored education counselling sessions directed 
at patients improved pain scores20-22,25-27,29,30,33,34,36 and altered any negative 
beliefs and misconceptions about pain.21,22,25,26,28,29,33,35 In twelve studies, the 
pain education was given by nurses20,21,23-25,27-29,31-33,35, in two studies it was 
given by other health care educators (e.g. research assistant, master 
student)22,26, in two studies this aspect was not mentioned30,34 and in one study 
a video was shown.36  Although the results of the patient-related RCTs were 
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generally positive, there is still a need to gain more insight into the efficacy of 
pain education programmes.27 The existing RCTs had methodological flaws in 
many areas. In most studies, only short-term effects were measured.21,22,24-
28,30,34,36 It is not clear whether short-term effects are sustained over longer 
periods of time. The education programmes were generally fairly light (e.g. one 
face-to-face education session or one session combined with one or more 
telephone calls)20-22,28-31,33-36, whereas patients and their family care providers 
are known to require ongoing assistance with problem-solving to optimise their 
pain management regimen.37 Little is known about which subgroups gain more 
from pain education programmes than other subgroups. This knowledge is 
necessary to tailor education programmes and maximize their effectiveness.38 
Only one study indicated that the educational level of the patients might 
influence the effects of pain education programmes.39 A very small proportion 
of the studies incorporated variables such as gender, age and stage of the 
disease.28,29 None of the studies mentioned incorporated pain scores at 
baseline, or anxiety and depression scores at baseline, although depression 
and pain form a well-known cluster40 and depressive disorders can affect 
compliance.41 In almost half of the RCTs the study population was small, with 
less than 35 participants in the intervention group and the control 
group22,25,26,30-32,36. Attention was paid to communication between the nurses 
who gave the education and the treating physicians in one study alone.21 
Whereas continuity of care and communication between health care providers 
is known to be of major importance in the pain management process.39  
 
In the present study, we tried to avoid making any of the above-mentioned 
methodological errors. Our aim was to evaluate how an intensive home-based 
pain education programme (PEP) given by nurses affected short-term and 
long-term effects of on levels of pain, pain knowledge, quality of life, anxiety 
and depression. 
Methods 
Source population 
Patients were recruited from two sources, firstly, from our previous prevalence 
study on pain and other symptoms in the region of Limburg in the south of the 
Netherlands. The outpatients who scored 4 or higher on the pain intensity scale 
(range 0-10, 10 = worst pain) and who gave signed consent to participate in the 
next research project, were asked to participate in this intervention study. This 
resulted in 54 patients. Secondly, patients were recruited by nurses and 
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physicians working at outpatient clinics and the Radiotherapy Department. This 
resulted in 65 patients. A total of 120 patients was included. 
Patients were eligible if they 1. had been diagnosed with cancer, 2. had been 
informed of their diagnosis, 3. were 18 years or older, 4. were able to 
understand and complete the questionnaire, 5. had a “present” pain score of 4 
or higher on a scale from 0-10 and 6. agreed to participate in the study. 
Treatment stages included e.g. curative anti-cancer treatment, palliative anti-
cancer treatment and no further treatment options available. Patients were 
excluded if they had completed their curative anti-cancer treatment before the 
year 2000.  
 
The study was approved by the Medical Ethics Committee of the University 
Hospital Maastricht. All the participants signed the informed consent 
agreement. 
Intervention 
All the patients were allocated at random to the intervention group (n=58) or 
the control group (n=62) on the basis of a computer-generated randomisation 
procedure.  
Patients in the control group received usual care, while the patients in the 
intervention group received specialised nursing care at home, in addition to the 
usual care (Figure 5.1). This specialised care included the Pain Education 
Programme (PEP) and the monitoring of symptoms other than pain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Study design. 
usual care control  T0 Baseline Measures intervention T0 
week 1: home visit 1
week 3: home visit 2
week 4: follow-up 1 (T1)
week 6: home visit 3
week 8: follow-up 2 (T2)
week 4: follow-up 1 (T1) (T((T1)
week 8: follow-up 2 (T2)
Recruitment and randomization
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The PEP was developed by de Wit et al.33 and has three components: 1. 
enhancing a patient’s knowledge about pain and pain management by means 
of a pain brochure, 2. instructing patients how to record their pain intensity in a 
pain diary and 3. stimulating a patient’s help-seeking behaviour. An extensive 
description of the PEP can be found in the original article.33. In the intervention 
group, palliative care nurses made three home visits, each with a duration of 1 
to 1.5 hours. 
The pain brochure offers information about the following topics: possible 
causes of pain, pain control, non-adherence, misconceptions and different non-
pharmacological pain management techniques (cold, heat, relaxation and 
massage). This brochure was tested in an earlier study.42 
First home visit 
The first home visit took place within one week after the baseline 
measurement. Intake data were recorded by the nurses to tailor the PEP to the 
patient’s situation. These concerned pain intensity, location of pain, type of 
pain, medication prescription, medication adherence, emotional well-being and 
other physical symptoms. A pain brochure was given to the patients and were 
discussed, if possible in the presence of a family caregiver. Patients was 
invited to ask questions. The patients also received a pain diary with a clear 
explanation about how to record their pain intensity twice daily on a numeric 
rating scale from 0 to 10. If any pain problems or other physical and emotional 
symptoms arose, the patient was encouraged to contact their health care 
provider.  
After the first visit, the nurse reported the findings to the treating physician by 
letter. If indicated, advice was formulated concerning the pain medication, in all 
cases in consultation with a specialist in pain treatment in oncology patients. 
Advices concerned: starting new pain medication, increasing dosages of pain 
medication, or rotating to other pain medication and was enclosed with the 
letter. 
Second home visit 
During the second home visit, which took place in week three, the nurse 
reviewed the pain intensity scores in the pain diary to detect any changes in 
pain intensity levels. Note was also made of any changes in type of pain, 
location of pain, prescription of pain medication and medication adherence. 
Patients were asked whether they had read the “Pain brochure” themselves 
and fully understood all the information. Care was taken to discuss anything in 
the brochure unclear to them and/or to repeat relevant information. If 
necessary, the patients were encouraged to contact their health care provider 
about their pain problems and/or other symptoms.  
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Third home visit 
The third (final) home visit, which took place in week 6, dealt with the same 
components as the second visit. Afterwards, the nurse wrote to the treating 
physician about the patient’s situation. If indicated advice was formulated 
concerning a change in pain medication and enclosed with the letter.  
Measurements 
Outcome measurements were assessed in the intervention group and the 
control group at baseline (T0), week 4 (T1) and week 8 (T2) (Table 5.1).  
 
Table 5.1 Study measurements at T0 (baseline), T1 (week 4) and T2 (week 8) 
 T0 T1 T2 
Outcome Measures    
   Pain intensity + + + 
   Pain Knowledge +  + 
   Quality of Life + + + 
   Anxiety and Depression +  + 
Process variables (intervention group only )    
   Patient Satisfaction   + 
   Use of pain diary   + 
   Use of cd   + 
   Use of information booklet   + 
   Medication Prescription + + + 
 
 
Relevant medical data and information about other interventions that targeted 
pain were obtained from the medical records. 
Pain was measured by 4 questions derived from the Brief Pain Inventory 
(BPI)43 (numeric rating scale). It has high internal consistency with coefficient 
alphas that ranged from .78 to .97 in various cancer population samples in 
different countries.44-53 The “present” pain score was chosen as a primary 
outcome, because it is less subject to the biases that affect recall 
measurements54 and patient recall accuracy depends, in part, on the stability of 
the pain.39 
Patients’ knowledge about pain was measured with a translated version of 
Ferrell’s Pain Questionnaire.55,56 The questionnaire has eight items, e.g., 
‘patients are often given too much pain medication’, ‘most patients will become 
addicted to the medication over time’, ‘it is better to take pain medication 
around the clock (following a schedule) than only when needed’. All the scores 
were transformed linearly into a scale from 0-100 (0 is the lowest score on 
knowledge, 100 the highest score on knowledge). The PKQ-DLV has 
demonstrated acceptable levels of validity and reliability.39 
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Quality of life and non-pain symptoms were measured using the EORTC-C30 
version 3.57 The EORTC-C30 is 1. cancer-specific, 2. multidimensional, 3. 
suitable for self-administration and 4. applicable across a range of cultural 
settings. It has five functional scales, three symptom scales, a global 
health/quality of life scale and six single items. The EORTC QLQ-C30 has 
shown acceptable levels of validity and reliability.57 
Depression and anxiety were measured using the Dutch version of the Hospital 
Anxiety and Depression Scale (HADS).58 The HADS has shown good 
performance to assess symptom severity and caseness of anxiety disorders 
(Cronbach’s α: .68 - .93) and depression (Cronbach’s α: .67 - .90) in somatic, 
psychiatric and primary care patients, with a sensitivity and specificity of 
approximately 0.80.59 
Participation satisfaction with the intervention was measured by asking the 
subject the following two questions: 1. Would you like to continue following the 
Pain Education Programme? 2. Would you advise other patients to take part in 
the Pain Education Programme? Response options were ‘yes’ and ‘no’.  
Use of materials was evaluated at the end of the study by asking the patients 
whether they had used the pain diary, cd and read the information booklet. 
Response options were ‘yes’ and ‘no’. 
Advice concerning a change in pain medication prescription at T0, T1 and T2 
was analysed by comparing the advice (as formulated in the letters to the 
treating physician) to the patients’ reports about pain medication. 
Statistics 
To achieve adequate power to test the main effect of treatment group on pain 
intensity, a total of 80 patients were needed. During the study period, many 
patients dropped-out because they were too ill or died. Therefore, 120 patients 
were recruited instead of 80 to ensure adequate power. The power analysis 
conducted in this study was based on the data from an earlier study on the 
Pain Education Programme.39. It was necessary to have 40 patients in the 
intervention group and the control group to detect a clinically relevant 
difference of 1.5 points on a 10 point scale, with an alpha of 0.05, a beta of 
0.20 and a sd of 2.4. Data were analysed using the Statistical Package for the 
Social Science (SPSS) version 12. Descriptive Statistics were used to evaluate 
the demographic variables, medical variables, pain, knowledge about pain and 
pain treatment, quality of life, depression and anxiety. At T0, comparability 
between the intervention group and control group was analysed by using 
Independent Student’s t tests and Chi-square tests.  
 
Mixed regression models were used to evaluate the longitudinal data on the 
effects of the PEP and changes over time. The many drop-outs in this study, 
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mainly due to severe illness and death, led to an unbalanced data set that 
could not be analysed using for traditional methods such as repeated-
measures analysis of variance (ANOVA). In the literature mixed regression 
models offer an alternative to deal with unbalanced data sets.60. Therefore, the 
changes in outcome measures and pain over time were tested using the 
Random Intercept Model. 
Results 
A total of 120 patients entered the study (Figure 5.2); 83 of them had 
completed the follow-up at T2. After randomisation, 13 patients were excluded 
(eight in the control group and five in the intervention group) because they did 
not meet the inclusion criteria: seven patients were not suffering from cancer-
related pain (3x arthrosis, 1x osteoporosis, 1x rheumatic disease, 1x dialysis 
and 1x carpal tunnel syndrome), four patients had completed their curative 
treatment before 2000 and one patient had previous exposure to the PEP 
brochure. Data were missing at baseline, T1 or T2 in 27 patients (10 in the 
control group and 17 in the intervention group). For further details, see Figure 
5.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Flowchart of participants. 
 
Allocated to control group 
N=62 
Allocated to intervention 
group  N=58 
N=47 completed baseline 
 
N=15 did not complete 
baseline (T0) 
Reasons: 
N=8 excluded 
 
N=4 too ill 
N=3 died before baseline 
measurement 
 
N=45completed baseline 
N=13 did not complete 
baseline (T0) 
Reasons: 
N=5 excluded 
 
N=3 * missed baseline  
measurement but 
completed follow-up 1 & 2 
N=2 too ill 
N=2 died before baseline 
measurement 
N=1 refused to participate 
 
 
 
N=45 completed follow-up 1 
 
 
N=2 did not complete 
follow-up 1 (T1) 
Reason: 
refused to participate 
N=38 + N=3 * Æ N=41 
completed follow-up 1 
 
(*N=3 missed baseline, but 
completed follow-up 1 and 2) 
N=7 did not complete 
follow-up 1 (T1) 
Reasons: 
N=2 too ill 
N=2 died 
N=3 refused to participate.  
N=44 completed follow-up 2 N=39 completed follow-up 2
N=1 did not complete 
follow-up 2 (T2) 
Reason: too ill 
N=2 did not complete 
follow-up 2 (T2) 
Reason: too ill 
Total randomised 
N=120
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At baseline, no significant differences were found in the demographic 
characteristics, treatment group and baseline pain level between the 
intervention and the control group (Table 5.2). Despite the randomisation 
procedure, the baseline level of pain knowledge was significantly better in the 
control group than in the intervention group (p=0.017). In the intervention group 
and the control group, the lowest score at baseline was observed on the item 
‘take the lowest dose of medication possible’ (16.9 and 27.7, respectively). No 
significant differences were found in domains of quality of life (except for role 
functioning). 
 
 
Table 5.2 Baseline characteristics in the intervention group and the control group. 
 Intervention group Control group p 
Age, years 
   Mean (SD) 
 
 62.0 (10.3) 
 
 60.5 (10.0) 
 
NS 
Gender, % 
   Men 
   Women 
 
 52.1 
 47.9 
 
 38.3 
 61.7 
 
NS 
NS 
Education, % 
   Primary school 
   Secondary school 
   College/university 
   Missing 
 
 77.1 
  6.3 
 10.4 
  6.3 
 
 70.2 
  4.3 
 23.4 
  2.1 
 
NS 
NS 
NS 
NS 
Treatment groupa % 
   Group 1 
   Group 2 
   Group 3 
   Missing 
 
 20.8 
 58.3 
 18.8 
  2.1 
 
 27.7 
 53.2 
 17.0 
  2.1 
 
NS 
NS 
NS 
NS 
Baseline painb    4.43   4.71 NS 
Pain knowledge  52.8  59.5 0.017 
a Group 1: Patient is currently under curative anticancer treatment or this treatment has finished (<5 
years). Group 2: Patient is currently under palliative anticancer treatment, or this is a treatment 
option. Group 3: No further treatment options available; b Present pain 
 
 
Changes in the level of pain, level of pain knowledge, quality of 
life, anxiety and depression  
At the short-term measurement (week 4), the intervention group showed 
significant pain reduction (p=0.02) compared to the control group (Figure 5.3a). 
No significant (p=0.14) long-term effect was found (Table 5.3).  
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Figure 5.3a Changes in the level of pain and the level of pain knowledge in the intervention and 
the control group over time.  
 * p=0.02 
 
Table 5.3 Mean “present” pain scores in the intervention group and the control group at baseline 
(T0), week 4 (T1) and week 8 (T2). 
 “present” pain P-value 
 Intervention group 
Mean (SD) 
Control group 
Mean (SD) 
 
 
T0 
T1 (week 4) 
T2 (week 8) 
 
4.71 (2.21) 
3.78 (2.63) 
4.00 (2.17) 
 
4.43 (2.33) 
4.84 (2.62) 
4.62 (2.25) 
 
0.72 
0.02 
0.14 
 
 
The level of pain knowledge was measured at baseline (T0) and after eight 
weeks (T2). At week 8, the level of pain knowledge was significantly better in 
the intervention group (p<0.00) than in the control group (Figure 5.3b). 
Significant improvement was seen on the items ‘take the lowest dose of 
medication possible’, ‘use of routine medication instead of on demand’ and 
‘becoming addicted’ in the intervention group. Levels of pain knowledge in the 
control group did not improve.  
No correlation was found between the increase in pain knowledge and the 
change in “present” pain scores (Pearson correlation 0.03, p= .860). 
Quality of life, did not show any significant effects over time.  
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Figure 5.3b Changes in the level of pain and the level of pain knowledge in the intervention and 
the control group over time.  
 *1 p=0.017; *2 p<0.00 
 
Factors related to short-term and long-term change in pain scores 
The “present” pain intensity at baseline had significant influence on the 
“present” pain intensity at the short-term and long-term measurements (Figure 
5.4).  
In the patients with a baseline pain score of 1-3, there were no differences in 
pain scores at T1 (week 4) and T2 (week 8) between the intervention group 
and the control group. In the patients with a baseline pain score of 4-6, pain at 
T1 was significantly lower in the intervention group than in the control group 
(p=0.02). However, at T2, this difference had disappeared (p=0.13). In the 
patients with a baseline score of 7-10, significant differences in pain were found 
between the intervention group and the control group at T1 (p=0.00) and T2 
(p=0.00). 
Gender, age, education level, severity of illness and baseline levels of anxiety 
and depression at baseline did not have any significant influence on the 
“present” pain intensity levels in the intervention group or the control group.  
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Figure 5.4 Changes in “present” pain over time in three subgroups according baseline pain (mild, 
moderate and severe baseline pain). 
 
Advices  
After the first and third home visits the nurse send a letter at about the patients’ 
pain problems (pain intensity, pain location and type of pain) and situation to 
the treating physician. If indicated, it was accompanied by advice concerning a 
change in pain medication. Such advice had accompanied 37 letters. However, 
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based on the patients’ reports about pain medication prescriptions at baseline 
(T0), week 4 (T1) and week 8 (T2), this advice had not been followed 22 times. 
In 8 cases, it was unclear whether or not the advice had been followed. 
Patients’ opinions about the Pain Education Programme 
When the patients with complete data sets were asked whether they would like 
to continue to follow the Pain Education Programme, 66% of 29 patients would 
have liked to continue to receive support from the specialised nurse. Their most 
important reasons were: support and somebody to answer questions about 
pain medication. The patients who did not want continue reported that the three 
education sessions had been enough for them to understand the information 
about pain and pain medication. In answer to the question whether they would 
advise other patients with pain complaints to take part in the Pain Education 
Programme all the patients would do so. The response to the third question on 
the pain brochure, the pain diary and the cd with education revealed that 73% 
of these patients had read the pain brochure and used the pain diary. 
Discussion 
In this randomised controlled trial, an intensive pain intervention programme 
given by nurses resulted in short-term pain reduction in patients with moderate 
pain at baseline and in long-term pain reduction in patients with severe pain at 
baseline. The intervention improved patients’ knowledge about pain and pain 
medication. Furthermore, they were satisfied with the intervention and would 
recommend it to other patients.  
 
In most RCTs concerning educational interventions in patients, pain reduction 
was found in the short-term (1–4 weeks).20-22,25,26,29,30,33,34,36 These interventions 
differed greatly in type and intensity that ranged from showing a video36, 
holding a single face-to-face meeting21,22,30,34, setting up a combination of one 
to three face-to-face meetings and one or more telephone 
consultations20,26,29,33, to conducting five face-to-face meetings in five days.25 
However, not all the results of short-term studies were positive.24,28,31,35 Again, 
these interventions differed in type and intensity. Far fewer studies focussed on 
long-term effects. The majority did not find any long-term (6 weeks – 6 months) 
effects of an intervention on pain intensity20,29,31,32,35, one showed a trend23 and 
two studies reported long-term pain reduction.27,33 These interventions differed 
widely in type and intensity.  
Apparently, the intensity of an intervention is not the only effective component 
of pain education programmes because neither the type, nor the intensity could 
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predict a positive outcome. In our study, the patients with more severe pain at 
baseline (VAS 7-10) derived the most benefit from the intervention, in the short-
term and long-term. We found that gender, age, education level, severity of 
illness and baseline levels of anxiety and depression did not significantly 
influence the “present” pain intensity levels in the intervention group or the 
control group. None of the other studies were suitable for comparison 
purposes. Only one study mentioned that demographic parameters did not 
greatly affect the impact of the intervention, but, it remained unclear what the 
authors meant exactly.28 Another study classified the population according to 
race and found a positive short-term effect in African-Americans, but not in 
Hispanics.20  
Besides better patient selection, other possible factors that can improve the 
long-term effectiveness of an intervention are: 1. close involvement of family 
caregivers in the education programme27,33 and 2. direct feedback from the 
nurse to the treating physician about the pain levels and other problems. The 
only other study in which the nurses directly communicated the results of the 
intervention to the patient’s treating physician was that by Aubin.21 However, it 
was unclear how they reported the results to the treating physicians and what 
effects this had. In our study, the specialised nurses wrote a letter to the 
treating physicians that contained details about the patient’s pain level, and 
further observations. If a patient had rated their pain as VAS >4, the letter also 
advised the physician to change the pain medication prescription. The contents 
of the advice were formulated in cooperation with a physician from the 
Palliative Care Team and according the Dutch guidelines for pain 
management.61 We observed that a great deal of this advice was not followed, 
which suggests that this mode of communication was inadequate. Possible 
explanations are that the letter was stored unread in the patient’s medical file, 
too much time had elapsed between receiving the letter and actual patient-
physician contact, or reluctance from the physicians to follow uninvited advice. 
Another explanation could be the scarce involvement of the treating physicians 
in the implementation of this intervention. Future comparable research projects 
might benefit from closer communication with the treating physicians. Support 
for this argument can be found in the study conducted by Vallieres.30 Direct 
access to a physician who could adjust the analgesic regimen formed part of 
the intervention. Patients were clearly instructed when (at which pain level, or 
after three rescue doses in 24 h.) to contact their doctor. In addition, they were 
asked to bring their pain diary to the consultation, which helped the doctor to 
adjust the analgesic prescription and also improved the communication 
between the patient and the doctor. Although the study sample was small, the 
results seemed promising. Unfortunately, no long-term effects have been 
reported.30 In all the above-mentioned RCTs, part of the education programme 
was to encourage the patients to talk to their treating physician about their pain. 
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However, no data are available on the effect of patient education on 
communication with treating physicians. 
 
In agreement with almost all the other RCTs our study showed an increase in 
pain knowledge following the intervention. In one trial, only the informal 
caregiver gained knowledge32, whereas in two trials, there was no effect on 
pain knowledge.31,35 The rationale behind pain education programmes for 
patients is based on the presumption that better educated patients will be more 
adherent to their medication and communicate more adequately with their 
treating physician. In our study, no correlation was found between increases in 
pain knowledge and decreases in pain level. In the field of cardiology, it was 
shown that patient education led to significantly lower levels of LDL cholesterol 
in high-risk patients (n=3053)62 and to significantly fewer admissions for heart 
failure.63 Three studies confirmed that fewer barriers (mainly e.g. less fear of 
addiction and tolerance and a better sense of control) led to better adherence 
to pain medication.22,26,28 In contrast, two other studies did not find any 
correlation between decreases in barriers and pain levels.29,32 Another study 
(n=342) showed that patients’ beliefs were not associated with reports about 
pain or adherence to medication.64 Probably, an intervention should have a 
multifaceted design that not only incorporates education about various disease-
related topics, but also implements strategies to change patient behaviour.65  
Limitations 
Our study population knew that they were enrolled in pain research, which may 
have stimulated the intervention and control groups to talk about their pain with 
their treating physicians or other health care providers and diminished the 
distinction between the two groups. Another factor that might have effected the 
comparability between the intervention and control groups is the very severely 
nature of illness in the patient population and the inherent inability to control 
disease progression.  
Recommendations 
We recommend that researchers consider the following components in future 
education programmes, because of their potential ability to reduce pain levels 
in the longer-term: 1. Involve patient and family caregivers as much as 
possible.27,38 2. Communicate with the patient by telephone to reinforce the 
information and to monitor pain.23,27,38 3. Integrate medical care into the 
 RCT of a nursing-based education programme for cancer patients⏐107 
nursing-based education programme: e.g., direct contact between the nurse 
and a physician who can adjust the analgesic regimen 4. Formulate clear 
instructions how and when to contact the doctor30 5. Have the patients keep a 
pain diary and refer to it during communication with their health care 
providers.30 
Further research is needed to test the effectiveness of the separate 
components and to establish the most effective intensity of pain education 
programmes. To investigate the exact mechanism of how pain levels can be 
reduced in the longer-term, we recommend that studies not only measure 
knowledge, pain, symptoms and quality of life, but also the pain medication 
prescription30, medication adherence (e.g. by using a pillbox)27 and 
communication between the patients and their physicians.  
Conclusion 
This study showed that a pain education programme given by nurses could 
lower the pain intensity in cancer patients. The patients with higher pain scores 
benefited more from the intervention and the effects lasted longer. 
Our results supported those from earlier studies in which nurses gave pain 
education to patients and increased their pain knowledge. However, no 
correlation was found between increases in pain knowledge and decreases in 
pain levels. Apart from educating patients, more attention should be paid to the 
communication between patients and professional care providers about pain 
and pain management. 
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Abstract 
Objective 
The present study had three aims: first, to evaluate the psychometric properties of the Dutch 
version of the CARS (CARS-DLV). Second, to measure the prevalence of concerns about disease 
recurrence in former breast cancer patients and identify potential predictors and third, to establish 
how fear of recurrence was effecting quality of life 
 
Methods 
A prospective study was carried out on breast cancer patients (n=136) who had undergone curative 
treatment. Eligible patients completed an extensive questionnaire consisting of the CARS (fear of 
recurrence), HADS (anxiety and depression), BPI (pain), RAND (quality of life), LOT (optimism) 
and the PCS (catastrophzing). 
 
Results 
This study confirmed the good internal consistency, test-retest stability and construct validity of the 
CARS (Dutch Language version). Moderate to high levels of fear of disease recurrence were found 
in 56% of 136 breast cancer survivors. Worries about health and death were the most prominent. 
Pain was a strong predictor of overall fear and of fear on the four sub domains of the CARS. The 
prevalence of fear decreased significantly with age. Education level, living arrangements and time 
since the last treatment did not predict the prevalence of overall fear. Fear of recurrence was 
negatively correlated with quality of life. 
 
Conclusion 
The CARS-DLV proved to be a valuable instrument to measure women’s’ concerns about breast 
cancer recurrence. More than half of former breast cancer patients indicated moderate to severe 
concerns about disease recurrence. Health and death worries were the most prominent. The levels 
of worry were independent of the time since diagnosis. 
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Introduction 
To cover all the relevant domains of quality of life (QoL) in breast cancer 
survivors, current QoL questionnaires should be complemented by aspects 
such as body image, sexuality and fear of disease recurrence.1 Breast cancer 
survivors are faced with many demands of illness, particularly across the 
physical, psychological, social and spiritual domains.2 A recent systematic 
review has shown that long-term survivors of breast cancer were experiencing 
good overall quality of life.3 In most women psychological distress (e.g. anxiety 
and depression) subsided during the first 24 months after diagnosis.5 However, 
30% of the women were still experiencing psychological distress many years 
after the completion of treatment.4 Specific problems often persisted, such as 
poor body image, decreased sexuality and fear of disease recurrence.1,5 Even 
twenty years after the initial treatment, there was an increased prevalence of 
post-traumatic stress disorder (PTSD), which indicated unremitting 
psychological sequelae long after diagnosis and treatment.6  
Fear of disease recurrence is one of the most prevalent long-term 
psychological consequences of surviving cancer. In women who survived 
breast cancer, fear of disease recurrence was reported by 29 to 97%.7-14 The 
most important long-term sources of distress following breast cancer surgery 
were shoulder-arm morbidity and fear of cancer recurrence.15 High levels of 
fear of recurrence can lead to dysfunctional behavior, including anxious 
preoccupation and excessive checking.16 Several cancer-related fears were 
found to be positively related to depression and anxiety, e.g. worries about 
disease recurrence or a second primary tumor.17 The aggregate data gathered 
from individuals concerning the nature of women’s fears about recurrence may 
help oncology professionals to better understand women’s coping and 
adjustment in the presence of such fears and to device more supportive 
interventions.9 
In the literature, four different instruments are described to measure fear or 
concerns about disease recurrence: the Fear of Recurrence Index (2 items),18 
the Worry about Cancer Scale (4 items),19 the Northouse Fear of Recurrence 
Scale (22 items)20 and the Concerns About Recurrence Scale.8 The most 
significant limitation of the first three questionnaires is that they evaluate 
women’s overall fear of tumor recurrence, without identifying which domains 
the various concerns relate to. In contrast, the Concerns About Recurrence 
Scale8 (CARS) is a multidimensional instrument that addresses different 
domains of women’s fear. Thus, the CARS is able to identify the aspects that 
patients fear most. Women’s fears about recurrence are likely to be influenced 
by their previous experiences with breast cancer, because expectancies 
regarding the future are shaped by past experiences.21 Research has 
documented numerous psychosocial effects of breast cancer, including the 
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following: emotional difficulties,22 problems associated with sexuality,23,24 body 
image,23,25 self-concept,26 femininity,27 financial strain,28 disruptions in daily 
activities,22 barriers to fulfilling roles or setting/reaching goals28 and/or problems 
with interpersonal relationships.29 Because the consequences of breast cancer 
are so numerous and varied, women’s fears about recurrence should be similar 
complex. 
We recently translated the CARS into Dutch for use in research and clinical 
work. 
 
The present study had three aims: first, to evaluate the psychometric properties 
of the Dutch version of the CARS (CARS-DLV) in terms of internal consistency, 
test-retest reliability and construct validity; second, to measure the prevalence 
of concerns about disease recurrence in former breast cancer patients and 
identify potential predictors and the third, to establish how fear of recurrence 
was effecting quality of life. 
Methods 
Study sample 
A prospective study was carried out on breast cancer patients (n=136) who had 
undergone curative treatment. All the patients had participated in an earlier 
study on the prevalence of pain in cancer patients (all disease stages, 
n=1429).30 Former breast cancer patients were selected if they had indicated in 
the earlier study that they were willing to provide information for future 
research. Eligible candidates were contacted by telephone to verify their 
willingness to cooperate and to check whether any of the exclusion criteria 
applied. Exclusion criteria were recurrent breast cancer or a new malignancy. 
Demographic data were available from the earlier study. All the participants 
gave informed consent.  
The study was approved by the Medical Ethics Committee of the University 
Hospital Maastricht, by the local ethics committees of the hospitals and by the 
group that coordinates studies that involve general practitioners (CEL). 
Instruments 
Concerns about recurrence of cancer were measured with the CARS-DLV. The 
CARS systematically assesses the extent and nature of women’s concerns 
about breast cancer recurrence.8 It has two main parts. In the first part, overall 
fear of recurrence is assessed with four questions on frequency, potential for 
upset, consistency and intensity of fear. Scores are given on a 6-point Likert 
 Concerns of Former Breast Cancer Patients about Disease Recurrence⏐117 
scale that can range from 1 (not at all) to 6 (continuously, terribly). In the 
second part, the nature of women’s concerns about recurrence is assessed 
with 26 items subdivided into four domains: health worries (eleven items), 
womanhood worries (seven items), role worries (six items) and death worries 
(two items). Scores are given on a 5-point Likert scale: not at all (0), a little (1), 
moderately (2), a lot (3) and extremely (4). The original CARS was found to be 
internally consistent (Cronbach’s α=0.89-0.94) and there is preliminary 
evidence of its validity.8  
The CARS was translated into Dutch by two independent translators (MdR, 
MvdB) and translated back into English by two other independent translators, 
one of who is a native English speaker (JP, C Lawrence). This back-translated 
English version was approved by Ms Johnson Vickberg who constructed the 
original version of the CARS.  
Pain was measured by four questions (pain now and pain over the past week: 
least, worst and average) derived from the Brief Pain Inventory (BPI).31 Scores 
could be given on an 11-point Likert scale that ranged from 0 (no pain) to 10 
(worst pain ever).  
Anxiety was measured by four questions (1, 3, 5, 7) from the Dutch version of 
the Hospital Anxiety and Depression Scale (HADS).32 The HADS was found to 
make good assessments of symptom severity and case ness of anxiety 
disorders (Cronbach’s α=0.68 -0.93) and depression (Cronbach’s α=0.67-0.90) 
in somatic, psychiatric and primary care patients, with a sensitivity and 
specificity of approximately 0.80.33 The four questions used in the present 
study showed high correlation (Sr=0.91) with the total fear scale of the HADS. 
Quality of life was measured with the RAND 36-item Short Form Health Survey 
1.0.34 The RAND evaluates eight health domains: physical functioning, bodily 
pain, role limitations due to personal or emotional problems, emotional well 
being, social functioning, energy/fatigue and general health perceptions. 
Internal consistency of the different scales varied from 0.71 to 0.92, while retest 
correlations varied from 0.58 to 0.82 after two months.35 
Dispositional optimism was measured with the Life Orientation Test (LOT).36 
The LOT is a 12-item questionnaire on generalized positive outcome 
expectancies (four items worded in a positive direction, 4 items worded in a 
negative direction and 4 filler items). 
Scores are given on a 5-point Likert scale that ranges from 0 (strongly 
disagree) to 4 (strongly agree). The test has shown adequate internal 
consistency (Cronbach’s α=0.76) and 4-week retest reliability (0.79).36  
Pain catastrophizing was measured using the Pain Catastrophizing Scale 
(PCS).37 The PCS consists of 13 items that are scored on a scale from 1 (not at 
all) to 5 (very much so). The Dutch version of the PCS (PCS-DV) showed good 
internal consistency (Cronbach’s α=0.85-0.91) and there is evidence of the 
construct validity and the concurrent validity.38 
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Procedure 
Each participant was sent the questionnaires and an informed consent form at 
their home address. They were asked to return the questionnaire even if they 
did not wish to participate. The first 50 respondents who returned a completed 
questionnaire were asked to complete a second questionnaire two weeks later 
that comprised the CARS and a health change score inventory. 
Statistics 
A confirmatory factor analysis was performed using Lisrel (version 8.30)39 to 
determine the loading of the different items in each domain. The fit was 
determined by the standardized Root Mean Square Residual (SRMR, adequate 
if ≤0.09)40 and the Comparative Fit Index (CFI, adequate if ≥0.95).40  
Internal consistency was estimated using Cronbach’s α coefficient.41 The 
Intraclass Correlation Coefficient (ICC) was used to determine the test-retest 
reliability of the CARS in the 50 participants who completed the questionnaire 
twice. 
Construct validity was tested by computing correlations between the CARS and 
related measures: anxiety (HADS), pain catastrophizing (PCS) and optimism 
(LOT).42 We predicted the various fear domains would correlate especially with 
anxiety and to a lesser extent with pain catastrophizing and optimism 
(negative).17  
Pain catastrophizing was expected to have the strongest correlation with health 
worries.  
As the scores on several of the questionnaires were not normally distributed, 
we employed nonparametric Spearman rank correlations. 
To examine whether fear of disease recurrence was significantly related with 
age, education level, living arrangements, pain and number of months since 
treatment, linear regression analyses were performed using SPSS version 
12.0.1. Age, number of months since treatment and pain were entered as 
continuous variables. Education was coded as a dichotomous variable (highest 
education completed: none, junior school or lower vocational training versus 
secondary school, advanced vocational training or university degree). The 
variable “living arrangements” (living alone versus with a partner) was coded 
dichotomously. Nonparametric Spearman rank correlations were used to 
investigate the correlation between quality of life and fear of disease 
recurrence.  
To further investigate whether the type of worries varied by time since 
treatment we created three subgroups: (<1 month, 1-12 months and >12 
months after treatment) and compared the scores of these subgroups on the 
different domains of the CARS using ANOVA. The two subgroups with a longer 
time since treatment were contrasted with the most recently treated group.  
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Results 
In the group of 174 eligible patients from the prevalence of pain study, fourteen 
could not be reached and nine had disease progression. A total of 136 out of 
the remaining 151 patients agreed to participate (response rate 90%). The 
response rate of the first 50 respondents who were asked to complete the 
second questionnaire for the test-retest was 100%. There were no differences 
in demographic characteristics between the responders and non-responders. 
Mean age of the participants was 59 years (SD 12). Most patients (n=84) 
finished their curative treatment six months or less before participation to this 
study. Only 12 women finished the therapy four or more years ago. 
Demographic features of the women are given in Table 6.1.  
 
Table 6.1 Demographic characteristics.  
 Responders 
n (%) 
Women  136 (100) 
Age groups (years) 20-40  
   40-60 
   60-80 
   ≥80 
 5 (4) 
 77 (56) 
 50 (37) 
 4 (3) 
Marital status Cohabiting 
   Widow 
   Divorced 
   Single 
   Missing 
 95 (70) 
 17 (12) 
 11 (8) 
 9 (7) 
 4 (3) 
Employment status Working 
   Housewife 
   Old-age pension 
   Disability pension 
   Sick leave 
   Missing 
 28 (21) 
 54 (40) 
 25 (18) 
 21 (15) 
 6 (4) 
 2 (1) 
Education Primary school 
   Secondary school  
   College/university 
 76 (56) 
 39 (29) 
 21 (15) 
Living arrangements At home with partner 
   At home alone 
   Other 
 107 (79) 
 27 (20) 
 2 (1) 
Months since treatment   0 
   1-6 
   7-12 
   13-24 
   25-36 
   37-48 
   49-60 
   >60 
   Missing 
 42 (31) 
 42 (31) 
 10 (8) 
 11 (8) 
 9 (6) 
 9 (6) 
 5 (4) 
 7 (5) 
 1 (1) 
Total  136 (100) 
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Reliability and validity of the Dutch version of the CARS 
Confirmatory factor analysis revealed adequate loading of all the items in each 
domain (Table 6.2). The SRMR was 0.088, while the CFI was 0.956.40  
Internal consistency (Cronbach’s α) was good in all the domains: overall fear 
α=0.94, health worries α=0.94, womanhood worries α=0.90, role worries 
α=0.88 and death worries α=0.90. 
 
Table 6.2 Confirmatory factor analysis of the Dutch version of the Concerns About Recurrence 
Scale. 
 Factor Loading 
Item (mean score) 1a 2 3 4 5 
How frequently do you think about the possibility of recurrence  
of the cancer? (item 1) 
.86     
How upset are you by the possibility of recurrence of your  
cancer? (item 2) 
.89     
How frequently are you concerned about the possibility that  
the cancer will recur? (item 3) 
.92     
How afraid are you about the recurrence of your cancer?  
(item 4) 
.92     
Upset me emotionally (item 5)  .79    
Will prevent me from planned activities (item 6)  .74    
Will threaten my physical health (item 7)  .83    
Require chemotherapy (item 9)  .76    
Make me feel I don’t have control over my life (item 11)  .83    
Make me feel less of a woman (item 8)   .80   
Threaten my identity ( how I see myself) (item 12)   .70   
Interfere with my sense of sexuality (item 18)   .74   
Threaten my spirituality or faith (item 23)   .62   
Lead me to feel less feminine (item 25)   .90   
Damage my romantic relationships (item 28)   .68   
Make me feel badly about how my body looks or feels (item 30)   .86   
Hurt my relationships with friends and family (item 10)    .56  
Interfere with my physical ability to carry out daily activities  
(item 13) 
   .82  
Harm my self-confidence (item 15)    .71  
Cause financial problems (item 17)    .44  
Keep me from fulfilling my responsibilities (in my home or at  
my job) (item 24) 
   .80  
Keep me from fulfilling important roles (in my home or at my  
job) (item 29) 
   .84  
Threaten my life (item 14)     .97 
Cause me to die (item 27)     .86 
a Factor 1 = overall fear, factor 2 = health worries, factor 3 = womanhood worries, factor 4 = role 
worries,  factor 5 = death worries 
 
 
The mean interval between the first assessment and the second assessment 
with the CARS was 22 days (range 9-54 days). There was no correlation 
between the interval and reproducibility. At the time of completing the second 
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list, 94% of the participants judged their condition to be the same, or slightly 
better or worse than at the first assessment. Only 6% of the participants called 
their condition (very) much better. The ICCs of all the domains were adequate: 
overall fear 0.78, health worries 0.86, womanhood worries 0.89, role worries 
0.79 and death worries 0.77. Construct validity was confirmed by Spearman’s 
correlation tests between the subscales of the CARS and the HADS, PCS and 
LOT (Table 6.3). All the correlations proved to be significant at the 0.01 level 
(two-tailed). 
 
Table 6.3 Construct validity of the CARS: Spearman’s correlation coefficients with the HADS, 
PCS and LOT. 
 HADS PCS LOT 
Overall worries 0.629a 0.336a -0.390a 
Health worries 0.665a 0.457a -0.307a 
Womanhood worries 0.504a 0.386a -0.309a 
Role worries 0.670a 0.375a -0.379a 
Death worries 0.594a 0.371a -0.335a 
a significant at the 0.01 level (two-tailed) 
Prevalence of worries and predictors 
Moderate to high overall levels of fear were reported by 56% of the women 
(Figure 6.1).  
Health worries (moderate to high (Likert 2-4) levels in 63%) and death worries 
(moderate to high levels in 61%) were the most prevalent. Moderate to high 
levels of role and womanhood worries were reported by 37% and 29%, 
respectively (Figure 6.1).  
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Figure 6.1 Prevalence of moderate to high levels of fear of overall disease recurrencea and for 
specific worry domainsb. 
 a moderate = CARS score of 3 or 4, high = CARS score of 5 or 6; b moderate = CARS 
score of 2, high = CARS score of 3 or 4 
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Pain was a strong predictor of overall fear and of fear on the four subdomains 
of the CARS (Table 6.4). The prevalence of fear decreased significantly with 
age. Education level, living arrangements (at home with partner or at home 
alone) and time since the last treatment did not have any predictive value on 
the prevalence of overall fear (Table 6.4). Older women were significantly less 
worried about health, role and death than the younger women. Women with 
high education levels had significantly more health and role worries than 
women with low education levels (Table 6.4). Women living alone had a lower 
level of role worries than the women living with a partner. 
 
Table 6.4 Results of the backward linear regression with the domains of the CARS as 
dependents: Predictors of the level of fear of disease recurrence. 
 Stand. β P 
Overall fear R2=0.127, F=9.288, p<0.001 
   Pain 
   Age 
   Months since last treatment 
   Living arrangements 
   Education 
Health worries R2=0.203, F=10.382, p<0.001 
   Pain 
   Age 
   Months since last treatment 
   Living arrangements 
   Education 
Womanhood worries R2=0.107, F=14.815, p<0.001 
   Pain 
   Age 
   Months since last treatment 
   Living arrangements 
   Education 
Role worries R2=0.295, F=14.282, p<0.001 
   Pain 
   Age 
   Months since last treatment 
   Living arrangements 
   Education 
Death worries R2=0.138, F=9,966, p<0.001 
   Pain 
   Age 
   Months since last treatment 
   Living arrangements 
   Education 
 
 0.286 
 -0.211 
 -0.035 
 -0.072 
 -0.046 
 
 0.359 
 -0.204 
 0.019 
 -0.005 
 0.167 
 
 0.328 
 -0.095 
 0.043 
 0.041 
 0.043 
 
 0.429 
 -0.300 
 0.053 
 -0.157 
 0.190 
 
 0.235 
 -0.293 
 -0.001 
 -0.007 
 0.051 
 
 0.001a 
 0.012a 
 0.679 
 0.422 
 0.587 
 
 <0.001a 
 0.014a 
 0.822 
 0.956 
 0.042a 
 
 <0.001a 
 0.294 
 0.629 
 0.655 
 0.628 
 
 <0.001a 
 <0.001a 
 0.492 
 0.050a 
 0.013a 
 
 0.006a 
 0.001a 
 0.986 
 0.934 
 0.552 
a significant predictors 
 
Differences in type of worries between the three subgroups of time since 
treatment (<1 month, 1-12 months and >12 months) were examined by 
ANOVA. Neither on overall fear nor on any of the subdomains significant 
differences in worries between the subgroups (Figure 6.2) were found (overall 
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fear: F(2,21)=0.12, p=0.89; health worries: F(2,21)=0.051, p=0.95; womanhood 
worries: F(2,21)=1.11, p=0.33; role worries: F(2,21)=0.08, p=0.92; death 
worries: F(2,21)=0.14, p=0.87). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Association between quality of life with worries about recurrence 
All the domains of the CARS were negatively associated with all the domains of 
the RAND (physical functioning, social functioning, role limitations (physical 
problems), role limitations (emotional problems), mental health, vitality, bodily 
pain, general health perception) (Table 6.5). 
The highest correlation was found between worries and mental health. Role 
worries had the most negative effect on quality of life. 
 
Table 6.5 Spearman’s correlation coefficientsa between fear of disease recurrence and quality of 
lifeb. 
 Overall 
worries 
Death 
worries 
Health 
worries 
Role 
worries 
Womanhood 
worries 
RAND2 
Physical functioning 
Social functioning 
Role limitations (physical problems) 
Role limitations (emotional problems) 
Mental health 
Vitality 
Pain 
General health perception 
 
-0.215 
-0.390 
-0.240 
-0.388 
-0.574 
-0.376 
-0.272 
-0.268 
 
-0.236 
-0.289 
  -0.179c
-0.264 
-0.417 
-0.289 
  -0.215c
-0.302 
 
-0.359 
-0.375 
-0.292 
-0.322 
-0.499 
-0.381 
-0.358 
-0.380 
 
-0.423 
-0.538 
-0.382 
-0.468 
-0.599 
-0.528 
-0.391 
-0.402 
 
-0.369 
-0.350 
-0.309 
-0.338 
-0.489 
-0.410 
-0.315 
-0.367 
a All bold correlations were significant on the 0.01 level (two-tailed); b RAND 36-item Health Survey 
1.0; c p=0.05. 
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Figure 6.2 Mean scores of health, womanhood, role, death and overall worries at different points 
after treatment. 
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Discussion 
This study on the Dutch Language version (CARS-DLV) of the CARS 
confirmed the good internal consistency, test-retest stability and construct 
validity found in the original study.8 In the literature on the four questionnaires 
constructed to measure fear of recurrence, data on reliability and validity have 
only been published on the Northouse Fear of recurrence questionnaire20 and 
the CARS. Although all the other available questionnaires will yield similar 
prevalence rates of fear of recurrence, the CARS gives extra valuable 
information about what the women fear most. 
Moderate to high levels of overall worry were found in 56% of the women. This 
is in concordance with earlier studies that reported prevalence rates of 
moderate to severe fear of recurrence in 55%,8 49% (in post-mastectomy 
patients) and 46% (after breast conserving therapy (BCT)).10 In a group of 
elderly patients (>70 years) the prevalence of moderate to severe fear was 
even as high as 85%.11 Other studies reported an overall (mild, moderate or 
severe) prevalence of fear of recurrence that ranged from 31 to 70%.7,12-14,17 
Several authors described fear of recurrence in more general terms: 22% of the 
women declared that fear of recurrence was their most distressing problem;15 
in many patients, fear of recurrence permeated day-to-day life one year post-
cancer diagnosis;43 fear of recurrence29 was a very commonly shared 
experience; fear of recurrence was a major concern45 or frequently expressed45 
or present to a considerable degree.1 
In agreement with the earlier study by Vickberg,8 women predominantly 
expressed worries about death and health, whereas role worries and 
womanhood worries seemed to be weaker concerns. 
Our data showed a high prevalence of fear of disease recurrence in former 
breast cancer patients. A few results have also been published on the 
prevalence of fear of recurrence in patients with other types of cancer, e.g. 
orofacial: >80% and 72% at three and seven months post-therapy, 
respectively,46 gynecological: between 22-64%,47-50 colorectal: between 
27-33%17 and prostate: 39%.17 Patients and their partners stated that disease 
recurrence was their greatest fear after colorectal cancer.51 
 
In our study, the time elapsed since the last treatment was not associated with 
the prevalence of fear of disease recurrence. The literature is contradictory 
about the influence of time on the fear of recurrence. Some studies suggested 
that as time progressed the fear of recurrence decreased,12,13,17,52,53 whereas 
most studies found that time made little difference,28,54-57 even more than 20 
years after diagnosis. Importantly, time since diagnosis was unrelated to the 
frequency of the most important trigger factors for fear of recurrence, e.g. 
hearing that someone else has cancer, new aches or pains, environmental 
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reminders (e.g. sights, sounds and smells associated with the period 
surrounding breast cancer diagnosis and treatment), information from the 
media and doctor’s appointments.57 In our study, pain was significantly 
correlated with all the domains of the CARS and thus appeared to be an 
important trigger.  
 
Women of more advanced age expressed lower levels of worry in the total, 
health, role and death domains than the younger women. For womanhood 
worries no differences were found between elder and younger women. These 
findings are in concordance with the existing literature.8,17,57 Explanations could 
be the generally more aggressive nature of breast cancer in younger women 
and/or the sense that developing cancer early in life is particularly unexpected 
or “off schedule”.8 Previous studies demonstrated that older women reported 
significantly fewer triggers than younger women.57 
In our study, the women with a higher education level expressed more health 
and role worries than the women with a lower education level. This may be 
explained by the fact that in earlier studies significantly more triggers were 
reported by the women with a higher education level.57  
We did not find any relationship between the fear of disease recurrence and 
living with a partner or alone. Only in the domain of role worries women living 
with a partner expressed more worries. An earlier study also reported that living 
arrangements did not influence the level of fear.20 However, a strong 
relationship was found with the presence of significant others, not necessarily 
living in the same house.20 In the present study, we did not record information 
on the presence of significant others. 
 
Although the literature showed an overall good quality of life in former breast 
cancer patients, fear of disease recurrence was significantly associated with a 
poorer quality of life: worries about cancer were negatively associated with all 
the domains of the RAND. Although the differences were small, especially role 
worries negatively influenced quality of life. More research into different 
predictive value of the various domains is warranted. Worries about disease 
recurrence exerted their negative influence on quality of life predominantly in 
the mental health domain of the RAND. So, worries about disease recurrence 
are mainly a psychological burden. This was also demonstrated by the 
increased prevalence of post-traumatic stress disorder (PTSD) in former breast 
cancer patients7 and the positive relation between cancer-related fears and 
anxiety and depression.17   
In our opinion, targeted interventions are warranted, because fear of 
recurrence can persist for many years after treatment and it has negative 
effects on quality of life. Unfortunately, very little is known about the effect of 
psychosocial interventions after the treatment phase.5 To bridge this gap, a trial 
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recently addressed women’s  concerns about disease recurrence 5-9 years 
after breast cancer treatment.58 Over a period of eight months, nurses guided 
the respondents (by means of four weekly telephone sessions) in the use of 
audio taped cognitive-behavioral strategies to manage concerns about disease 
recurrence. At ten months after the start of the intervention, the women 
demonstrated enhanced coping skills directed towards their fear of tumor 
recurrence.  
 
A potential limitation of our study is the relatively small sample size. This could 
raise questions about the validity of the confirmatory factor analysis. However, 
the empirical basis for the common rule that a researcher needs at least 10 
participants per variable is unclear.59 More recently it was indicated that as 
communalities become lower the importance of sample size increases.60 With 
communalities above 0.6, relatively small samples (less than 100) may be 
perfectly adequate. According to MacCallum60 our study with communalities 
around and above 0.6, a variables to factor ratio of 30:5 and a sample size of 
136 will achieve a convergence of 100%. 
Another limitation is the use of only one fear of recurrence questionnaire. For 
further validation of the overall fear component the use of other questionnaires 
is recommendable. Future research should also include more potential 
predictors like TNM stage and treatment modalities. Finally, in our study most 
women had had there last treatment less than one year ago. For long-term 
conclusions about the worries in the different domains future research should 
concentrate on women longer after diagnosis and treatment. 
Conclusion 
The CARS-DLV proved to be a valuable instrument to measure womens’ 
concerns about breast cancer recurrence. It not only measured the prevalence 
of overall fear, but also specified worry levels in different domains. More than 
half of former breast cancer patients indicated moderate to severe concerns 
about disease recurrence. Health and death worries were the most prominent. 
The levels of worry were independent of the time since diagnosis, which was in 
agreement with reports in the literature that worries about recurrence tended to 
compromise quality of life for many years. 
In response to the increasing number of long-term breast cancer survivors, 
research should focus on quality of life and psychosocial adjustment to the 
disease. 
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Summary and general discussion 
The number of people with cancer is growing due to its early detection and the 
progress being made in anti-cancer treatment.1 In 2005, the 20-year 
prevalence of cancer in the Netherlands was estimated to be over 450,000 
persons (2.8%), and is expected to rise to 692,000 in 2015.1  
Patients with cancer often have multiple symptoms that may considerably 
affect their sense of well-being and physical and social functioning. The aim of 
this thesis is to gain insight into the prevalence of physical (pain and non-pain) 
and psychological symptoms in patients with cancer, and the influence these 
have on quality of life. Both physical and psychological symptoms are 
addressed in patients with cancer at all stages of the disease, ranging from 
cured to far-advanced. 
The main findings of this thesis will be discussed by addressing our original 
research questions. Methodological issues including strengths and limitations 
will be discussed. Thereafter, the results of the studies will be discussed in 
order to demonstrate the consequences to health care practice, leading to 
further research. 
Main findings 
Review of the literature on prevalence of pain in patients with 
cancer 
Despite the abundance of literature on pain in cancer patients, no previous 
reviews provide accurate estimates regarding prevalence. We performed a 
systematic review that included the statistical pooling of study results in an 
attempt to obtain accurate figures on the prevalence of cancer pain during the 
period 1966-2005. 
The pooled data from 52 articles showed that pain was prevalent in cancer 
patients: 64% of patients with metastatic or advanced-stage disease, 59% of 
patients on anti-cancer treatment, and 33% of patients after curative treatment. 
More than one-third of patients with pain in the reviewed articles graded their 
pain as being moderate or severe.  
Only 34% of the retrieved articles reached the predefined quality score. A 
combination of shortcomings in representativeness and data collection method 
(the two criteria with the heaviest weighting) was the main reason for not 
reaching an adequate quality score. In the bivariate regression analyses, none 
of the covariates (type of cancer, period of publication, continent of origin, 
mean age of the study population, type of prevalence, use of validated or non-
validated questionnaires or interviews) were significantly associated with the 
134⏐Chapter 7 
prevalence rates of pain. We concluded that: (1) future studies on the 
prevalence of pain in cancer patients should take representativeness, response 
rates, and the description of non-responders into consideration, and should 
provide information on the severity, duration, frequency, and amount of 
interference. The use of multi-dimensional tools during research will facilitate 
the comparison of studies and the planning of what is necessary from pain 
services.  
Studies on the prevalence of pain in cancer survivors are scarce. This topic 
should be addressed in future studies; and (2) despite the clear WHO 
recommendations, cancer pain still is a major problem. The increasing number 
of cancer survivors who live to an advanced age means that it is of paramount 
importance to reduce the prevalence of pain at all stages of the disease 
process. 
Prevalence of pain in patients with cancer 
A population-based study was conducted in a large group of cancer patients 
(all disease phases) in order to make reliable estimations of the prevalence and 
severity of pain in these patients, to map predictors of cancer pain, and to 
establish the adequacy of pain treatment.  
We found that 55% of the 1429 respondents had experienced pain in the 
preceding week; in 44% (n=351), the pain was moderate to severe (BPI score 
≥4).  
Positive predictors of the prevalence of pain were lower educational level, more 
advanced disease, and haematological (excluding (non)-Hodgkin lymphoma), 
gastro-intestinal, lung, or breast malignancies. According to the PMI, analgesic 
treatment was inadequate in 42% of patients. Negative predictors of adequate 
treatment were current curative anti-cancer treatment and low educational 
level.  
We concluded that the prevalence of pain in patients with cancer is still far too 
high. The prevalence of moderate to severe pain in patients treated with 
curative intent was as high as that of back pain. One-quarter of the patients on 
anti-cancer treatment and more than half the patients with advanced/terminal 
disease suffered from moderate to severe pain. Pain management was 
insufficient in almost half the patients in this study. We recommend better 
education with regard to pain and pain treatment in the curricula of medical 
professionals, and systematic recording of pain intensity in cancer patients, 
irrespective of the phase of the disease.  
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Prevalence of non-pain physical and psychological symptoms in 
patients with cancer 
A population-based study was conducted in a large group of cancer patients in 
order: (1) to measure the prevalence of non-pain symptoms (classified 
according to treatment status and tumour type); (2) to determine the quality of 
life of patients with different types of cancer and at different treatment phases, 
and to investigate the impact of physical and psychological symptoms on their 
quality of life; and (3) to inquire whether the patients had received treatment for 
their complaints/symptoms. 
In the 1429 respondents, the prevalence of all non-pain physical and 
psychological symptoms increased with the progression of the disease. 
Patients (being) treated with curative intent experienced symptoms that were 
independent of cancer type. Symptoms experienced by patients treated with 
palliative anti-cancer therapy varied according to type of cancer. Feelings of 
weakness, tiredness, and the need to rest were the most prevalent symptoms 
in patients with moderate to severe physical complaints in all disease groups. 
Vomiting was the least prevalent physical symptom in all disease groups. With 
regard to psychological symptoms, moderate to severe worry was the most 
prevalent in all disease groups and irritability was the least prevalent.  
Quality of life decreased significantly as the disease progressed. Fatigue, loss 
of appetite, constipation, dry mouth, depression, and anxiety all had an 
independent negative influence on quality of life.  
Our study showed that many non-pain symptoms remained untreated, although 
(partially) effective treatment is available for most symptoms. This illustrates 
the need for better education with regard to symptoms and symptom control in 
the curricula of medical professionals. Systematic recording of symptom 
intensity in patients with cancer, irrespective of the phase of the disease, is 
mandatory. 
An intensive nursing intervention for cancer patients suffering 
from pain in their home situation 
Factors relating to the ineffective treatment of pain fall into three categories: the 
health care system, professional care providers, and patients. In patients, 
various barriers can lead to non-compliance. Previous educational 
interventions have increased patients’ knowledge of pain and decreased short-
term pain levels. In this randomised controlled trial, we investigated how an 
intensive home-based educational programme given by nurses affected short- 
and long-term pain levels.  
At week four, pain was significantly lower in the intervention group (n=45) than 
in the control group (n=48). By week eight, this difference had disappeared. 
During the eight-week intervention period, knowledge of pain was significantly 
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increased in the intervention group. Over time, no significant effects were noted 
with regard to quality of life, anxiety or depression. Of the 37 times that advice 
was given (in writing to the primary care-giver) with regard to a change of 
medication in order to optimise pain control, this was only followed in 19%. 
We conclude that a nursing intervention programme can help patients with 
cancer to deal with their pain, increase the level of knowledge of pain, and 
have a short-term positive effect on pain levels.  
Concerns of former breast cancer patients about disease 
recurrence 
The present study had three aims: firstly, to evaluate the psychometric 
properties of the Dutch version of CARS (CARS-DLV) in terms of internal 
consistency, test-retest reliability, and construct validity; secondly, to measure 
the prevalence of concerns about the recurrence disease in former breast 
cancer patients and to identify potential predictors; and thirdly, to establish how 
fear of recurrence effects quality of life.  
Moderate to high levels of fear of recurrence were noted in 56% of 136 breast 
cancer survivors. Worries about health and death were seen most frequently. 
Pain was a strong predictor of overall fear and of fear in the four sub-domains 
of CARS. The prevalence of fear decreased significantly with age. Educational 
level, living arrangements, and time since the last treatment did not predict the 
prevalence of overall fear. Fear of recurrence was negatively correlated with 
quality of life. 
CARS appeared to be a valuable tool for researchers and clinicians seeking to 
understand patients’ fears regarding the recurrence of breast cancer. 
We concluded that, in response to the increasing number of long-term breast 
cancer survivors, research should focus on quality of life and psychosocial 
adjustment to the disease. 
Methodological considerations 
Sample size 
We recruited a fairly large sample of patients for the prevalence studies 
described in Chapters 3 and 4. However, despite the proper format used and 
all our efforts to encourage GPs, nursing home physicians, and hospice 
nursing staff to recruit patients with advanced disease, the number of these 
patients was small. Therefore, this particular group may not be representative 
of patients with metastatic/advanced disease. Selection by GPs, nursing home 
physicians, and hospice nursing staff could have excluded those patients in the 
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most terminal phase of their illness. It is not clear how this selection influenced 
the prevalence of pain. Several studies have shown that pain prevalence 
decreases at the very end of life2-5 which would mean that we slightly 
overestimated the prevalence of pain in group 3. However, other studies have 
shown an increase in the prevalence of pain at that phase.6,7 Very few studies 
have been published with regard to non-pain symptoms at the very end of life. 
One such study2 showed that the prevalence of confusion, anorexia and 
dysphagia increased during the final 48 hours of life. On the other hand, a 
decrease in the prevalence of depression, coughing, and nausea was also 
seen. Another study showed an increase of dyspnoea during the final week of 
life, but no differences regarding the other symptoms.3  
 
In the CARS validation study (Chapter 6), the sample size of only 136 
participants could raise questions with regard to the validity of the confirmatory 
factor analysis.  
However, the empirical basis for the common rule that a researcher needs at 
least ten participants per variable is unclear.8 More recently, it was indicated 
that as communalities become lower, the importance of sample size 
increases.9 With communalities of above 0.6, relatively small samples (less 
than 100) may be perfectly adequate. According to MacCallum, our study with 
communalities of around and above 0.6, a variables-to-factor ratio of 30:5, and 
a sample size of 136 would achieve a convergence of 100%. 
Quality criteria 
The studies used for the review in Chapter 2 were evaluated based on the 
methodological criteria of Leboeuf-Yde and Lauritsen,10 which were the first to 
be especially constructed for prevalence studies. Walker11 improved these 
criteria by adding a test to identify proxy reporting, and suggested that some 
weighting should be given to the various criteria. In our paper, the criteria 
specific for lower back pain were substituted by an adequate description of the 
disease stage and/or condition of the cancer patients, and a weighting factor 
was introduced for each criterion. This resulted in a quality score that ranged 
from 0 to 19 points. The cut-off level for methodological acceptability was set at 
14 points, which was 75% of the total points that could be achieved.10 
The fact that the instrument used to judge methodological quality was devised 
subjectively to review the prevalence of lower back pain should be taken into 
consideration.10,11 The 75% threshold for acceptability was set as 
conservatively as possible. In order to make the instrument suitable to review 
the prevalence of cancer pain, we substituted the criteria for the definition of 
lower back pain for the criteria on disease stage in cancer. These may be 
points for further improvement. Proxy reporting and the retrospective study of 
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medical records probably merit even less weighting. Adequate description of 
the disease stage probably merits more weighting, but subdivision of the use of 
validated or non-validated questionnaires does not appear to be necessary. 
When are symptoms mild, moderate or severe? 
Cancer pain has been the model for symptom assessment. In order to derive 
meaningful classifications of pain severity, on from 0- to 10-point rating scales, 
patients’ reports of each severity level have been paired with ratings on how 
such pain interferes with their lives.12 However, the subdivision of pain severity 
into mild, moderate, or severe remains arbitrary. In particular, the NRS scores 
4 (mild12-20 or moderate21-26) and 7 (moderate18,22,23,26 or severe12-15,18-
21,24,25,27,28) give rise to discussion. We chose Serlin’s criteria for our review 
(Chapter 2).12 However, in our own prevalence study (Chapter 3), both the brief 
pain inventory and the EORTC quality of life questionnaire were used to 
measure pain: the majority of our patients considered a score of 4 to represent 
moderate pain rather than mild pain, while slightly more than half considered a 
score of 7 to represent severe pain rather than moderate pain. Therefore, we 
used different criteria for moderate and severe pain in this thesis. It is important 
to realise that the interpretation of pain by the patient is the most important 
parameter on which treatment is based, while most patients will accept mild 
pain, moderate and severe pain will require attention.12  
Much less work was carried out to establish the cut-of points for mild, 
moderate, and severe non-pain symptoms. Recently, it was found that cut-of 
points differ between symptoms.29 Cut-points were related to limitations in 
physical functioning, suggesting differences in the quality of patients’ lives.29 
For example, with fatigue, an NRS score of 1 is considered mild, 2-4 moderate, 
and 5-10 severe, whereas with dry mouth, an NRS score of 1-4 is considered 
mild, 5-6 moderate, and 7-10 severe. 
General discussion 
Pain 
In cancer patients, pain is one of the most feared and burdensome symptoms. 
Our review with the pooled data from 52 articles showed that pain is still highly 
prevalent in cancer patients: 64% of patients with metastatic or advanced stage 
disease, 59% of patients on anti-cancer treatment, and 33% of patients after 
curative treatment. More than one-third of patients with pain in the articles 
reviewed graded their pain as moderate or severe. Moreover, in our study of 
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pain in patients with cancer, the prevalence rate was far too high (55%). The 
prevalence of moderate to severe pain in patients treated with curative intent 
was just as high as that of back pain in the general population. One quarter of 
patients undergoing anti-cancer treatment and more than half the patients with 
advanced/terminal disease were suffering from moderate to severe pain. These 
high prevalence figures contrast sharply with the rapidly increasing interest in 
pain and pain relief over the past decade. Apparently, greater insight into the 
pathophysiological mechanisms of pain, and the wider availability of anti-
nociceptive therapies, such as opioids, co-analgesics, and NMDA-receptor-
antagonists, have not influenced the prevalence rates of pain in cancer 
patients. Moreover, the WHO introduced a pain ladder in 1986,30 which has 
been accepted worldwide. Combined with appropriate dosage guidelines, this 
pain ladder should be able to provide the proper tools for adequate pain relief 
in 70-90% of patients.31-36 The gap between what is possible in pain control and 
what is actually achieved, is caused by many different care-provider-related, 
patient-related and society- and tradition-related factors.37 Fear of medication in 
general and opioids in particular, patients wanting to be ‘good’, lack of 
knowledge, lack of interest, and requests from care providers, are well-known 
barriers against adequate pain control.38-47  
Care providers 
Important barriers to effective pain management created by physicians and 
nurses are: 
1. lack of formal assessment procedures for pain (57-76%);48-50  
2. misconceptions about medications and side effects (23-61%);51-55 and  
3. insufficient knowledge of / training in pain (23-54%).47,48, 51-58  
 
Addendum 1. In less than half the cancer in-patients did nurses talk about pain 
with the patient.59 In only 27% of medical and nursing dossiers was the word 
pain mentioned.59,60 Conflicting reports exist on the agreement about symptoms 
between patients, nurses, and physicians. Some studies found that physicians 
tend to underestimate the severity of pain,61-64 while others found adequate 
agreement between patients, district nurses and GPs about the severity of 
pain.65 However, physicians do underestimate the influence of pain on daily 
life58,66  
 
Addendum 2. Approximately half the physicians had misconceptions about 
drug tolerance,51,54 20-25% of nurses and physicians expressed concerns 
regarding addiction,52,54 and 20–30% of physicians and nurses believed that 
moderate to severe pain is inevitable in patients who are terminally ill.48,52 
Moreover, 31% of physicians waited with optimal pain control until the patient’s 
prognosis was less than six months,47 and 41% of nurses reported that use of 
140⏐Chapter 7 
analgesics should be limited, based on the patient’s prognosis.67 And finally, 
only 74% of in-patients receive their prescribed (breakthrough) pain 
medication.68 
 
Addendum 3. Several studies have attempted to evaluate physicians’ 
knowledge and behaviour in prescribing pain medication. Although the majority 
of physicians expressed familiarity with the WHO analgesic ladder, and 44% 
indicated that they used these guidelines in their clinical practice, when replying 
to a hypothetical scenario, only 7% of GPs and 13% of specialists used the 
principles of the WHO ladder.56 Other studies revealed that, in 54% of cancer 
patients, pain specialists disagreed with the pain medication prescribed,69 23% 
of patients only received breakthrough medication,70 and 13–20% of patients 
were inadequately informed about their medication and how to use it.70  
A recent review of physician-related barriers to cancer pain management 
concluded: concerns about the side effects of opioids, prescription of inefficient 
doses of opioids, and very poor prescription for treatment of the side effects of 
opioids, are the most general and common physician-related barriers to cancer 
pain management.71  
 
The barriers of care providers lead to the undertreatment of cancer-related 
pain. In our prevalence study, the treatment of pain was insufficient in 42% of 
1383 patients, according to the pain management index (PMI). Previous 
studies reported negative PMI scores in 30-82% of patients.19,22,38,58,72-80 
Although PMI is widely used to determine the adequacy of pain management, it 
does not take into account adequate dosage and the use of co-analgesics.72 
The not taking into account of adequate dosing probably leads to the 
underestimation of undertreatment. This explains why patients with metastatic 
disease (who make greater use of strong opioids) have the highest pain 
scores, despite their encouraging PMI rates.72,73 On the other hand, it could be 
hypothesized that not taking co-analgesics into account leads to an 
overestimation of undertreatment. However, both in our study and in others, the 
use of co-analgesics was extremely low (5-7%),74 so this hypothesis does not 
hold. 
Interventions 
Goldberg and Morison (2007) conducted a systematic review of institutional 
interventions designed to improve the assessment and treatment of pain in 
cancer patients.75 This review included three trials which studied the effects of 
educational sessions for nurses.76-78 It was concluded that didactic sessions for 
nurses can improve their knowledge and attitude. However, these interventions 
did not result in a significant decrease in the severity of pain.75 Only one study 
compared usual pain management with treatment, based on a multilevel 
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treatment algorithm by specialized physicians: a statistically significant 
reduction in pain intensity was seen.79 
One interesting study requested 320 patients to complete pain 
questionnaires.80 In half these patients, summaries of the questionnaires were 
placed in their charts and reviewed by their oncologists. Summaries were not 
provided for patients in the control group. In the experimental group, 25% of 
prescriptions were altered, and there was a significant decrease in the reports 
of pain. 
Both from our study and from the literature, it can be concluded that physicians 
play a major role in undertreatment, and thus in the high prevalence of pain in 
patients with cancer patients 
Several studies have pointed to a wide range of patient-related barriers to 
adequate pain management in 37-85% of patients.38 There is a significant 
relationship between the number of concerns and the prevalence of pain and 
undertreatment.38 These include the reluctance of patients to report pain to 
their care provider and their reluctance to take medication. Patients are loath to 
inform their care providers about pain because they worry that this would 
distract their physician from treating their cancer.42,45 Half the patients want to 
be ‘good’, and a good patient does not complain.38,42,61 Twenty to seventy 
percent of patients believe that nothing can be done to ease their pain 
(fatalism),61,81 or they believe that having to bare pain is part of having cancer.81 
Moreover, patients may fear that their pain is indicative of the progression of 
the disease, and they do not want to have to face that possibility.46  
Patients are reluctant to take medication: fear of addiction continues to be a 
major concern in patients and their families (27-83%).45,61,81 Thirty to seventy-
two percent of patients express concerns about tolerance,61,81 and about 25% 
believe that pain medication is ‘bad’ for the body.82 Moreover, in our study, the 
items ‘taking the lowest amount of medicine possible’, “using routine 
medication instead of on demand’ and ‘becoming addicted’ had the lowest 
score levels. 
It is widely believed that the barriers perceived by patients lead to non-
adherence to analgesic regimens. Self-reported adherence was found to be 40-
67% for all analgesics.83,84 The proportion of patients who adhered to ‘around-
the-clock’ analgesics varied from 59-91%.43,74 Adherence to ‘as needed’ 
analgesics regimens was only 17-27%.43,74  
Interventions 
 Several studies have shown pain education programmes to have a positive 
effect on patients with respect to the experience of pain,85-91 medication 
adherence,85,87,90,91 and worries about addiction and tolerance.85,87,90 
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Unfortunately, many studies were small in size, used low-intensity education 
programmes, and only measured the short-term effects. Our study, as well as 
that of Syrjala91 also looked for the long-term effects. However, the chosen 
outcomes of pain were only found in the short term. 
Recently, Bender et al. identified over 200 questions about pain and pain 
management in 18 patients.92 The pain management statistics of 11 patients 
revealed that the main reasons for being reluctant to take analgesic medication 
were: previous experience with chronic pain treatment, including stigmatising 
interactions with clinicians and family; bad experience with pain medication, 
including constipation; and strongly held conventions about the use of 
medication, including the belief that all medications are ‘poisons’.93 It would be 
hard to address all these questions and worries in the context of a typical 
consultation.9  
Health system 
In many European countries (excluding the Netherlands, Belgium and 
Scandinavia), governments and legislators are very restrictive about the use of 
opioids.37 Other system-related barriers are the lack of one physician being 
responsible for the treatment of pain and too infrequent contacts.94  
Summary 
The education of health care providers and patients into pain and the proper 
use of the tools provided by the WHO is urgently needed. Physicians and 
nurses should ask about pain, patients should tell their care providers about 
their pain. Lowering the prevalence of pain in patients with cancer will be time 
consuming, both for patients and for health care professionals. Nursing 
services being available to assess symptoms and to train patients and answer 
questions, could be a step in the right direction. 
Non-pain physical symptoms 
 Apart from pain, cancer patients suffer from many other symptoms that 
interfere with their quality of life. By definition, patients with cancer are poly-
symptomatic.23,27,95-98 The prevalence of non-pain physical symptoms has been 
addressed much less frequently than the prevalence of pain, and then mainly in 
patients with advanced or metastatic disease.23,99-103 Studies of non-pain 
symptoms in ambulatory or cured patients are rare and mainly focus on a 
particular symptom in a particular type of cancer.104-106 However, non-pain 
physical symptoms are extremely frequent in cancer patients. In patients who 
had been cured and who had received their final anti-cancer treatment more 
than six months earlier, the only symptoms that were more frequent than in a 
general population were sleeping problems and tiredness. In all other patients, 
 General discussion⏐143 
all non-pain physical symptoms were more frequent than in a general 
population. Of the non-pain physical symptoms, fatigue (p<0.001), appetite loss 
(p=0.004) and dry mouth (p=0.039) had an independent significant negative 
effect on overall quality of life. In patients after or during curative anti-cancer 
treatment, both the number of symptoms and their type depended on the type 
of cancer. However, in patients at the palliative phase, not the type of cancer 
but the severity of the disease determined the number and type of symptoms. 
In our study, demographic characteristics were not significant in the regression 
analyses. However, Bradley et al.23 reported significantly higher rates of the 
prevalence of nausea and anxiety in females, and significantly higher anxiety 
scores in patients aged 69 years or less. Sex of the patients was also 
associated with an increased symptom burden, with females scoring higher 
than males.23  
As stated earlier, it is important to realise that, in measuring the severity of non-
pain symptoms, the cut-of points for mild, moderate and severe, differ between 
symptoms, due to limitations in physical functioning.29 For example, in the case 
of fatigue, an NRS score of 1 is considered mild, 2-4 moderate, and 5-10 
severe, whereas in dry mouth, an NRS score of 1-4 is considered mild, 5-6 
moderate, and 7-10 severe. 
 
Although symptom management research has, in general, focused on 
individual symptoms, patients and the clinicians caring for them know that 
symptoms clearly occur together and that they may exacerbate the severity of 
each other.107 Several investigations have shown that the presence of multiple 
symptoms was associated with poorer patient outcome.27,108-116 In order to 
increase our scientific understanding of multiple, complex disease- and 
treatment-related symptoms that influence patient outcomes, the concept of 
symptom clusters was introduced in 2001.109 A symptom cluster is defined as a 
stable group of two or more concurrent symptoms that are related to each 
other.117 Cluster symptoms may or may not share the same aetiology.118 
However, the clinical implications of the current state of knowledge on 
symptom clusters are limited.119 For example, when symptoms are related, the 
treatment of one symptom in the cluster should have an impact on the other 
symptoms in the cluster. As yet, there is no reported research on the treatment 
of formally identified symptom clusters.107 Although they are grouped, we will 
discuss the various symptoms independently, while realising the impact they 
may have on each other. 
Dyspnoea 
The prevalence of moderate to severe dyspnoea increases with progression of 
the disease (14% in group 1a to 46% in group 3). In a general Norwegian 
population, moderate to severe dyspnoea was found in 10% of participants.120 
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In a review, Ripamonti121 demonstrated moderate to severe dyspnoea in 
10-63% of advanced cancer patients. In a recent review, 35% (19-77%) of 
advanced cancer patients experienced dyspnoea,122 while in the final two 
weeks of life, 39% experienced dyspnoea.122 Much less is known about the 
prevalence of dyspnoea in general cancer outpatients. One study reported 
moderate to severe dyspnoea in 15% of outpatients.123 No reports on cancer 
patients who had been cured were found. 
Dyspnoea is most prevalent in patients with lung cancer. Our findings of 
moderate to severe dyspnoea in 30-58% of ambulatory lung cancer patients 
are in accordance with the existing literature. Shortness of breath was found to 
be as prevalent as 73% in one study,105 and clinical dyspnoea, defined as 
dyspnoea interfering with daily life, was found in 55% of ambulatory lung 
cancer patients.124  
Fifty-seven percent of patients with moderate to severe dyspnoea indicated 
that they were not being treated for their complaint. Whenever possible, an 
attempt should be made to treat the underlying cause of the dyspnoea: by 
treating the cancer, pleural effusion, thrombo-embolism, infection, etc. 
However, even when a cause-targeted therapy is no longer possible, much can 
be done to reduce the feeling of breathlessness (opioids, psychotropic drugs, 
corticosteroids).125  
Fatigue and trouble sleeping 
Feelings of weakness, tiredness, and the need to rest (together forming the 
EORTC construct ‘fatigue’) were the most prevalent symptoms in all disease 
groups: moderate to severe complaints in disease group 1a (curative anti-
cancer therapy >6 months earlier) compared to a general Norwegian 
population (16%, 22% and 21%).120 As the disease progressed, there was a 
rapid increase in the prevalence of feelings of weakness, tiredness, and the 
need to rest to 65%, 69%, and 74% in group 3. These figures are in 
accordance with the existing literature. In patients who had survived breast 
cancer, 35% and 34% reported fatigue at one to five years and five to ten 
years, respectively, after completion of treatment.126 More than 80% of 
outpatients receiving chemotherapy or radiotherapy reported some degree of 
fatigue,127 and patients with advanced disease reported fatigue, lack of energy, 
and weakness in 74%, 69% and 60%, respectively.122 
Moderate to severe sleeping problems (22-35%) did not differ very much from 
a general Norwegian population (26%).120 These findings are lower than those 
seen in previous reports. Sleeping disorders have been reported in 30-50% of 
cancer patients,128 which is twice as high as in the general population.129 In 
33% of 300 breast cancer patients, the onset of insomnia started after the 
diagnosis of cancer.130 Regardless of cancer type, patients diagnosed in the 
previous six months had more complaints of excessive daytime sleepiness 
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(37%) than those diagnosed five or more years previously (27%).131 Seventy 
percent of patients in a palliative care setting had symptoms of insomnia.132 
Finally, approximately 25-50% of all prescriptions for cancer patients are for 
hypnotics.133,134 The majority of studies that assessed the relationship between 
fatigue and sleep prospectively in patients with cancer or cancer survivors, 
revealed strong correlations between fatigue and various sleep parameters.135  
Fatigue had a significant negative effect on overall quality of life, and therefore 
treatment of this complaint is of paramount importance. 
 
In patients with moderate to severe fatigue or sleeping difficulties, 89% and 
68%, respectively, reported that they received no treatment for that complaint. 
The concept that fatigue and insomnia are reciprocally related suggests the 
possibility that treatment for one may impact the other.135 Treating conditions 
that may contribute to cancer-related fatigue (e.g., anaemia, metabolic 
disorders, pain, depression) is a reasonable first step in the management of 
fatigue.136 When fatigue persists, both non-pharmacological (exercise, 
nutritional support) and pharmacological (psycho stimulants, CNS stimulants, 
corticosteroids, hypnotics) treatment should be considered.136 
Lack of appetite, nausea and vomiting 
 The prevalence of moderate to severe lack of appetite, nausea and vomiting in 
patients who had finished curative treatment more than six months previously, 
was similar to a general Norwegian population (12% lack of appetite, and 3% 
nausea and vomiting).120  
The prevalence of these complaints rose with more advanced disease to 49%, 
26% and 10%, respectively, in patients for whom anti-cancer therapy was no 
longer an option. These figures are in accordance with an extensive systematic 
review of symptom prevalence in patients with incurable cancer.122  
 
Ninety-seven percent of patients with moderate to severe complaints of loss of 
appetite indicated that they were not being treated for that symptom. However, 
loss of appetite has a significant influence on overall quality of life. 
Corticosteroids, however short-lived,137 and megestrol acataat138 have proved 
to be effective in treating appetite loss in cancer patients. Fifty-eight and 45% 
received no treatment for nausea and vomiting, respectively. The treatment of 
nausea and vomiting during chemotherapy or radiotherapy is beyond the scope 
of this article. In patients with advanced disease, there are often several 
causes for nausea and vomiting. The identification of triggers and 
administration of receptor-specific anti-emetics should be successful in 93% of 
patients.139 
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Constipation and diarrhoea 
Moderate to severe complaints of constipation and diarrhoea were prevalent in 
7% and 6%, respectively, of patients in group 1a, similar to a general 
Norwegian population.120 In group 3, these figures rose to 22% and 16%, 
respectively. No differences were found between the various types of cancer. 
The prevalence of constipation in advanced cancer was seen to be 
considerably lower than reported previously.122,140 Possibly, the increased 
awareness of physicians, nurses and pharmacists, due to ongoing education, is 
paying off. Diarrhoea is increasingly being seen as a complication of anti-
cancer treatment.140 Its causes in advanced cancer are diverse.140 Forty-seven 
percent of patients with moderate to severe constipation and 70% of patients 
with moderate to severe diarrhoea claimed not to have been treated for those 
symptoms. If possible, causative treatment is the preferred treatment. In 
refractory diarrhoea somatostatin analogues have proved to be highly 
effective.141, 142 
Dry mouth 
Moderate to severe complaints of dry mouth were prevalent in 17% and 58% of 
groups 1a and three patients, respectively. Earlier studies reported complaints 
of xerostomia in 78-97% patients with advanced cancer.143-145 As expected, dry 
mouth was most prevalent in head and neck cancer. Xerostomia had a 
considerable negative impact on quality of life and was ranked the third most 
distressing symptom in advanced cancer patients.144 Patients tend to 
underreport mouth pain and dryness;145 90% of patients indicated that they had 
received no treatment for this complaint. The usual cause of xerostomia is drug 
treatment.144 Unfortunately, it is not usually possible to discontinue or substitute 
all xerostomic drugs. Management consists of saliva stimulants or substitutes. 
Saliva substitutes are rarely effective,146,147 but pilocarpine was shown to 
provide significant improvement of oral dryness in approximately 50% of 
patients.148,149  
Psychological symptoms 
Cancer-related psychological symptoms occur in one-third of patients.150 Major 
depressive disorders are estimated to occur in 10-25% of cancer patients.150 
Most authors consider the criteria over-inclusive and prefer to focus on 
‘depressive symptoms’. In three systematic reviews, depressive symptoms in 
cancer patients ranged from 7-58%151,152 to 20-50% for solid tumours.153 
Anxiety disorders were found in 15-28%.154 These estimates were made 
around the time of diagnosis. Almost no research has been carried out to 
establish the prevalence of depressive disorders in the years following 
diagnosis. Psychiatric morbidity and other psychological symptoms have been 
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well studied in breast cancer patients, while fewer reports have studied other 
types of cancer.155-157  
Dullness, difficulties concentrating, difficulties remembering 
Moderate to severe dullness was primarily a complaint in group 3 patients 
(30%). In earlier studies, the prevalence was 12-32%.122 Cognitive functioning 
(composite scale of difficulty in concentrating and difficulty in remembering) in 
groups 1a, 1b and 2, was comparable to a normal reference population.120 The 
main problems in cognitive functioning were seen in advanced cancer patients. 
No differences were found between the different types of cancer. Most cancer 
patients receive medication with sedative (side-)effects, such as opioids, 
tricyclic anti-depressives, hypnotics, etc. Careful examination of all 
prescriptions is warranted. 
Anxiety and depression 
According to the HADS questionnaire, 32% of patients suffered from an anxiety 
disorder (HADS ≥8). Anxiety was most prevalent (48%) in patients with 
advanced disease. In all disease groups, anxiety was more prevalent than in 
the general population (18%).158 The prevalence of anxiety disorders in cancer 
patients has been studied the most in patients with advanced disease. 
Reported prevalence rates range from 3-74%.122,159,160 In breast cancer 
patients, no significant differences in the prevalence of anxiety were found 
between stage 1 and stage 4 patients.161 Tagay described anxiety in 63% of 
hypothyroid patients with thyroid cancer scheduled for the administration of 
radioiodine.162 Anxiety disorders were reported in 22-34% of 
outpatients.156,163,164 Korfage described the five-year follow-up of anxiety after 
the diagnosis and treatment of prostate cancer: high anxiety pre-treatment was 
present in 28% of patients and decreased significantly post-treatment. The 
sensitivity of anxiety at baseline as a screenings tool was 71%.157 In a cohort of 
breast cancer patients, the prevalence of anxiety decreased from 40% post-
surgery to 16% six months later.165 
With regard to the presence of anxiety and its influence on overall quality of life, 
it appears to have a considerable negative impact on quality of life. However, in 
the regression analysis, anxiety did not appear to be an independent factor. A 
few studies have assessed the relationship between the presence of symptoms 
and anxiety. The results are contradictory: in advanced cancer patients, one 
study found no correlations between symptoms and anxiety,159 while another 
reported significant associations between anxiety and fatigue and nausea after 
correction for pain and disease severity.166  
Depression or a depressive disorder were most prevalent in patients with 
advanced disease (48%). In all disease groups, depression was more 
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prevalent than in the general population (6%).167 A strong body of evidence 
demonstrates the coexistence of depression and cancer.153 The prevalence 
rates of depression in the case of solid tumours range from 20-50%.153 In a 
cohort of breast cancer patients, the prevalence of anxiety and depression was 
33% at diagnosis, 15% after one year, and 45% after diagnosis of 
recurrence.168 In a cohort of patients with prostate cancer, the improvement in 
mental health at the six-month follow-up was statistically significant and 
clinically meaningful.157 In contrast, in two other studies, one in early and late 
breast cancer169 and one in early and late chronic lymphatic leukaemia (CLL), 
depression and anxiety disorders and quality of life were not statistically 
different between the two groups.150 Pancreatic cancer had the highest rates of 
depression (56.3%) and anxiety (56.7%).156 Distress was significantly higher in 
lung cancer (43%) and brain cancer (42.7%), while lower levels were seen in 
gynaecological (29.6%), prostate (30.5%), and colon (31.6%) cancers.156  
Depression had a significant negative influence on quality of life. Other studies 
also showed that psychological symptoms had a considerable negative 
influence on quality of life in patients with chronic diseases170-173 and cancer.153, 
160 Inadequate diagnosis of distress, particularly of depression, in cancer 
patients can cause higher rates of non-compliance173 and possibly shorter 
survival.174 
A recent review on the treatment of depression in cancer patients concluded 
that there is limited evidence for the effectiveness of pharmacological and 
psychological interventions in the treatment of cancer patients with depressive 
disorders, and no evidence for the superiority of one modality over another.175 
Psychological interventions for mixed types of cancers have noted beneficial176-
179 and non-beneficial180,181 effects on survival. Further research is necessary. 
Concerns about recurrence 
Another form of psychological distress in patients cured of cancer is the fear of 
recurrence. Worries about the recurrence of disease have a negative influence 
on quality of life, predominantly in the mental health domain of the RAND. This 
was demonstrated by the increased prevalence of post-traumatic stress 
disorder (PTSD) in former breast cancer patients182 and by the positive 
relationship between cancer-related fears and anxiety and depression.183  
In former breast cancer patients, the prevalence of fear of recurrence ranges 
from 31-70%.183-187 A few results have also been published on the prevalence 
of fear of recurrence in patients with other types of cancer, e.g., orofacial: 
>80% and 72% at three and seven months post-therapy, respectively;188 
gynecological: between 22% and 64%;189-192 colorectal: between 27% and 
33%;183 and prostate: 39%.183 Patients and their partners stated that recurrence 
of disease was their greatest fear after colorectal cancer.193 Articles in the 
literature are contradictory about the influence of time on the fear of recurrence. 
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Some studies suggested that, as time progressed, the fear of recurrence 
subsided,183,186,187,194,195 whereas most studies found that time made little 
difference,196-200 even at more than 20 years after diagnosis. 
Unfortunately, very little is known about the effect of psychosocial interventions 
after the treatment phase.201 
Conclusion 
The education of health care providers and patients into non-pain physical 
symptoms and psychological symptoms and their treatment is urgently needed. 
Physicians and nurses should ask patients about symptoms, and patients 
should tell their care providers about their symptoms. Reducing the prevalence 
of bothersome symptoms in cancer patients will be time consuming both for 
patients and health care professionals alike. Nursing services being available 
to assess symptoms and to train patients and answer questions, could be a 
step in the right direction. 
Final conclusion 
In the last decennia, much progression has been made in the curing of patients 
with cancer. However, there is still a long way to go in the field of care. 
The prevalence of pain and non-pain symptoms is still far too high. Analgesic 
treatment is inadequate in almost 50% of patients, and many non-pain 
symptoms still go untreated. By using the WHO pain ladder, in combination 
with appropriate dosage guidelines, it should be possible to achieve adequate 
pain relief in 70-90% of patients with cancer, and (partially) effective treatment 
is available for most other symptoms. 
The prime responsibility for symptom control lies with the physician. 
Unfortunately, no studies have yet been published on the effects of the 
education of physicians on symptom prevalence. However, with 
misconceptions about medications and side effects in 23-61%, and insufficient 
knowledge / training in pain in 23-54%, a positive effect from training might well 
be expected. On the other hand, a change of attitude and the systematic 
recording of pain levels have been shown to improve the management of pain. 
At our RCT, ‘not-asked-for’ advice with regard to a change in prescriptions for 
pain medication was rarely followed. Respectful, open communication between 
professional caregivers on symptom control should speak for itself. 
The education of patients has proved to have a positive effect on levels of pain. 
 
This leads us to the following recommendations: 
1. The consistent recording of symptoms should be carried out in all patients, 
e.g., by standardized questionnaires or nurse practitioners. 
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2. Patients should be encouraged to discuss their symptoms with the treating 
physician, and they should be instructed about symptom management and 
the existing barriers regarding medication. 
3. More and better education of all health care professionals with regard to 
symptoms and symptom management is warranted.  
and 
4. There should be one, easily assessable, telephone number for patients 
who have questions about their symptoms and/or medication. 
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Samenvatting  
Door vroege opsporing en verbeterde behandeling is de overleving voor 
verschillende vormen van kanker de laatste jaren aanzienlijk gestegen.1 Naar 
verwachting zal het aantal mensen dat recent of langer geleden de diagnose 
kanker heeft gekregen tussen 2000 en 2015 toenemen van 366.000 tot 
692.000.1 Patiënten met kanker hebben vaak meerdere symptomen die een 
negatieve invloed hebben op hun gevoel van welzijn en hun fysieke en sociale 
functioneren. 
In dit proefschrift proberen wij inzicht te geven in de prevalentie van 
symptomen bij patiënten met kanker en de invloed hiervan op hun kwaliteit van 
leven. Beschreven worden zowel fysieke als psychologische symptomen bij 
patiënten met kanker in alle ziekte stadia: van genezen tot terminaal ziek. 
Hoofdstuk 1 
Introductie 
In de introductie schetsen wij de aanleiding voor dit proefschrift. Ondanks de 
overvloedige hoeveelheid literatuur over dit onderwerp is de prevalentie van 
pijn bij patiënten met kanker niet goed bekend. De vroegste studies (1959-
1975) spreken over een prevalentie van pijn van 52-77%.2-6 Studies na 2004 
laten een pijnprevalentie van 24-60% zien bij patiënten tijdens actieve 
antikanker behandeling7-10 en van 62-86% bij patiënten met een vergevorderd 
stadium van de ziekte.11-16 Deze cijfers staan in schril contrast met de snel 
groeiende interesse in pijn en pijnbehandeling in de laatste twee decennia. 
Blijkbaar hebben het grotere inzicht in de pathosfysiologische mechanismen 
van pijn en de grotere beschikbaarheid van verschillende soorten pijn 
medicatie, zoals opioïden, co-analgetica en NMDA-receptor-antagonisten, niet 
geleid tot een daling in de prevalentie van pijn bij patiënten met kanker. Dit, 
terwijl een goed gebruik van de WHO-pijnladder zou kunnen leiden tot 
adequate pijnverlichting bij 70-90% van de patiënten.17-20  
Over fysieke symptomen anders dan pijn is in de literatuur veel minder te 
vinden. De studies die naar andere symptomen gekeken hebben betreffen 
meestal patiënten met vergevorderde of terminale kanker.11,21-25 In een recente 
review26 bleken vijf symptomen (vermoeidheid, pijn, gebrek aan energie, 
zwakte en verlies van eetlust) bij meer dan 50% van de patiënten met 
vergevorderde ziekte voor te komen. Studies naar niet-pijn fysieke symptomen 
bij niet-terminale patiënten zijn schaars en focussen meestal op één symptoom 
bij één soort kanker o.a. benauwdheid bij patiënten met longkanker27 of 
vermoeidheid bij borstkanker.28 
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Kanker gerelateerde psychologische stress wordt gezien bij eenderde van de 
patiënten.29 De prevalentie van depressie wordt geschat op 10-25%, die van 
angststoornissen op 15-28%.29 Deze schattingen berusten echter op 
onderzoeken uitgevoerd op een tijdstip rond de diagnose. Veel minder is 
bekend over psychologische problemen jaren na de diagnose. Studies met een 
longitudinaal karakter spreken elkaar tegen: psychologische problemen nemen 
af in de loop van de tijd30,31 ten opzicht van: geen verschil in prevalentie van 
angst en depressie tussen vroege en late borstkanker32 of chronische 
lymfatische leukemie.33  
 
De oorzaken voor de nog steeds zeer hoge prevalenties van fysieke 
symptomen bij patiënten met kanker zijn het best bestudeerd bij pijn. De kloof 
tussen wat mogelijk is in pijnbestrijding en wat wordt bereikt wordt veroorzaakt 
door vele zowel patiëntgerelateerde, hulpverlener gerelateerde als logistiek 
gerelateerd factoren. “Een goede patiënt” willen zijn en angst voor medicatie in 
het algemeen en opioïden in het bijzonder bij patiënten en  gebrek aan kennis 
en ”vragen naar” bij de hulpverleners zijn bekende barrières voor adequate 
pijnbehandeling.34-43  
In een recente review44 van interventies gericht op het verbeteren van de 
behandeling van pijn, kon geen enkele interventie gevonden worden welke zich 
specifiek op medici richtte. Didactische interventies bij verpleegkundigen 
verhoogden de kennis van de verpleegkundigen en rekende af met een aantal 
mythes. Echter, deze interventies lieten geen verbetering van de pijn bij 
patiënten zien, noch een grotere patiënt tevredenheid. Verschillende studies 
lieten zien dat interventies gericht op patiënten wel de pijnscores kunnen 
verbeteren en negatieve gevoelens over pijnmedicatie kunnen veranderen.44  
Hoofdstuk 2 
Prevalentie van pijn bij patiënten met kanker: een systematische 
review over de afgelopen 40 jaar 
(Prevalence of pain in patients with cancer: a systematic review of the past 40 
years. Annals of Oncology, 2007;18:1437-1449) 
 
In hoofdstuk 2 beschrijven wij een systematische review naar de prevalentie 
van pijn bij patiënten met kanker. Bij een search in Medline 1966-Sept 2005, 
Embase 1989- Sept 2005, Pubmed1975- Sept 2005, Cinahl 1982- Sept 2005, 
Cochrane Systematic reviews, Cochrane Central en de Cancer Library 2002 
met de zoektermen “pain” en “prevalence”, of “symptom” en “prevalence”  in 
combinatie met de volgende termen: “cancer”, “neoplasm”, “terminal”, “end-
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stage”, “advanced”, “hospice” of  “palliative” werden 160 studies naar de 
prevalentie van pijn bij patiënten met kanker geïdentificeerd. De voorafgestelde 
kwaliteitsnorm  (gebaseerd op Leboeuf-Yde45) werd gehaald door 54 artikelen 
(34%). 
De prevalentie van pijn was 33% bij patiënten na curatieve antitumor therapie, 
59% bij patiënten tijdens antitumor therapie en 64% bij patiënten voor wie 
antitumor behandeling geen optie meer was. In slechts17 studies werd ook de 
ernst van de pijn gerapporteerd. In de groep tijdens antitumor therapie bleek 
36% van de patiënten matig tot ernstige (VAS>4) pijn te ervaren, in de 
uitbehandelde groep was dit 45%. 
In de bivariate analyse bleek dat noch type kanker noch periode van publicatie, 
continent, leeftijd, type gemeten prevalentie noch gebruik van al dan niet 
gevalideerde vragen lijsten een significante invloed had op de prevalentie van 
pijn.  
In de discussie gaan wij in op de barrières voor adequate pijn bestrijding en 
doen wij aanbevelingen voor verder onderzoek. 
Hoofdstuk 3 
Hoge prevalentie van pijn bij patiënten met kanker in een grote 
population-based studie in Nederland 
(High Prevalence of Pain in Patients with Cancer in a Large Population-Based 
Study in the Netherlands. Pain 2007;132:312-320) 
 
In hoofdstuk 3 beschrijven wij de resultaten van een onderzoek naar 
prevalentie van pijn en de kwaliteit van pijn behandeling bij patiënten met 
kanker in de regio van het Integraal Kankercentrum Limburg (IKL). Een 
representatieve groep van 1429 patiënten (response 76%) met kanker vulden 
een vragenlijst in bestaande uit de Brief Pain Inventory (BPI), de Pain 
Management Index (PMI) en de EORTC-C30 (pijn en kwaliteit van leven).  
Van de totale onderzoeksgroep rapporteerde 44% matig tot ernstige pijn. De 
onderzoekspopulatie werd gesplitst in 4 groepen: groep 1a: patiënten voor wie 
curatieve behandeling >6 maanden geleden was afgerond, groep 1b: patiënten 
tijdens curatieve antitumor therapie of behandeling ≤ 6 maanden geleden 
afgerond, groep 2: patiënten tijdens palliatieve antitumor behandeling en groep 
3: patiënten voor wie antitumor behandeling geen optie meer was. De 
pijnpercentages in deze groepen was respectievelijk: 49%, 57%, 56% en 75%. 
Patiënten met lagere opleidingsniveaus hadden significant meer kans op pijn. 
Patiënten met gastro-intestinale tumoren, mamma carcinoom en 
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hematologische maligniteiten (zonder maligne lymfomen) hadden significant 
meer kans op matig tot ernstige pijn dan patiënten met prostaat carcinoom. 
Pijnbehandeling was inadequaat bij 42% van de respondenten. Opnieuw gaf 
een laag opleidingsniveau een grotere kans op onderbehandeling. Ook 
patiënten in groep 1b (tijdens curatieve antitumor therapie) hadden een 
significante hogere kans op onderbehandeling van de pijn. 
In de discussie gaan wij in op de onderverdeling van pijn in mild, matig en 
ernstig, bespreken we kort de beperkingen van de Pain Management Index 
(PMI) en zoeken wij naar een verklaring voor de grotere kans op pijn en 
onderbehandeling van patiënten met een lager opleidingsniveau en de grotere 
kans op onderbehandeling van patiënten in groep 1b. 
Wij concluderen dat aandacht voor pijn in alle ziektestadia een stringente 
noodzaak is en dat in de curricula voor medische professionals meer aandacht 
moet komen voor pijn- en pijnbehandeling. 
Hoofdstuk 4 
Prevalentie van niet-pijn fysieke symptomen en psychologische 
symptomen en hun invloed op kwaliteit van leven bij patiënten 
met kanker. 
(Prevalence of Non-pain Physical Symptoms and Psychological Symptoms and 
their influence on Quality of Life in Patients with Cancer. Journal of Pain and 
Symptom Management; in press) 
 
In hoofdstuk 4 beschrijven wij de resultaten van een onderzoek naar de 
prevalentie van niet-pijn fysieke symptomen en psychologische symptomen bij 
patiënten met kanker in de regio van het Integraal Kankercentrum Limburg 
(IKL). Een representatieve groep van 1429 patiënten (response 76%) met 
kanker vulden een vragenlijst in bestaande uit de EORTC-C30 (kwaliteit van 
leven en fysieke symptomen) en de Hospital Anxiety and Depression Scale 
(HADS). De onderzoekspopulatie werd gesplitst in vier groepen: groep 1a: 
patiënten voor wie curatieve behandeling >6 maanden geleden was afgerond, 
groep 1b: patiënten tijdens curatieve antitumor therapie of behandeling ≤ 6 
maanden geleden afgerond, groep 2: patiënten tijdens palliatieve antitumor 
behandeling en groep 3: patiënten voor wie antitumor behandeling geen optie 
meer was. 
Behalve bij diarree nam de prevalentie van matig tot ernstige fysieke 
symptomen (braken, obstipatie, misselijkheid, sufheid, slaapproblemen, 
benauwdheid, gebrek aan eetlust, droge mond, zwakte, vermoeidheid en 
behoefte om te rusten) significant toe met de ernst van de ziekte. Braken was 
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het minst frequente symptoom in alle groepen (1–10%). Matig tot ernstige 
klachten van zwakte, vermoeidheid en de behoefte om te rusten waren het 
meest frequent aanwezig: respectievelijk 16–24% in groep 1a en 65-74% in 
groep 3. 
Behalve geïrriteerdheid namen ook de psychologische symptomen (moeite met 
herinneren, depressie, gespannen, moeite met concentreren, angst en zorgen) 
significant toe met de ernst van de ziekte. Geïrriteerdheid was in alle groepen 
het minst voorkomende symptoom. Zorgen was het meest frequent 
voorkomende symptoom (20-55%). Diarree was het meest prevalent bij 
patiënten met gastro-intestinale tumoren en droge mond en angst het meest 
prevalent bij patiënten met hoofd-hals tumoren. 
Patiënten met gastro-intestinale tumoren, maligne lymfomen en andere 
hematologische tumoren hadden een significant slechter kwaliteit van leven 
dan patiënten met een prostaat carcinoom. De symptomen vermoeidheid, pijn, 
gebrek aan eetlust, obstipatie, angst en depressie hadden een significante 
negatieve invloed op de kwaliteit van leven. Voor 45-90% van de matig tot 
ernstige symptomen werden patiënten niet behandeld, met name de 
symptomen met de meest negatieve invloed op de kwaliteit van leven werden 
het minst frequent behandeld. 
In de discussie relateren wij de prevalentie van de verschillende symptomen 
aan die in de algemene bevolking en vergelijken onze cijfers met eerdere 
studies. 
Wij concluderen dat patiënten met kanker vaak polisymptomatisch zijn en dat 
veel symptomen onbehandeld blijven, ondanks hun negatieve invloed op 
kwaliteit van leven. Meer aandacht voor de verschillende fysieke en 
psychologische symptomen in alle stadia van de ziekte is van groot belang 
voor de kwaliteit van leven van patiënten met kanker. 
Hoofdstuk 5 
Een randomised contolled trial (RCT) naar het effect van een 
intensieve verpleegkundige interventie bij patiënten met kanker 
en pijn in de thuissituatie. 
(A randomised controlled trial of an intensive nursing intervention for cancer 
outpatients suffering from pain and other symptoms. submitted) 
 
In hoofdstuk 5 beschrijven wij een RCT naar de effecten van een 
verpleegkundige interventie bij patiënten met pijn of andere symptomen als 
gevolg van kanker of kanker therapie in de thuissituatie. Honderdtwintig 
patiënten werden gerandomiseerd naar de interventiegroep of de 
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controlegroep. De interventie (Pain Education Program PEP) bestond uit drie 
huisbezoeken van 1 tot 1,5 uur waarin 1. met behulp van een pijnbrochure de 
patiënt onderwijs werd gegeven over pijn en pijnbehandeling, 2. de patiënt 
werd geïnstrueerd hoe een pijndagboek bij te houden en 3. de patiënt werd 
gestimuleerd contact te zoeken met zijn of haar behandelaar bij matig tot 
ernstige symptomen. Na het eerste en derde huisbezoek werd een schriftelijk 
verslag en zonodig suggesties voor veranderingen in de behandeling 
opgestuurd naar de behandelaar. De patiënten in de controlegroep kregen 
care-as-usual.  
Pijnkennis nam significant toe in de interventiegroep. Bij alle patiënten in de 
interventiegroep was er een significante afname van de pijn score op korte 
termijn (vier weken). Alleen bij de patiënten met een hoge pijnscore (VAS 7-10) 
bij aanvang van de studie bleef deze significante daling bestaan op de lange 
termijn (acht weken). Geslacht, leeftijd, opleidingsniveau, angst en depressie 
bij aanvang hadden geen significante invloed op de afname van de pijnscore 
op korte en lange termijn. Er werd geen correlatie gevonden tussen toename 
van kennis en afname van pijn. 
Van de in totaal 37 geformuleerde medicatie adviezen werden er 22 niet 
opgevolgd en van 8 adviezen is onbekend of deze opgevolgd werden.  
Alle patiënten gaven aan andere patiënten te willen aanraden om deel te 
nemen aan het scholingsprogramma. Zesenzestig procent van de patiënten 
wilde graag doorgaan met het programma, 34% vond drie sessies voldoende. 
In de discussie pleiten wij voor een betere patiënt selectie voor educatie 
programma’s, bediscussiëren wij het ontbreken van de correlatie tussen 
toename van pijnkennis en afname in pijn en bepleiten wij een intensievere 
samenwerking tussen de behandelaren, waardoor mogelijk medicatie 
aanpassingen sneller en adequater kunnen worden doorgevoerd. 
Hoofdstuk 6 
Zorgen van voormalige borstkanker patiënten over een mogelijke 
terugkeer van de ziekte: een validatie en prevalentie studie 
(Concerns of former breast cancer patients about disease recurrence: a 
validation and prevalence study. Psycho-Oncology, 2008;17:1137-1145) 
 
In hoofdstuk 6 beschrijven wij de validatie van de Nederlandse versie van de 
Concerns About Recurrence Scale (CARS) en rapporteren wij over de 
prevalentie van angst voor terugkeer van borstkanker en de invloed hiervan op 
kwaliteit van leven. 
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Voor het meten van angst voor terugkeer van borstkanker werd gekozen voor 
de oorspronkelijk Amerikaanse vragenlijst CARS omdat dit het enige 
beschreven multi-dimensionele instrument is. Naast vier vragen over overall 
angst voor terugkeer voor borstkanker bekijkt de CARS ook waar patiënten met 
name bang voor zijn in 4 subdomeinen: vrees voor gezondheid, vrouwelijkheid, 
rol-functioneren en dood. De CARS werd vertaald en de psychometrische 
eigenschappen onderzocht. De confirmerende factor analyse liet een adequate 
lading van alle items zien op de verschillende domeinen. De interne 
consistentie (Cronbach’s alfa) van de domeinen was adequaat. De intraclass 
coëfficiënten (ICC) van 0.77–0.89 gaven aanwijzingen voor een goede test-
hertest stabiliteit. De constructvaliditeit werd bevestigd dor adequate 
Spearman’s correlaties met de Hospital Anxiety and Depression Scale (HADS), 
de Pain Catastrophizing Scale (PCS) en de Life Orientation Test (LOT). 
Van de participerende vrouwen (n=136, reponse rate 90%) gaf 56% matige tot 
ernstige overall angst voor terugkeer van de borstkanker aan. Met name vrees 
voor gezondheid en dood waren prominent aanwezig (respectievelijk 63% en 
61%). Pijn was een onafhankelijke voorspeller voor de angst voor terugkeer, 
oudere vrouwen hadden significant minder vrees voor gezondheid, rol-
functioneren en dood. Er was geen significante relatie tussen tijd verlopen 
sinds laatste behandeling en de mate van vrees voor terugkeer. 
Alle domeinen van de CARS waren negatief gecorreleerd met kwaliteit van 
leven, waarbij rol-functioneren de meeste invloed had op de kwaliteit van leven. 
Hoofdstuk 7 
Algemene discussie 
In de algemene discussie bespreken wij allereerst enige methodologische 
aspecten van dit proefschrift.   
Groepsgrootte 
Groep 3 (patiënten voor wie antitumor therapie niet meer geïndiceerd is) is 
relatief klein en mogelijk niet representatief. Het is onduidelijk op welke wijze dit 
de uitkomsten van de studie beïnvloedt. Sommige studies laten een afname 
van pijn zien in de laatste twee weken van het leven, hetgeen zou betekenen 
dat wij een overschatting van de prevalentie van pijn maken. Andere studies 
echter, laten een toename van pijn zien in de laatste twee weken. Er zijn 
slechts weinig studie naar andere symptomen in de laatste twee weken. Eén 
studies liet een toename zien van de prevalentie van verwardheid, anorexie en 
slikklachten, een andere studie een afname van depressie, hoest en 
misselijkheid, terwijl een derde studie een toename van de prevalentie van 
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dyspnoea, maar gelijkblijvende prevalentie van alle andere symptomen liet 
zien. 
Er zou een vraagteken geplaatst kunnen worden bij het aantal patiënten 
geïncludeerd in de validatie studie van de CARS. Echter, de rationale voor de 
regel dat voor een factor analyse tien deelnemers per vraag benodigd zijn is 
onduidelijk. Meer recent werd aangetoond dat bij communaliteiten van ≥0.6 
relatief kleine aantallen (<100) voldoende kunnen zijn voor een adequate factor 
analyse. 
Kwaliteitscriteria 
De kwaliteitscriteria voor de beoordeling van prevalentie studies gebruikt in 
hoofdstuk 2 werden gebaseerd op het werk van Leboeuf-Yde and Lauritsen. 
Wij hebben deze criteria aangepast door gewicht toe te kennen aan de 
afzonderlijke criteria en de specifieke items over lage rug pijn te vervangen 
door kankerspecifieke items. Wij bevelen een verdere verfijning van deze 
criteria aan door oa minder gewicht toe te kennen aan retrospectieve studies 
en studies die gebruik maken van proxy-reporting of medische dossiers. Meer 
gewicht zou toegekend mogen worden aan een adequate beschrijving van het 
ziektestadium van de patiënten en het item gebruik van al-dan-niet 
gevalideerde vragenlijsten lijkt overbodig. 
Wanneer noem je een symptoom mild, matig of ernstig? 
Om een betekenisvolle classificatie van de ernst van symptomen te maken 
werden de NRS en VAS schalen (0–10) omgezet in woorden: geen, mild, matig 
en ernstig door koppeling van de NRS- en VAS schalen aan de mate waarin 
een symptoom een patiënt in het dagelijks leven beperkt. De onderverdeling in 
mild, matig en ernstig blijft echter een punt van discussie: mn is een NRS/VAS 
van 4 mild of matig en, in mindere mate, is een NRS/VAS van 7 matig of 
ernstig? Voor de review (hoofdstuk 2) hebben wij gekozen voor de indeling van 
Serlin (4 = mild, 7 = ernstig). Echter, in onze prevalentie studie (hoofdstuk 3) 
gaven de patiënten aan een NRS van 4 als matige pijn te beoordelen. Dit was 
reden om in de hoofdstukken 3 en 4 de indeling NRS 1-3 = mild, 3-6 = matig en 
7–10 = ernstig aan te houden. 
Algemene discussie 
In de algemene discussie gaan we allereerst uitgebreid in op de mogelijke 
oorzaken (barrières) van de nog altijd te hoge prevalenties van pijn en andere 
symptomen. Oorzaken kunnen gevonden worden op drie niveaus: 1. artsen en 
verpleegkundigen hebben te weinig aandacht voor en te weinig kennis van 
symptomen en symptoom controle, 2. patiënten melden hun klachten 
onvoldoende bij behandelaren en zijn therapie ontrouw, vaak op basis van 
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allerlei mythes welke over medicatie bestaan en 3. binnen het 
gezondheidssysteem is het voor een patiënt vaak onduidelijk bij wie hij/zij voor 
welke klacht moet zijn en is er te weinig tijd om een gedegen pijn/symptoom 
anamnese af te nemen. 
Vervolgens worden de verschillende symptomen afzonderlijk besproken. 
 
De conclusie luidt: 
De afgelopen decennia is er veel progressie geboekt in de genezing van 
patiënten met kanker. Echter op het gebied van “care” valt nog veel te winnen. 
Meer en betere educatie over symptomen en symptoombestrijding van allen 
die professioneel met patiënten met kanker te maken krijgen is een 
randvoorwaarde voor de verbetering van de kwaliteit van leven van deze 
patiënten. 
In iedere setting moeten symptomen systematisch bij ieder patiënt contact 
genoteerd worden, b.v. via een korte vragenlijst of door een nurse-practitioner.  
Patiënten moeten worden aangemoedigd hun klachten te uiten bij hun 
behandeld arts en zouden beter geïnstrueerd moeten worden over het hoe en 
waarom van medicatie om de therapietrouw te verbeteren. 
Tenslotte zou iedere patiënt, laagdrempelig, toegang moeten hebben tot een 
telefoonnummer voor vragen of opmerkingen over hun symptomen en/of 
medicatie. 
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Appendix I 
Quality criteria for prevalence studies  of pain in patients with cancer  
(adapted from Leboeuf-Yde)1  
 
A. The final sample should be representative of 
the target population 
1.  At least one of the following should apply for 
the study: an entire target population, 
randomly selected sample, or sample stated 
to represent the target population (2 points). 
 2.  At least one of the following: reasons for non-
response described, non-responders 
described, comparison of responders and 
non-responders, or comparison of sample 
and target population (2 points). 
 3.  Response rate >90% (2 points). 
     Response rate 70-90% (1 point). 
     Response rate <70% (0 point). 
B. Quality of Data 4.  Were the data primary from a prevalence 
study (2 points) or was it taken from a survey 
not specifically designed for that purpose (1 
point)? 
 5.  The same mode of data collection should be 
used for all subjects (2 points) if not (1 point). 
 6.  The data have been collected directly from 
the patient by means of a validated 
questionnaire/interview (3 points). 
 No validated questionnaire/interview (2 
points). 
 Data have been collected from proxies or 
retrospectively from medical record (1 point). 
C. General description of the method and 
results should include: definitions of pain 
prevalence 
7.  Description of the target population and 
setting where patients were found (2 points). 
8.  Description of stage of disease, type of 
cancer, sex, age. All: 2 points, 2 or 3: 1 point. 
9.  Final sample size (1 point). 
10. Prevalence recall periods should be stated (1 
point). 
 
 
 
1. Leboeuf-Yde, C. and J.M. Lauritsen, The prevalence of low back pain in the literature. A 
structured review of 26 Nordic studies from 1954 to 1993. Spine 1995;20:2112-8. 
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Appendix II 
Dutch version of the CARS1 
Zorgen over het terugkomen van de kanker 
Met de volgende vragen verzoeken wij u aan te geven of u wel eens bezorgd 
bent dat de borstkanker terugkomt. Onder terugkomen bedoelen we dat de 
kanker terug komt in dezelfde borst, of op een andere plek van het lichaam of 
een nieuwe borstkanker in de andere borst. 
 
Alhoewel de meeste vrouwen bij wie borstkanker in een vroeg stadium is 
ontdekt nooit meer een probleem met kanker zullen krijgen, weten we dat veel 
vrouwen zich toch zorgen maken over het terugkomen van de kanker. Er zullen 
ook vrouwen zijn die zich helemaal geen zorgen maken. Hoe dan ook, uw 
antwoorden op de volgende vragen zijn voor ons erg belangrijk. We begrijpen 
dat u van streek kan raken door te denken aan of antwoord te geven op vragen 
over de mogelijkheid van het terugkomen van de kanker. We hebben uw hulp 
echter nodig om te begrijpen hoe vrouwen denken over deze mogelijkheid. 
 
Wij vragen u bij de volgende vier vragen het nummer te omcirkelen welke 
het beste aansluit bij uw gevoel. Bijvoorbeeld, bij de eerste vraag moet u “1” 
omcirkelen wanneer u nooit denkt aan de mogelijkheid van het terugkomen 
van de kanker. Omcirkel een “6“ wanneer u constant denkt aan het 
terugkomen van de kanker, of omcirkel “2 “, “3”, “4” of ”5” als de tijd dat u 
hieraan denkt hier ergens tussenin zit. 
 
1. Hoe vaak denkt u aan de mogelijkheid dat de borstkanker terug kan komen? 
 
1  2  3  4  5  6 
Ik denk er         Ik denk er 
helemaal         de hele tijd aan 
niet aan 
 
2. Hoe erg maakt  de mogelijkheid dat de borstkanker kan terugkomen u van streek? 
 
1  2  3  4  5  6 
Ik raak er         Ik raak er heel erg  
helemaal niet         door van streek 
door van streek 
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3. Hoe vaak maakt u zich zorgen over de mogelijkheid dat de borstkanker terug zal komen? 
 
1  2  3  4  5  6 
Ik maak mij          Ik maak mij    
helemaal geen         de hele tijd zorgen 
zorgen 
 
4. Hoe bang bent u dat de borstkanker terug zal komen? 
 
1  2  3  4  5  6 
Ik ben helemaal         Ik ben ontzettend     
niet bang         bang 
 
 
Wij zijn nu geïnteresseerd in uw zorgen ten aanzien van een mogelijke 
terugkeer van de borstkanker. Wanneer u denkt aan een mogelijke terugkeer 
van de borstkanker, waar maakt u zich dan het meest zorgen over? 
 
Alhoewel elk van de volgende beweringen het gevolg zouden kunnen zijn van 
het terugkomen van de kanker, willen wij specifiek weten of u zich nu hierover 
ook echt zorgen maakt. U zou bijvoorbeeld kunnen geloven dat wanneer de 
borstkanker terug zou komen een (nieuwe) operatie nodig is. Wij willen graag 
weten of u zich ook echt zorgen maakt over deze mogelijkheid. 
 
Omcirkel bij de volgende vragen alstublieft het cijfer dat aangeeft hoeveel 
zorgen u zich maakt over de achtereenvolgende beweringen. Wanneer u zich 
geen zorgen maakt of wanneer u denkt dat een bewering niet op u van 
toepassing is kunt u een “0” omcirkelen voor ”helemaal niet”. 
 
0= helemaal niet 
1= een klein beetje 
2= matig 
3= veel 
4= ontzettend veel 
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Ik maak me zorgen dat het terugkomen van de kanker: 
 
5. mij emotioneel van streek zou maken. 0 1 2 3 4 
 
6. mij zou afhouden van dingen die ik van plan was te doen. 0 1 2 3 4 
 
7. mijn lichamelijke gezondheid zou bedreigen. 0 1 2 3 4 
 
8. mij minder vrouw zou doen voelen.  0 1 2 3 4 
 
9. chemotherapie nodig zou maken. 0 1 2 3 4 
 
10. nadelig zou zijn voor mijn relaties met vrienden en familie.  0 1 2 3 4 
 
11. mij het gevoel zou geven dat ik geen controle  
 meer heb over mijn leven. 0 1 2 3 4 
 
12. mijn identiteit zou bedreigen (hoe ik mijzelf zie). 0 1 2 3 4 
 
13. in zou grijpen op mijn lichamelijk vermogen tot het 
  uitvoeren van dagelijkse bezigheden. 0 1 2 3 4 
 
14. mijn leven zou bedreigen. 0 1 2 3 4 
 
15. mijn zelfvertrouwen zou beschadigen. 0 1 2 3 4 
 
16. ernstiger zou zijn dan de eerste keer. 0 1 2 3 4 
 
17. financiële problemen voor mij zou veroorzaken. 0 1 2 3 4 
 
18. in zou grijpen op mijn gevoel van seksualiteit. 0 1 2 3 4 
 
19. bestraling nodig zou maken. 0 1 2 3 4 
 
20. mij pijn en lijden zou brengen. 0 1 2 3 4 
 
21. zou betekenen dat ik mijn borst(en) verlies. 0 1 2 3 4 
 
22. In zou grijpen  in mijn vermogen plannen te maken 
 voor de toekomst. 0 1 2 3 4 
 
23. mijn spiritualiteit of geloofsovertuiging zou bedreigen. 0 1 2 3 4 
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24. mij ervan zou weerhouden belangrijke rollen  
 te vervullen (op mijn werk of thuis). 0 1 2 3 4 
 
25. er voor zou zorgen dat ik mij minder vrouwelijk zou voelen. 0 1 2 3 4 
 
26. een (nieuwe) operatie nodig zou maken. 0 1 2 3 4 
 
27. de oorzaak van mijn overlijden zou zijn. 0 1 2 3 4 
 
28.mijn romantische relaties zou beschadigen.  0 1 2 3 4 
 
29. mij er van zou weerhouden om mijn verantwoordelijkheden 
  na te komen (op mijn werk of thuis). 0 1 2 3 4 
 
30. mij een naar gevoel zou geven  
 over hoe mijn lichaam eruit ziet of voelt.  0 1 2 3 4 
 
 
1. Vickberg SM, The Concerns About Recurrence Scale (CARS): a systematic measure of 
women's fears about the possibility of breast cancer recurrence. Ann Behav Med 2003;25:16-
24. 
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Dankwoord 
Aan een mooie tafel eet je nooit alleen! 
En een mooie tafel is het geworden, zeker met alle initiatieven, mede 
geïnitieerd op basis van dit proefschrift, om ervoor te zorgen dat we over tien 
jaar niet weer met dezelfde prevalentie cijfers hoeven te komen. 
 
Dank, dank, dank aan mijn co-promotores: Marjan de Rijke en Jaap Patijn. 
Marjan, ik zie ons nog in de auto zitten op de weg terug van een deelnemende 
locatie: beiden met een vreselijke hoofdpijn, maar wel opgetogen: weer 
mensen enthousiast gekregen! Zonder jou was dit project al heel vroeg 
gestrand. Je fungeerde, zeker in de beginfase, regelmatig als bliksemafleider. 
Je maakte me wegwijs in SPSS en je hebt me veel geleerd door de 
helicopterview vast te houden: wat willen we nu eigenlijk zeggen? Je stuurde 
me steeds met heldere blik, vastberaden, maar altijd alsof ik het ook zelf een 
beetje had bedacht, de goede kant op. Jouw vertrek naar Zeeland (alhoewel 
van harte gegund) was voor mij een aderlating. 
Jaap, ieder mens heeft zo zijn gebruiksaanwijzing en dat geldt zeker ook voor 
ons beiden. Nu we de handleidingen hebben doorgenomen is er iets moois 
ontstaan. Allereerst ben jij de grote initiator van dit proefschrift. Jouw vragen 
die geen vragen waren, dwongen me steeds opnieuw tot verder nadenken. 
“Dat staat er niet” is niet één van mijn meest geliefde uitspraken geworden, 
maar, eerlijk is eerlijk: door jouw inbreng werden de artikelen alleen maar beter 
en beter. Daarnaast heb ik veel respect gekregen voor je uitstekende klinische 
blik. De wekelijkse gezamenlijke “pijnvisites” zijn goed voor de patiënten en 
altijd leerzaam voor ons allen.  
 
Dank aan mijn promotores: Maarten van Kleef en Harry Schouten. 
Alhoewel jullie enige afstand hadden van de dagelijkse gang van zaken wisten 
jullie steeds de puntjes op de i te zetten als er weer een lap tekst op de mail 
stond. Dank voor jullie hulp bij het vinden van de juiste fora voor de artikelen, 
zodat we denk ik ook de mensen hebben bereikt die we wilden bereiken. 
Maarten, ik ben er trots dat ik mij als internist staflid anesthesie mag noemen. 
Moge dit leiden tot een betere behandeling van pijn bij patiënten met kanker. 
 
Mijn speciale dank gaat uit naar alle patiënten die geparticipeerd hebben aan 
de verschillende onderzoeken. De mensen die het gehele traject van kanker en 
behandeling (soms al jaren) achter de rug hadden: een nieuwe confrontatie 
met deze periode was misschien niet altijd gemakkelijk. De patiënten die 
ernstig ziek waren en toch de moeite hebben genomen onze vragenlijsten in te 
vullen. En de patiënten die nog midden in het traject zaten en al veel te veel 
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“ziekenhuis” aan hun hoofd hadden. Wij zullen er alles aan doen dit onderzoek 
zijn vruchten te laten afwerpen. 
 
Dank aan twee heren bij wie ik regelmatig met grote ogen en, naar ik vrees, 
open mond heb gezeten: Fons Kessels en Erik Schouten. Erik dank voor de 
factor analyse van de Cars. Fons, naast jouw verhelderende commentaar op 
de diverse concepten heb jij me door de rest van de statische geheimen 
geloodst. En alhoewel je dat misschien betwijfelt: ik heb veel van je geleerd. 
Dank aan twee dames die beiden grote bijdragen hebben geleverd aan twee 
van de in dit boekje beschreven artikelen: Madelon Peters en Evelien van der 
Peet. Madelon, tussen alle professerabele activiteiten door vond je steeds de 
tijd snel en adequaat suggesties te doen voor het CARS-artikel. Evelien, jouw 
naam staat als eerste op het artikel van hoofdstuk 5. En terecht, ook nadat 
jouw dienstverband er al lang opzat heb je doorgebeten en de interventie 
studie beschreven in een duidelijk artikel. Hartelijk dank. 
 
Mijn dank gaat ook uit naar de leden van de beoordelingscommissie, prof. dr. 
M.F. von Meyenfeldt, prof. dr. C.D.A. Stehouwer, prof. dr. R. de Wit, prof. dr. 
W.W. Zuurmond en prof. dr. S.H. Ahmedzai. Ik wil hen bedanken voor de 
aandacht die zij aan mijn proefschrift hebben geschonken en voor hun 
bereidheid om het te beoordelen. 
 
Dank aan de lokale coördinatoren van het Atrium Centrum te Heerlen, het 
Maaslandziekenhuis te Sittard, het Laurentius Ziekenhuis te Roermond, het St. 
Jans Gasthuis te Weert, de huisartsenvereniging, de diverse verpleeghuizen 
en thuiszorgorganisaties: 
AVRJ Bell, FLJ Custers, JJ Jager, JCAH van de Loo, Mw HJMM Mertens, Mw 
B van Doorn, Mw M Vromen, Mw L Ars, Mw W Habets, M vandenHoff, R 
Persoon, F Slot, Mw P Vleugels en Mw R Palmen: dank voor jullie tijd en inzet. 
 
Dank aan onze student hulptroepen en in het bijzonder aan Jeroen Delbeke, 
de leider van onze ondersteuners. Yvonne, Lilly, Karien, Katrin, Mirella, 
Elsbeth, Eveliene, Danielle, Stijn, Esther, Dominique en Mirjam dank voor het 
verzorgen van de logistiek op de diverse locaties, het plegen vele telefoontjes, 
het versturen van alle vragenlijsten en het met precisie invoeren van alle 
gegevens. Ik hoop dat deze ervaring jullie niet afhoudt van een 
wetenschappelijke carrière: het ga jullie goed. 
 
Dank aan Tiny Wouters. Daar sta je weer achterin een boekje. Dank voor de 
fraaie lay-out en de razendsnelle correcties. Het geeft veel rust te weten dat jij 
in de lay-out fase de leiding hebt. 
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Dank aan Judith Abma: met alleen middelbare school Engels blijven tijden en 
voorzetsels moeilijk. Dankzij jou zal ook een native speaker zijn/haar rode pen 
in de zak kunnen houden. 
 
Annemie Courtens, Riet Janssen, Eliane Perree, Paul Oyen, Pauline Vleugels, 
Marjan van Dijk en Melanie van der Pol, samen zijn wij HET palliatieteam! De 
het staat niet voor niets in hoofdletters. Ik ben zeer blij dat ik deel mag 
uitmaken van een team dat kwalitatief en kwantitatief op een hoog niveau 
presteert, in een sfeer die meer dan aangenaam is. Wij zijn kritisch naar 
onszelf en naar elkaar, wat zeer stimulerend werkt. Wij hebben wat voor elkaar 
over en dat maakt werken binnen deze club zeer waardevol. 
Riet, we zien elkaar te weinig: sparren met jou levert altijd nieuwe 
gezichtspunten en helaas ook heel veel nieuwe vragen op. We zijn nog lang 
niet uit-onderzocht: jouw beurt? 
Paul en Eliane, wanneer jullie zagen dat ik achter mijn laptop zat, begon ieder 
overleg standaard met “opslaan”! Dat heeft me veel ellende bespaard. 
Een speciaal woord van dank ook voor Hans Fiolet die mij op het pad der 
palliatieve geneeskunde heeft gezet. Je hebt het gemerkt: eerst sprak het vak 
me aan, nu heeft het me gegrepen. Dank voor de ruimte en het vertouwen dat 
ik steeds van je heb gekregen. 
 
Lieve mama, gaan studeren was in ons gezin normaal. Er werd dan ook niet 
veel over gesproken. Het was belangrijker dat je goed in je vel zat en je je 
gelukkig voelde met de mensen om je heen. En dat is, zeker ook in onze jeugd, 
uitstekend geslaagd. Het is ontzettend jammer dat papa niet heeft 
meegemaakt hoe eerst zijn jongste zoon, en nu zijn oudste dochter de s van 
hun titel hebben afgehaald. Maar ik weet zeker dat hij ergens trots zit te 
glimlachen. 
 
Lieve mannen, Joop, Sef, Wisse en Dirk. 
Eerlijk gezegd denk ik dat jullie niet zo heel veel last hebben gehad van deze 
exercitie. De jongens hebben wel eens getwijfeld aan mijn vaardigheden als 
arts: “mama, nu ben je zo vaak bij mevrouw….. geweest en nu is ze toch 
overleden!” Inmiddels begrijpen jullie veel beter wat ik doe en waarom: zoveel 
hebben jullie wel meegekregen van dit boekje. 
Joop, eens in de zoveel tijd krijg je een avondje ellende over je uitgestort. Met 
name patiënten die me geraakt hebben door hun moed en kracht ondanks de 
ellendige situatie waarin zij verkeren komen dan (anoniem uiteraard) langs. 
Een luisterend oor is dan goud waard. 
Maar het allerbelangrijkste is natuurlijk dat ik gewoon heel gelukkig ben met 
jullie en dat nog in lengte van jaren hoop te blijven. 
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Curriculum vitae 
Marieke van Everdingen werd op 20 oktober 1960 geboren te Utrecht. Na het 
behalen van het Gymnasium-β diploma in 1979 aan het Maurick college te 
Vught, studeerde zij Geneeskunde aan de Rijksuniversiteit Utrecht. Zij 
behaalde haar artsexamen in 1986, waarna zij als arts-assistent ging werken 
op de intensive care in het Catharina ziekenhuis te Eindhoven. Een jaar later 
startte zij met de opleiding interne geneeskunde. Na twee jaar in het Juliana 
ziekenhuis, thans Gelre ziekenhuizen, te Apeldoorn (opleider dr. A. van Gelder) 
werd de opleiding vervolgd in het Catharina ziekenhuis te Eindhoven (opleider 
prof. dr. H.F.P. Hillen) en het academisch ziekenhuis Maastricht (opleider prof. 
Dr. J.A. Flendrig). De registratie als algemeen internist vond plaats in 1992. Zij 
werkte één jaar op de intensive care van het academisch ziekenhuis Maastricht 
en daarna gedurende vijf jaar als algemeen internist in ziekenhuis de Wever te 
Heerlen (thans Atrium Medisch Centrum Heerlen). 
In 1998 startte zij bij het Centrum Ontwikkeling Palliatieve Zorg (COPZ) in 
Maastricht. In 2000 behaalde zij het “Diploma Palliative Care” te Cardiff. 
Momenteel is zij werkzaam als algemeen internist bij het regionaal palliatie 
team en bij de Maastricht Pain Collaboration  
Zij is zeer gelukkig getrouwd met Joop van den Beuken en samen hebben zij 
drie zonen: Sef (1993), Wisse (1994) en Dirk (1997). 
 
